

Devi, S.
09/489711

09/489711

17oct01 13:05:42 User219783 Session D1751.2

SYSTEM:OS - **DIALOG OneSearch**

File 35:Dissertation Abs Online 1861-2001/Oct
(c) 2001 ProQuest Info&Learning
File 65:Inside Conferences 1993-2001/Oct W2
(c) 2001 BLDSC all rts. reserv.
*File 65: For variance in UD's please see Help News65.
File 77:Conference Papers Index 1973-2001/Sep
(c) 2001 Cambridge Sci Abs
File 144:Pascal 1973-2001/Oct W2
(c) 2001 INIST/CNRS
File 266:FEDRIP 2001/Sep
Comp & dist by NTIS, Intl Copyright All Rights Res
File 440:Current Contents Search(R) 1990-2001/Oct W3
(c) 2001 Inst for Sci Info
File 348:EUROPEAN PATENTS 1978-2001/Oct W01
(c) 2001 European Patent Office
File 357:Derwent Biotechnology Abs 1982-2001/Dec B1
(c) 2001 Derwent Publ Ltd
*File 357: Price changes as of 1/1/01. Please see HELP RATES 357.
File 113:European R&D Database 1997
(c) 1997 Reed-Elsevier(UK) Ltd All rts reserv
*File 113: This file is closed (no updates)

Set Items Description

Set Items Description
S1 372713 STABILIS? OR STABILIZ? OR (METAL OR AL OR ALUMIN??? OR AL -
OR CALCIUM OR CA OR ZINC OR ZN) (W) (OH OR HYDROXIDE) OR ALOH OR
CAOH OR ZNOH
S2 37806 (METAL OR ALUMIN??? OR AL OR CALCIUM OR AL OR CA) (W) (PO? ?
OR PHOSPHATE) OR CAPO? ? OR ALPO? ? OR ALUM
S3 402384 S1 OR S2
S4 20 S3 AND RHUSIOPATH?
S5 19 RD (unique items)
>>>No matching display code(s) found in file(s): 65, 113

5/3,AB/1 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online
(c) 2001 ProQuest Info&Learning. All rts. reserv.

213713 AAD5802369

A PARTIAL AND COMPARATIVE EVALUATION IN MICE OF AN *ALUMINUM***
*PHOSPHATE*** ADSORBED ANTI-SWINE ERYSIPELAS BACTERIN PREPARED BY THE SONIC
BACTERIOCLASIS OF ERYSIPELOTHRIX *RHUSIOPATHIAE***

Author: TIFFANY, LOYD WAYNE

Degree: PH.D.

Year: 1955

Corporate Source/Institution: MICHIGAN STATE UNIVERSITY (0128)

Source: VOLUME 19/01 OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 23. 47 PAGES

5/3,AB/2 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

-key terms

09/489711

01276120

Oil-based adjuvant vaccine

Oladjuvierter Impfstoff

Adjuvant pour vaccin a base d'huile

PATENT ASSIGNEE:

NOF CORPORATION, (1558205), 20-3, Ebisu 4-chome, Shibuya-ku, Tokyo
150-6019, (JP), (Applicant designated States: all)

Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute,
(283933), 6-1, Okubo 1-chome, Kumamoto-shi, Kumamoto 860-8568, (JP),
(Applicant designated States: all)

INVENTOR:

Saito, Koichi, 2-20-8-101, Minamitsukaguchi-cho, Amagasaki-shi, Hyogo
661-0012, (JP)

Kishimoto, Yoko, 1-7-8, Nishikigaoka, Uozumi-cho, Akashi-shi, Hyogo
674-0081, (JP)

Miyahara, Tokuji, 1866-1445, Kikudomi, Koushi-machi, Kikuchi-gun,
Kumamoto 861-1112, (JP)

Takase, Kouzou, 3410-30, Sugimizu, Ohzu-machi, Kikuchi-gun, Kumamoto
869-1236, (JP)

LEGAL REPRESENTATIVE:

von Kreisler, Alek, Dipl.-Chem. et al (12437), Patentanwalte, von
Kreisler-Selting-Werner, Bahnhofsvorplatz 1 (Deichmannhaus), 50667 Koln
, (DE)

PATENT (CC, No, Kind, Date): EP 1097721 A2 010509 (Basic)
EP 1097721 A3 010523

APPLICATION (CC, No, Date): EP 2000123909 001103;

PRIORITY (CC, No, Date): JP 99316121 991105

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE; TR

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: A61K-009/113

ABSTRACT EP 1097721 A3

The present invention provides a W/O/W type oil adjuvant vaccine containing an outer aqueous phase containing 0.5 wt% - 20 wt% of a polyethylene glycol derivative having a molecular weight of 400 - 20,000, and an inner aqueous phase containing a biologically acceptable and effective amount of an antigen. The constitution of the present invention that a polyethylene glycol derivative having a specific molecular weight is contained in the outer aqueous phase enables preparation of a W/O/W type oil adjuvant vaccine showing a high adjuvant effect, reduced side effects such as topical response, superior preparation stability and superior workability to allow a person to give an injection easily due to the lowered viscosity.

ABSTRACT WORD COUNT: 114

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200119	457
SPEC A	(English)	200119	7301
Total word count - document A			7758
Total word count - document B			0
Total word count - documents A + B			7758

5/3,AB/3 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

Searcher : Shears 308-4994

09/489711

(c) 2001 European Patent Office. All rts. reserv.

01270274

Lawsonia intracellularis proteins, and related methods and materials
Lawsonia intracellularis Proteine sowie Methoden und Materialien die diese
verwenden

Proteines de Lawsonia intracellularis et procedes et materiaux relatifs a
ces proteines

PATENT ASSIGNEE:

Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut
06340, (US), (Applicant designated States: all)

INVENTOR:

Rosey, Everett Lee, Pfizer Central Research, Eastern Point Road, Groton,
Connecticut 06340, (US)

LEGAL REPRESENTATIVE:

Eddowes, Simon et al (87482), Urquhart-Dykes & Lord, 30 Welbeck Street,
London W1G 8ER, (GB)

PATENT (CC, No, Kind, Date): EP 1094070 A2 010425 (Basic)

APPLICATION (CC, No, Date): EP 309125 001017;

PRIORITY (CC, No, Date): US 160922 991022

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: C07K-014/205; C12N-015/31

ABSTRACT EP 1094070 A2

Isolated polynucleotide molecules contain a nucleotide sequence that
encodes a L. intracellularis HtrA, PonA, HypC, LysS, YcfW, ABC1, or
Omp100 protein, a substantial portion of the sequences, or a homologous
sequence. Related polypeptides, immunogenic compositions and assays are
described.

ABSTRACT WORD COUNT: 40

NOTE:

Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200117	864
SPEC A	(English)	200117	25111
Total word count - document A			25975
Total word count - document B			0
Total word count - documents A + B			25975

5/3,AB/4 (Item 3 from file: 348).

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

01179843

Erysipelothrix *rhusiopathiae*** antigens and vaccine compositions
Erysipelothrix *rhusiopathiae*** Antigene und Impfstoff-Zusammensetzungen
Antigenes de Erysipelothrix *rhusiopathiae*** et compositions vaccinales

PATENT ASSIGNEE:

Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut
06340, (US), (Applicant designated States: all)

INVENTOR:

Roberts, David Stewart, 604 Washington Square South, Philadelphia,

09/489711

Pennsylvania 19106, (US)
Suiter, Brian Thomas, 7425 Plum Creek Drive, Lincoln, Nebraska 68516,
(US)

Swearingin, Leroy Allen, 653 Vauxhall Street Extension, Waterford,
Connecticut 06385, (US)

LEGAL REPRESENTATIVE:

Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 30
Welbeck Street, London W1G 8ER, (GB)

PATENT (CC, No, Kind, Date): EP 1027895 A2 000816 (Basic)
EP 1027895 A3 010718

APPLICATION (CC, No, Date): EP 99309202 991118;

PRIORITY (CC, No, Date): US 117704 P 990129

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: A61K-039/08; A61K-039/39

ABSTRACT EP 1027895 A2

The invention relates to *stabilized*** antigen compositions of
Erysipelothrix *rhusiopathiae*** and vaccine formulations containing such
antigen compositions. Antigens of the invention are effective in
providing long-term protection against erysipelas in animals.

ABSTRACT WORD COUNT: 32

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200033	236
SPEC A	(English)	200033	7050
Total word count - document A			7286
Total word count - document B			0
Total word count - documents A + B			7286

5/3,AB/5 (Item 4 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

01159829

PREVENTIVES/REMEDIES FOR INFECTION, ANTI-ENDOTOXIN AGENTS, VACCINE
ADJUVANTS AND GROWTH PROMOTERS

PRAVENTIVA/MITTEL FUR INFEKTION, ANTI-ENDOTOXIN MITTEL, IMPFSTOFF-ADJUVANZI
EN SOWIE WACHSTUMSPROMOTOREN

PROPHYLACTIQUES/MEDICAMENTS POUR L'INFECTION, AGENTS ANTI-ENDOTOXINE,
ADJUVANTS DE VACCIN ET PROMOTEURS DE CROISSANCE

PATENT ASSIGNEE:

Shin Mitsui Sugar Co., Ltd., (1427013), 8-2, Nihonbashi Honcho 2-chome,
Chuo-ku, Tokyo 103-8423, (JP), (Applicant designated States: all)

INVENTOR:

MIZUTANI, Takeo, 1194-33, Hazawa-cho, Kanagawa-ku, Yokohama-shi, Kanagawa
221-0863, (JP)

KOGE, Kenji, 12-9-201, Dai 4-chome, Kamakura-shi, Kanagawa 247-0061, (JP)

NAGAI, Yukie, 5-44, Enzo 1-chome, Chigasaki-shi, Kanagawa 253-0084, (JP)

MURAKAMI, Hiroshi, 5-1-305, Kobukuroya 2-chome, Kamakura-shi, Kanagawa
247-0055, (JP)

KAWAI, Toshikazu, 5-1-304, Kobukuroya 2-chome, Kamakura-shi, Kanagawa
247-0055, (JP)

KASHIMURA, Jun, 22-3, Shinkamata 2-chome, Ota-ku, Tokyo 144-0054, (JP)

09/489711

SHIMIZU, Takeo, Fujinodai-danchi 2-27-501, 3549-3, Honmachida,
Machida-shi, Tokyo 194-0032, (JP)
ARAKI, Seiichi, 1-35, Nagakunidai, Tsuchiura-shi, Ibaraki 300-0810, (JP)
SUZUKI, Mamoru, 30-2-A101, Matsushiro 1-chome, Tsukuba-shi, Ibaraki
305-0035, (JP)

LEGAL REPRESENTATIVE:

Prins, Adrianus Willem et al (20903), Vereenigde, Nieuwe Parklaan 97,
2587 BN Den Haag, (NL)

PATENT (CC, No, Kind, Date): EP 1120118 A1 010801 (Basic)
WO 200021546 000420

APPLICATION (CC, No, Date): EP 99970325 991008; WO 99JP5583 991008

PRIORITY (CC, No, Date): JP 98301745 981009; JP 9935047 990212

DESIGNATED STATES: DE; ES; FR; GB; IT; NL

INTERNATIONAL PATENT CLASS: A61K-035/78; A61K-039/39; A23L-001/214;
A23L-001/30; A23K-001/16

ABSTRACT EP 1120118 A1

A preventive or remedy for infection, an anti-endotoxin agents, a
vaccine adjuvants and a growth promoter each comprising a sugar
cane-derived extract as an active ingredient which agent is safe to man
and animals . Also presented are foods and feeds comprising these agents.

ABSTRACT WORD COUNT: 45

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; Japanese

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200131	1674
SPEC A	(English)	200131	13040
Total word count - document A			14714
Total word count - document B			0
Total word count - documents A + B			14714

5/3,AB/6 (Item 5 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

01148679

Outer membrane proteins from actinobacillus pleuropneumoniae
Hauptproteine der Aussenmembran von actinobacillus pleuropneumoniae
Proteines principales de la membrane externe de actinobacillus
pleuropneumoniae

PATENT ASSIGNEE:

Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut
06340, (US), (Applicant designated States: all)

INVENTOR:

Ankenbauer, Robert Gerard, Pfizer Inc., Central Research Division,
Eastern Point Road, Groton, Connecticut 06340, (US)
Baarsch, Mary Jo, Pfizer Inc., Central Research Division, Eastern Point
Road, Groton, Connecticut 06340, (US)
Campos, Manuel, Pfizer Inc., Central Research Division, Eastern Point
Road, Groton, Connecticut 06340, (US)
Keich, Robin Lee, Pfizer Inc., Central Research Division, Eastern Point
Road, Groton, Connecticut 06340, (US)
Rosey, Everett Lee, Pfizer Inc., Central Research Division, Eastern Point
Road, Groton, Connecticut 06340, (US)

09/489711

Warren-Stewart, Lynn Marie, Pfizer Inc., Central Research Division,
Eastern Point Road, Groton, Connecticut 06340, (US)
Suiter, Brian Thomas, Pfizer Inc., Central Research Division, Eastern
Point Road, Groton, Connecticut 06340, (US)

LEGAL REPRESENTATIVE:

Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 91
Wimpole Street, London W1M 8AH, (GB)

PATENT (CC, No, Kind, Date): EP 1001025 A2 000517 (Basic)

APPLICATION (CC, No, Date): EP 99308262 991020;

PRIORITY (CC, No, Date): US 105285 981022

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: C12N-015/12; C12N-015/62; C07K-014/285;
A61K-039/07; G01N-033/68

ABSTRACT EP 1001025 A2

The present invention is directed to five novel, low molecular weight
proteins from Actinobacillus pleuropneumoniae (APP), which are capable of
inducing, or contributing to the induction of, a protective immune
response in swine against APP. The present invention is further directed
to polynucleotide molecules having nucleotide sequences that encode the
proteins, as well as vaccines comprising the proteins or polynucleotide
molecules, and methods of making and using the same.

ABSTRACT WORD COUNT: 70

NOTE:

Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200020	3435
SPEC A	(English)	200020	24943
Total word count - document A			28378
Total word count - document B			0
Total word count - documents A + B			28378

5/3,AB/7 (Item 6 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00985690

Clostridium perfringens vaccine

Clostridium perfringens Impfstoff

Vaccine contre clostridium perfringens

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),

(applicant designated states:

AT;BE;CH;CY;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

Sergers, Ruud Philip Antoon Maria, Groenling 3, 5831 MZ Boxmeer, (NL)

Waterfield, Nicolas Robin, 20 Lucerne Close, Cherry Hinton, Cambridge CB1
4YR, (GB)

Frandsen, Peer Lyng, 56 Borgmester Schneiders Vej, 2840 Holte, (DK)

Wells, Jeremy Mark, The Cottage Old House RD, Balsham, Cambridge CB1 GEF,
(GB)

LEGAL REPRESENTATIVE:

Searcher : Shears 308-4994

09/489711

Ogilvie-Emanuelson, Claudia Maria et al (80441), Patent Department Pharma
N.V. Organon P.O. Box 20, 5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 892054 A1 990120 (Basic)
APPLICATION (CC, No, Date): EP 98202032 980617;
PRIORITY (CC, No, Date): EP 97201888 970620
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/31; A61K-039/08; C07K-014/33;
C12N-001/21;

ABSTRACT EP 892054 A1

The present invention relates to detoxified immunogenic derivatives of Clostridium perfringens (beta)-toxin or an immunogenic fragment thereof that have as a characteristic that they carry a mutation in the (beta)-toxin amino acid sequence, not found in the wild-type (beta)-toxin amino acid sequence. The invention also relates to genes encoding such (beta)-toxins, as well as to expression systems expressing such (beta)-toxins. Moreover, the invention relates to bacterial expression systems expressing a native (beta)-toxin. Finally, the invention relates to vaccines based upon detoxified immunogenic derivatives of Clostridium perfringens (beta)-toxin, and methods for the preparation of such vaccines.

ABSTRACT WORD COUNT: 96

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9903	583
SPEC A	(English)	9903	7428
Total word count - document A			8011
Total word count - document B			0
Total word count - documents A + B			8011

5/3,AB/8 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00964612

Live attenuated bacteria of the species Actinobacillus pleuropneumoniae
Lebende attenuierte Bakterien der Spezies Actinobacillus pleuropneumoniae
Bacteries atteneues vivantes de l'espece Actinobacillus pleuropneumoniae
PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),
(Applicant designated States: all)

INVENTOR:

Segers, Ruud, P.A.M., Groenling 3, 5831 MZ Boxmeer, (NL)
Frey, Joachim, Hoheweg 53, 3054 Schupfen, (CH)

LEGAL REPRESENTATIVE:

Mestrom, Joannes Jozef Louis et al (74851), P.O. Box 20, 5340 BH Oss,
(NL)

PATENT (CC, No, Kind, Date): EP 875574 A2 981104 (Basic)
EP 875574 A3 000322

APPLICATION (CC, No, Date): EP 98201115 980408;

PRIORITY (CC, No, Date): EP 97201032 970410

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

09/489711

INTERNATIONAL PATENT CLASS: C12N-015/31; A61K-039/102; A61K-039/295;
G01N-033/569; G01N-033/68; C12N-001/20; C12N-001/21

ABSTRACT EP 875574 A2

The present invention relates to live attenuated bacteria of the genus *Actinobacillus pleuropneumoniae* that have a mutation in an *apxIV* gene such that no functional *ApxIV* toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an *ApxIV* toxin, to methods for the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus *Actinobacillus pleuropneumoniae*. In addition, the invention relates to the promoter of the *apxIV* gene. Finally, the invention relates to diagnostic tests for the selective diagnosis of *Actinobacillus pleuropneumoniae* infections and to diagnostic tests discriminating between *Actinobacillus pleuropneumoniae* field strains and vaccine strains.

ABSTRACT WORD COUNT: 137

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9845	580
SPEC A	(English)	9845	8249
Total word count - document A			8829
Total word count - document B			0
Total word count - documents A + B			8829

5/3,AB/9 (Item 8 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00916244

European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)

Europäische Vakzinastämme des Fortpflanzungs-Atmungs-Syndromsvirus des Schweins (PRRSV)

Souches vaccinales Européennes du virus du syndrome respiratoire reproducteur porcin (PRRSV)

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),
(Proprietor designated states: all)

INVENTOR:

van Woensel, Petrus A.M., Krekelzanger 49, 5831 NL Boxmeer, (NL)
Demaret, Jean G.J., Spoorstraat 7, 5831 CH Boxmeer, (NL)

LEGAL REPRESENTATIVE:

Mestrom, Joannes Jozef Louis et al (74855), N.V. Organon, Postbus 20,
5340 BH Oss, (NL)

PATENT (CC, No, Kind, Date): EP 835930 A1 980415 (Basic)
EP 835930 B1 010131

APPLICATION (CC, No, Date): EP 97203111 971007;

PRIORITY (CC, No, Date): EP 96202804 961009

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU;
MC; NL; PT; SE

09/489711

INTERNATIONAL PATENT CLASS: C12N-007/00; A61K-039/12; A61K-039/295

ABSTRACT EP 835930 A1

The present invention is concerned with European strains of the Porcine Reproductive Respiratory Syndrome (PRRS) virus, having as a unique feature that they are non-infectious to macrophages, and to methods for the production of such strains. The invention also provides vaccines for the protection of pigs against PRRS, based on these strains, as well as methods for the production of such vaccines.

ABSTRACT WORD COUNT: 63

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200105	365
CLAIMS B	(German)	200105	377
CLAIMS B	(French)	200105	404
SPEC B	(English)	200105	4570
Total word count - document A			0
Total word count - document B			5716
Total word count - documents A + B			5716

5/3,AB/10 (Item 9 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00885807

Live attenuated RTX-producing bacteria of the family Pasteurellaceae
Lebende attenuierte RTX-produzierende Bakterien aus der Familie
pasteurellaceae

Bacteries vivantes atténuees de la Famille Pasteurellaceae produisant des
RTX

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),
(applicant designated states:
AT;BE;CH;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

Segers, Ruud Philip Antoon Maria, Groenling 3, 5831 MZ Boxmeer, (NL)
van den Bosch, Johannes Franciscus, Spoorstraat 9, 5831 CH Boxmeer, (NL)
Frey, Joachim, Hoheweg 53, 3054 Schupfen, (CH)

LEGAL REPRESENTATIVE:

Mestrom, Joannes Jozef Louis et al (74855), N.V. Organon, Postbus 20,
5340 BH Oss, (NL)

PATENT (CC, No, Kind, Date): EP 810283 A2 971203 (Basic)
EP 810283 A3 971210

APPLICATION (CC, No, Date): EP 97201613 970530;

PRIORITY (CC, No, Date): EP 96201557 960531

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU;
MC; NL; PT; SE

INTERNATIONAL PATENT CLASS: C12N-001/21;

ABSTRACT EP 810283 A3

The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family

09/489711

Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.

ABSTRACT WORD COUNT: 67

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9711W4	477
SPEC A	(English)	9711W4	6497
Total word count - document A			6974
Total word count - document B			0
Total word count - documents A + B			6974

5/3,AB/11 (Item 10 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00786496

T CELL STIMULATING PROTEIN OF PESTIVIRUS

T-ZELLEN STIMULIERENDES PROTEIN VON PESTIVIRUS

PROTEINE DE VIRUS DE LA PESTE STIMULANT LES CELLULES T

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),

(Proprietor designated states: all)

INVENTOR:

THIEL, Heinz-Jurgen, Sandfeld 15, D-35396 Giessen, (DE)

ELBERS, Knut, Gosstrasse 33, D-72070 Tubingen, (DE)

PAULY, Thomas, Vischerstrasse 18, D-72072 Tubingen, (DE)

LEGAL REPRESENTATIVE:

Mestrom, Joannes Jozef Louis (74851), P.O. Box 20, 5340 BH Oss, (NL)

PATENT (CC, No, Kind, Date): EP 772632 A2 970514 (Basic)

EP 772632 B1 011004

WO 9619498 960627

APPLICATION (CC, No, Date): EP 95943175 951220; WO 95EP5066 951220

PRIORITY (CC, No, Date): EP 94203696 941220

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;

NL; PT; SE

INTERNATIONAL PATENT CLASS: C12N-015/40; C07K-014/185; A61K-039/187

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200140	105
CLAIMS B	(German)	200140	109
CLAIMS B	(French)	200140	130
SPEC B	(English)	200140	7627
Total word count - document A			0
Total word count - document B			7971
Total word count - documents A + B			7971

5/3,AB/12 (Item 11 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00742869

09/489711

RECOMBINANT PRRS PROTEINS, DIAGNOSTIC KITS AND VACCINES CONTAINING SAID
RECOMBINANT PROTEINS

Recombinante PRRS Viren -Proteine und dieselben Diagnosesätze und
Impfstoffe enthaltenden

PROTEINES RECOMBINANTES DU PRRSV, KITS DE DIAGNOSTIC ET VACCINS CONTENANT
LES DITES PROTEINES RECOMBINANTES

PATENT ASSIGNEE:

CYANAMID IBERICA, SA, (1998690), Cristobal Bordiu, 35, E-28003 Madrid,

(ES), (applicant designated states:

AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE)

INVENTOR:

PLANA DURAN, Juan, Carretera Camprodon, "La Riba", E-17813 Vall de Bianya
, (ES)

CASAL ALVAREZ, Jose Ignacio, Hermanos Garcia Noblejas, 41-2, E-28037
Madrid, (ES)

CLIMENT SANCHEZ, Isabel, Carretera Camprodon, "La Riba", E-17813 Vall de
Bianya, (ES)

LEGAL REPRESENTATIVE:

Walters, Philip Bernard William (73282), Wyeth Laboratories, Patents &
Trade Marks Department, Huntercombe Lane South, Taplow, Maidenhead,
Berkshire SL6 0PH, (GB)

PATENT (CC, No, Kind, Date): EP 717108 A1 960619 (Basic)

WO 9531550 951123

APPLICATION (CC, No, Date): EP 95917990 950510; WO 95ES53 950510

PRIORITY (CC, No, Date): ES 94102 940513; ES 9581 950427

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL;
PT; SE

INTERNATIONAL PATENT CLASS: C12N-015/40; C07K-014/08; C12N-007/01;

A61K-039/12; G01N-033/569;

ABSTRACT EP 717108 A1

The present invention discloses the production of recombinant proteins
of the virus causing the porcine respiratory and reproductive syndrome
(PRRS), corresponding to the ORFs 2-7 of the PRRSV isolated in Spain,
(PRRS-Olot), in a system of expression of recombinant baculoviruses
multiplied in a cell culture of a permissive host. Said recombinant
proteins are appropriate to formulate vaccines capable of efficiently
protecting pigs against PRRS as well as to prepare diagnostic kits
appropriate to detect both the presence of antibodies which recognize
PRRSV and the presence of PRRSV in a porcine biological sample. This
invention applies to veterinary.

ABSTRACT WORD COUNT: 108

LANGUAGE (Publication, Procedural, Application): English; English; Spanish

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
----------------	----------	--------	------------

CLAIMS A	(English)	EPAB96	1498
----------	-----------	--------	------

SPEC A	(English)	EPAB96	11142
--------	-----------	--------	-------

Total word count - document A	12640
-------------------------------	-------

Total word count - document B	0
-------------------------------	---

Total word count - documents A + B	12640
------------------------------------	-------

5/3, AB/13 (Item 12 from file: 348)

DIALOG(R) File 348: EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00714272

09/489711

European vaccine strains of the porcine reproductive respiratory syndrome virus (PRRSV)

Europäische Vakzinstämme des Fortpflanzungs-Atmungs-Syndromsvirus des Schweins

Souches vaccinales Européennes du virus du syndrome respiratoire reproducteur porcin (PRRSV)

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),

(Proprietor designated states: all)

INVENTOR:

Visser, Nicolaas, De Sering 26, NL-5831 RV Boxmeer, (NL)

van Woensel, Petrus Alphonsus Maria, Krekelzanger 49, NL-5831 NL Boxmeer, (NL)

Ohlinger, Volker, Pieperfeldweg 131, D-48239 Havixbeck, (DE)

Weiland, Emilie, Panoramastrasse 15, D-72119 Ammerbuch, (DE)

LEGAL REPRESENTATIVE:

Mestrom, Joannes Jozef Louis et al (74853), Akzo Nobel Pharma B.V.,

Postbus 20, 5340 BH Oss, (NL)

PATENT (CC, No, Kind, Date): EP 676467 A2 951011 (Basic)

EP 676467 A3 990929

EP 676467 B1 011004

APPLICATION (CC, No, Date): EP 95200877 950407;

PRIORITY (CC, No, Date): EP 94200964 940411

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE

INTERNATIONAL PATENT CLASS: C12N-007/00; A61K-039/12; C07K-016/10

ABSTRACT EP 676467 A2

The present invention is concerned with European strains of the Porcine Reproductive Respiratory Syndrome (PRRS) virus, which are attenuated, and show a characteristic reaction pattern with two monoclonal antibodies against wild-type PRRSV.

The invention also relates to vaccines for the protection of pigs against PRRS, to monoclonal antibodies reactive with PRRS virus and monoclonal antibodies specifically non-reactive with the attenuated strains.

ABSTRACT WORD COUNT: 63

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200140	295
CLAIMS B	(German)	200140	310
CLAIMS B	(French)	200140	309
SPEC B	(English)	200140	4299
Total word count - document A			0
Total word count - document B			5213
Total word count - documents A + B			5213

5/3,AB/14 (Item 13 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00681732

PASTEURILLA MULTOCIDA TOXOID VACCINES

09/489711

PASTEURELLA MULTOCIDA TOXOID ENTHALTENDE IMPFSTOFFE
VACCINS CONTRE L'ANATOXINE PASTEURELLA MULTOCIDA
PATENT ASSIGNEE:

PFIZER INC., (200962); 235 East 42nd Street, New York, N.Y. 10017-5755,
(US), (Proprietor designated states: all)

INVENTOR:

FRANTZ, Joseph, C., 3027 Browning Road, Lincoln, NB 68506, (US)
ROBERTS, David, S., 6420 Meeker Circle, Lincoln, NB 68506, (US)
SWEARINGIN, Leroy, A., 934 South 33rd, Lincoln, NB 68510, (US)
KEMMY, Richard, J., 437 Brentwood Drive, Gretna, NB 68028, (US)

LEGAL REPRESENTATIVE:

Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 91
Wimpole Street, London W1M 8AH, (GB)

PATENT (CC, No, Kind, Date): EP 651609 A1 950510 (Basic)
EP 651609 B1 990811
WO 9119419 911226

APPLICATION (CC, No, Date): EP 91913518 910610; WO 91US4092 910610

PRIORITY (CC, No, Date): US 537454 900613

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C07K-014/285; A61K-039/102; A61K-039/116

NOTE:

No A-document published by EPO

LANGUAGE (Publication, Procedural, Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9932	1426
CLAIMS B	(German)	9932	1278
CLAIMS B	(French)	9932	1472
SPEC B	(English)	9932	8885
Total word count - document A			0
Total word count - document B			13061
Total word count - documents A + B			13061

5/3,AB/15 (Item 14 from file: 348)

DIALOG(R) File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00649588

Vaccine against Streptococcus suis infection

Impstoff gegen Streptococcus suis-Infektion

Vaccin contre une infection par streptococcus suis

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),
(Proprietor designated states: all)

INVENTOR:

Jacobs, Antonius Arnoldus Christiaan, Ondersteweg 2, NL-5995 PS Kessel,
(NL)

LEGAL REPRESENTATIVE:

Mestrom, Joannes Jozef Louis et al (74851), P.O. Box 20, 5340 BH Oss,
(NL)

PATENT (CC, No, Kind, Date): EP 626452 A1 941130 (Basic)
EP 626452 B1 990811

APPLICATION (CC, No, Date): EP 94201295 940509;

PRIORITY (CC, No, Date): EP 93201401 930517

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; PT; SE

INTERNATIONAL PATENT CLASS: C12P-021/02; C07K-014/315; A61K-039/09

09/489711

ABSTRACT EP 626452 A1

The present invention relates to a polypeptide of the bacterium *Streptococcus suis* with a molecular weight of about 54 kD, capable of inducing neutralising antibodies against *Streptococcus suis*. The invention also relates to a vaccine against *Streptococcus suis* infection, and a method for the preparation of such a vaccine.

ABSTRACT WORD COUNT: 51

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9932	258
CLAIMS B	(German)	9932	251
CLAIMS B	(French)	9932	288
SPEC B	(English)	9932	6142
Total word count - document A			0
Total word count - document B			6939
Total word count - documents A + B			6939

5/3,AB/16 (Item 15 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00625751

PORCINE REPRODUCTIVE RESPIRATORY SYNDROME (PRRS) VACCINE AND DIAGNOSTIC.
Impfstoff gegen das Fortpflanzungs- und Atmungssyndrom bei Schweinen (PRRS) und Diagnose.

VACCIN CONTRE LE SYNDROME RESPIRATOIRE REPRODUCTIF PORCIN (PRRS).

PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, NL-6824 BM Arnhem, (NL),
(applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;SE)

INVENTOR:

VISSER, Nicolaas, De Sering 26, NL-5831 RV Boxmeer, (NL)

OHLINGER, Volker, Hagellocher Weg 38/1, D-7400 Tübingen, (DE)

LEGAL REPRESENTATIVE:

Mestrom, Joannes Jozef Louis et al (74851), P.O. Box 20, NL-5340 BH Oss,
(NL)

PATENT (CC, No, Kind, Date): EP 610250 A1 940817 (Basic)

EP 610250 B1 951206

WO 9307898 930429

APPLICATION (CC, No, Date): EP 92920950 921009; WO 92EP2331 921009

PRIORITY (CC, No, Date): EP 91202646 911014

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/12; G01N-033/569; C12N-007/00;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB95	2393
CLAIMS B	(German)	EPAB95	2737
CLAIMS B	(French)	EPAB95	1856
SPEC B	(English)	EPAB95	6408

09/489711

Total word count - document A 0
Total word count - document B 13394
Total word count - documents A + B 13394

5/3,AB/17 (Item 16 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00577676

SWINE PNEUMONIA VACCINE AND METHOD FOR THE PREPARATION THEREOF
IMPFSTOFF GEGEN DIE PNEUMONIE BEI SCHWEINEN UND VERFAHREN ZU SEINER
HERSTELLUNG

VACCIN CONTRE LA PNEUMONIE PORCINE ET PROCEDE DE PREPARATION DUDIT VACCIN
PATENT ASSIGNEE:

AMERICAN CYANAMID COMPANY, (212593), Five Giralda Farms, Madison, New
Jersey 07940, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

DAYALU, Krishnaswamy, I., 2336 S. 75th Street, Lincoln, NB 68506, (US)
PEETZ, Richard, H., 3818 Dudley Street, Lincoln, NB 68503, (US)
FRANTZ, Joseph, C., 3027 Browning, Lincoln, NB 68516, (US)
ROBERTS, David, S., 6420 Meeker Circle, Lincoln, NB 68506, (US)
SWEARINGIN, Leroy, A., 934 South 33rd, Lincoln, NB 68510, (US)
KEMMY, Richard, J., 437 Brentwood Drive, Gretna, NB 68028, (US)

LEGAL REPRESENTATIVE:

VOSSIUS & PARTNER (100311), Postfach 86 07 67, 81634 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 597852 A1 940525 (Basic)
EP 597852 B1 971203
WO 9118627 911212

APPLICATION (CC, No, Date): EP 91911598 910524; WO 91US3689 910524
PRIORITY (CC, No, Date): US 530669 900529; US 575921 900831; US 634237
901226

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/02;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9711W4	1245
CLAIMS B	(German)	9711W4	1213
CLAIMS B	(French)	9711W4	1432
SPEC B	(English)	9711W4	4869

Total word count - document A 0
Total word count - document B 8759
Total word count - documents A + B 8759

5/3,AB/18 (Item 17 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00476975

Actinobacillus pleuropneumoniae subunit vaccine.
Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae.
Vaccin de sous-unites d'actinobacillus pleuropneumoniae.
PATENT ASSIGNEE:

09/489711

Akzo Nobel N.V., (200754), Velperweg 76, NL-6824 BM Arnhem, (NL),
(applicant designated states: BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;NL;SE)

INVENTOR:

van den Bosch, Johannes Franciscus, Spoorstraat 9, NL-5831 CH Boxmeer,
(NL)

LEGAL REPRESENTATIVE:

Hermans, Franciscus G.M. et al (20111), Patent Department AKZO NOBEL N.V.
Pharma Division P.O. Box 20, NL-5340 BH Oss, (NL)

PATENT (CC, No, Kind, Date): EP 453024 A1 911023 (Basic)
EP 453024 B1 950531

APPLICATION (CC, No, Date): EP 91200849 910411;

PRIORITY (CC, No, Date): EP 90200989 900420

DESIGNATED STATES: BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/102;

ABSTRACT EP 453024 A1

The present invention is concerned with vaccines effective in
protecting pigs against porcine pleuropneumonia. Said vaccines comprising
a hemolysin and/or macrophage toxin and a 42 kD OMP preparation derived
from Actinobacillus pleuropneumoniae (App) cells induce a complete and
heterologous protection against App infection.

ABSTRACT WORD COUNT: 45

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	343
CLAIMS B	(English)	EPAB95	695
CLAIMS B	(German)	EPAB95	693
CLAIMS B	(French)	EPAB95	827
SPEC A	(English)	EPABF1	7944
SPEC B	(English)	EPAB95	7993
Total word count - document A			8288
Total word count - document B			10208
Total word count - documents A + B			18496

5/3,AB/19 (Item 18 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00361231

Preparation of a recombinant subunit vaccine against pseudorabies
infection.

Verfahren zur Herstellung von Rekombinat-Impfstoffen gegen Pseudorabische
Infektionen.

Preparation d'un vaccin recombinant contre les infections pseudorabiques.

PATENT ASSIGNEE:

SMITHKLINE BECKMAN CORPORATION, (201242), One Franklin Plaza P O Box 7929
, Philadelphia Pennsylvania 19103, (US), (applicant designated states:
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Jones, Elaine Verne, 1217 Andover Road Green Hill Farms, Wynnwood, PA
19151, (US)

Mellencamp, Mark William, 5394 Leafback Drive, West Chester, OH 45069,
(US)

Miller, Timothy Joe, 102 Crestside Way, Malvern, PA 19355, (US)

LEGAL REPRESENTATIVE:

09/489711

Wood, David John et al (37881), PFIZER LIMITED, Ramsgate Road, Sandwich,
Kent CT13 9NJ, (GB)

PATENT (CC, No, Kind, Date): EP 327305 A2 890809 (Basic)
EP 327305 A3 901205

APPLICATION (CC, No, Date): EP 89300913 890131;

PRIORITY (CC, No, Date): US 151736 880203

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/245; A61K-039/225; C12N-015/38;

ABSTRACT EP 327305 A2

A method of preparation of a vaccine for use in immunizing animals
against pseudorabies virus (PRV) infection which comprises inactivated
recombinant PRV subunit antigens. Also described is a diagnostic kit for
detection of PRV infection which distinguishes vaccinated animals from
naturally exposed animals.

ABSTRACT WORD COUNT: 47

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1277
SPEC A	(English)	EPABF1	9456
Total word count - document A			10733
Total word count - document B			0
Total word count - documents A + B			10733

Set	Items	Description
S6	4818	LECITHIN AND OIL? ?
S7	282	S6 AND (AMPHIPHIL?(3N) (SURFACTANT? ? OR SURFACE(W)ACTIVE) -
		OR (TWEEN OR SPAN) (W)80)
S8	4	S7 AND RHUSIOPATH?
S9	182	S3 AND S7
S10	156	S9 AND (ANTIGEN? ? OR FILTRATE? ? OR SUPERNATANT? ? OR PRO-
		TEIN? ? OR POLYPROTEIN? ? OR POLYPEPTIDE? ? OR PEPTIDE? ? OR -
		CARBOHYDRATE? ? OR POLYSACCHARIDE? ? OR POLY(W)SACCHARIDE? ?)
S11	108	S9 AND (GLYCOPROTEIN? ? OR (GLYCO OR LIPO) (W)PROTEIN? ? OR
		LIPOPROTEIN? ? OR LIPID? ?)
S12	76	(S10 OR S11) AND (ADJUVANT? ? OR VACCIN? OR IMMUNIS? OR IM-
		MUNIS?)

S15 20 S12/TI, DE, MAJ

S17 16 (S8 OR S15) NOT S4

S18 16 RD (unique items)

>>>No matching display code(s) found in file(s): 65, 113

18/3,AB/1 (Item 1 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

01088669

Methods of increasing lean tissue mass using ob *protein*** compositions
Verfahren zur Erhogung der mageren Fleischmasse mit
*Fettleibigkeitsprotein*** (OB) Zusammensetzungen
Procedes permettant d'accroitre la masse tissulaire maigre a l'aide de
compositions a base de *proteine*** ob

PATENT ASSIGNEE:

AMGEN INC., (923234), 1840 DeHavilland Drive, Thousand Oaks California

Searcher : Shears 308-4994

09/489711

91320 -1789, (US), (Applicant designated States: all)

INVENTOR:

Pelleymounter, Mary Ann, 3806 Fallon Circle, San Diego, CA 92130-1867,
(US)

Toombs, Christopher Francis, 5076 Ladera Vista Drive, Camarillo, CA 93012
, (US)

Mann, Michael Benjamin, 1506 Rugby Circle, Thousand Oaks, CA 91360, (US)

LEGAL REPRESENTATIVE:

Brown, John David et al (28811), FORRESTER & BOEHMERT

Franz-Joseph-Strasse 38, 80801 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 956862 A1 991117 (Basic)

APPLICATION (CC, No, Date): EP 98119160 961104;

PRIORITY (CC, No, Date): US 561732 951122

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU;
MC; NL; PT; SE

EXTENDED DESIGNATED STATES: AL; LT; LV; RO; SI

RELATED PARENT NUMBER(S) - PN (AN):

EP 866720 (EP 96938773)

INTERNATIONAL PATENT CLASS: A61K-038/22; C07K-014/575

ABSTRACT EP 956862 A1

Methods of using OB protein compositions for increasing lean tissue mass are provided. Also provided are methods of using OB protein compositions for increasing insulin sensitivity, as well as increasing overall body strength and decreasing bone resorption. Furthermore fusion proteins comprising a Fc protein and an OB protein are provided.

ABSTRACT WORD COUNT: 51

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9946	460
SPEC A	(English)	9946	9623
Total word count - document A			10083
Total word count - document B			0
Total word count - documents A + B			10083

18/3,AB/2 (Item 2 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

01085200

Polynucleotide molecules encoding neospora *proteins***

Fur Neospora *Proteine*** kodierende polynukleotid Molekule

Molecules nucleotidiques encodant des proteines de Neospora

PATENT ASSIGNEE:

Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut
06340, (US), (Applicant designated States: all)

INVENTOR:

Brake, David Alan, 196 Upper Plattagansett Road, East Lyme, Connecticut
06333, (US)

Madura (nee Coleman), Rebecca Anne, 43 Beach Street, Westerly, Rhode
Island 02891, (US)

Durtschi, Becky Ann, 4 Barton Lane, Ledyard, Connecticut 06339, (US)

Krishnan, Balakrishnan Rajendra, 81 Charter Oak Drive, East Lyme,
Connecticut 06333, (US)

Yoder, Susan Christine, 163 Music Vale Road, Salem, Connecticut 06340,

09/489711

(US)

LEGAL REPRESENTATIVE:

Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH, (GB)
PATENT (CC, No, Kind, Date): EP 953641 A2 991103 (Basic)
APPLICATION (CC, No, Date): EP 99301746 990309;
PRIORITY (CC, No, Date): US 79389 980326; US 112282 981215
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C12N-015/30; C07K-014/44; C07K-016/20; C12N-005/16; A61K-039/002

ABSTRACT EP 953641 A2

The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1/MAG1 promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.

ABSTRACT WORD COUNT: 85

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9944	1947
SPEC A	(English)	9944	21082
Total word count - document A			23029
Total word count - document B			0
Total word count - documents A + B			23029

18/3,AB/3 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00995337

Neospora *vaccine**

Neospora Impstoff

*Vaccin** Neospora

PATENT ASSIGNEE:

Pfizer Products Inc., (2434220), Eastern Point Road, Groton, CT 06340-5146, (US), (Applicant designated States: all)

INVENTOR:

Brake, David Alan, 196 Upper Pattagansett Road, East Lyme, Connecticut 06333, (US)

Campos, Manuel, 106 Stonybrook Road, Stonington, Connecticut 06378, (US)

LEGAL REPRESENTATIVE:

Hayles, James Richard et al (75142), Pfizer Limited, Patents Department, Ramsgate Road, Sandwich Kent CT13 9NJ, (GB)
PATENT (CC, No, Kind, Date): EP 898969 A2 990303 (Basic)
EP 898969 A3 010207
APPLICATION (CC, No, Date): EP 98306431 980812;
PRIORITY (CC, No, Date): US 56956 970826

09/489711

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61K-039/002; A61K-039/002; A61K-39:02;
A61K-039/002; A61K-39:12

ABSTRACT EP 898969 A2

The present invention provides an homogenate prepared from cells of
Neospora, and vaccines against neosporosis prepared therefrom which are
useful in the prevention of clinical disease and abortion in mammals.

ABSTRACT WORD COUNT: 31

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9909	766
SPEC A	(English)	9909	8302
Total word count - document A			9068
Total word count - document B			0
Total word count - documents A + B			9068

18/3,AB/4 (Item 4 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00958718

*Vaccines***

Impfstoffe

*Vaccins***

PATENT ASSIGNEE:

SMITHKLINE BEECHAM BIOLOGICALS S.A., (1311860), 89 rue de l'Institut,
1330 Rixensart, (BE), (Applicant designated States: all)

INVENTOR:

Momin, Patricia Marie, Smithkline Beecham Biologicals s.a., 89, Rue de l'
, Institut, 1330 Rixensart, (BE)
Garcon, Marie-Josephe, Smithkline Beecham Biologicals s.a., 89, Rue de l'
, Institut, 1330 Rixensart, (BE)

LEGAL REPRESENTATIVE:

Dalton, Marcus Jonathan William (60102), SmithKline Beecham plc Corporate
Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8
9EP, (GB)

PATENT (CC, No, Kind, Date): EP 868918 A2 981007 (Basic)
EP 868918 A3 000426

APPLICATION (CC, No, Date): EP 98201308 941220;

PRIORITY (CC, No, Date): GB 9326253 931223

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; PT; SE

EXTENDED DESIGNATED STATES: SI

RELATED PARENT NUMBER(S) - PN (AN):

EP 735898 (EP 95904511)

INTERNATIONAL PATENT CLASS: A61K-039/39

ABSTRACT EP 868918 A2

The present invention provides vaccine compositions comprising an
oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl

09/489711

lipid A and QS21. The vaccines compositions are potent inducers of a range of immune responses.

ABSTRACT WORD COUNT: 32

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9841	346
SPEC A	(English)	9841	3629
Total word count - document A			3975
Total word count - document B			0
Total word count - documents A + B			3975

18/3,AB/5 (Item 5 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00938127

FUNGAL *ANTIGENS*** AND PROCESS FOR PRODUCING THE SAME

PILZLICHE *ANTIGENE*** UND VERFAHREN ZU DEREN HERSTELLUNG

ANTIGENES FONGIQUES ET PROCESSUS DE FABRICATION

PATENT ASSIGNEE:

TAKARA SHUZO CO. LTD., (710324), 609 Takenaka-cho Fushimi-ku, Kyoto-shi, Kyoto 612, (JP), (Applicant designated States: all)

INVENTOR:

TAKESAKO, Kazutoh, 4-20-208, Akibadai, Otsu-shi, Shiga 520, (JP)

MIZUTANI, Shigetoshi, 1-86, Miyazu, Azuchi-cho, Gamo-gun, Shiga 521-13, (JP)

ENDO, Masahiro, Hamoparesu-Kusatsu 405, 12-1, Nishishibukawa 2-chome, Kusatsu-shi, Shiga 525, (JP)

KATO, Ikunoshin, 1-1-150, Nanryo-cho, Uji-shi, Kyoto 611, (JP)

LEGAL REPRESENTATIVE:

VOSSIUS & PARTNER (100314), Siebertstrasse 4, 81675 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 970966 A1 000112 (Basic)

WO 9809990 980312

APPLICATION (CC, No, Date): EP 97937856 970829; WO 97JP3041 970829

PRIORITY (CC, No, Date): JP 96255400 960904; JP 9799775 970331

DESIGNATED STATES: DE; FR; GB; IT; NL

INTERNATIONAL PATENT CLASS: C07K-014/37; C12N-015/31; A61K-039/00;

A61K-039/35; C12N-015/31; C12R-1:725

ABSTRACT EP 970966 A1

There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.

ABSTRACT WORD COUNT: 85

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; Japanese

09/489711

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200002	1918
SPEC A	(English)	200002	22461
Total word count - document A			24379
Total word count - document B			0
Total word count - documents A + B			24379

18/3,AB/6 (Item 6 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00852251

*Vaccines*** and diagnostic assays for Haemophilus influenzae
Impfstoffe und Diagnostest für Haemophilus influenzae
*Vaccins*** et analyses diagnostiques pour l'haemophilus influenzae
PATENT ASSIGNEE:

PRAXIS BIOLOGICS, INC., (693522), 30 Corporate Woods, Rochester NY
14623-1493, (US), (applicant designated states:
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

Deich, Robert A., 10 Fallbrook Circle, Rochester, NY 14625, (US)
Green, Bruce, 49 Northfield Gate, Pittsford, NY 14534, (US)
Zlotnick, Gary, 17 Redwood Drive, Penfield, NY 14526, (US)

LEGAL REPRESENTATIVE:

Warcoin, Jacques (19071), Cabinet Regimbeau, 26, avenue Kleber, 75116
Paris, (FR)

PATENT (CC, No, Kind, Date): EP 786472 A1 970730 (Basic)

APPLICATION (CC, No, Date): EP 96119698 871223;

PRIORITY (CC, No, Date): US 948364 861231; US 20849 870302; US 132073
871211

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

RELATED PARENT NUMBER(S) - PN (AN):

EP 294469 (EP 889009270)

INTERNATIONAL PATENT CLASS: C07K-014/285; C07K-016/12; C12Q-001/68;
C12N-015/62;

ABSTRACT EP 786472 A1

Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of PBOMP-1 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passage immunization. Use of the nucleotide sequences encoding the PBOMP related peptides and proteins in hybridization assays is also described.

ABSTRACT WORD COUNT: 151

LANGUAGE (Publication,Procedural,Application): English; English; English

09/489711

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9707W5	762
SPEC A	(English)	9707W5	19520
Total word count - document A			20282
Total word count - document B			0
Total word count - documents A + B			20282

18/3,AB/7 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00802353

Mammalian *vaccines*** composition comprising squalene or squalane,
*phospholipid*** and a surfactant as *adjuvant***
Impfstoffzusammensetzung fur Saugetiere enthaltend Squalen oder Squalan,
*Phospholipid*** und ein Tensid als Adjuvans
Composition de *vaccin*** pour mammiferes comprenant du squalene ou du
squalane, des phospholipides et un agent tensio-actif comme
*adjuvant***

PATENT ASSIGNEE:

AMERICAN HOME PRODUCTS CORPORATION, (201462), Five Giralda Farms,
Madison, New Jersey 07940-0874, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Hjorth, Richard Norman, 570 West DeKalb Pike, no. 209, King of Prussia,
Pennsylvania 19406, (US)

LEGAL REPRESENTATIVE:

Walters, Philip Bernard William et al (73282), Wyeth Laboratories,
Patents & Trade Marks Department, Huntercombe Lane South, Taplow,
Maidenhead, Berkshire SL6 0PH, (GB)

PATENT (CC, No, Kind, Date): EP 745388 A1 961204 (Basic)

APPLICATION (CC, No, Date): EP 96303930 960531;

PRIORITY (CC, No, Date): US 459602 950602

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU;
NL; PT; SE

INTERNATIONAL PATENT CLASS: A61K-039/39;

ABSTRACT EP 745388 A1

The present invention discloses mammalian vaccine compositions having
an effective amount of an adjuvant, the adjuvant comprising squalene or
squalane, one or more phospholipids and a surfactant. These compositions
also optionally contain an aluminium salt and one or more
pharmaceutically acceptable buffers.

ABSTRACT WORD COUNT: 52

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB96	563
SPEC A	(English)	EPAB96	2591
Total word count - document A			3154
Total word count - document B			0
Total word count - documents A + B			3154

18/3,AB/8 (Item 8 from file: 348)

Searcher : Shears 308-4994

09/489711

DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00802307

*Adjuvants*** for viral *vaccines***
Adjuvans fur vitale Impfstoffe
*Adjuvants*** pour *vaccins*** viraux
PATENT ASSIGNEE:

AMERICAN HOME PRODUCTS CORPORATION, (201462), Five Giralda Farms,
Madison, New Jersey 07940-0874, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Hjorth, Richard Norman, 570 West DeKalb Pike, no. 209, King of Prussia,
Pennsylvania, 19406, (US)

LEGAL REPRESENTATIVE:

Walters, Philip Bernard William et al (73282), Wyeth Laboratories,
Patents & Trade Marks Department, Huntercombe Lane South, Taplow,
Maidenhead, Berkshire SL6 0PH, (GB)

PATENT (CC, No, Kind, Date): EP 745387 A2 961204 (Basic)
EP 745387 A3 980311

APPLICATION (CC, No, Date): EP 96303835 960529;

PRIORITY (CC, No, Date): US 459600 950602

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU;
NL; PT; SE

INTERNATIONAL PATENT CLASS: A61K-039/39;

ABSTRACT EP 745387 A2

The present invention discloses mammalian vaccine compositions having
an effective amount of an adjuvant, the adjuvant comprising squalene or
squalane, glycerol and a surfactant. These compositions also optionally
contain an aluminium salt and one or more pharmaceutically acceptable
buffers.

ABSTRACT WORD COUNT: 49

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB96	551
SPEC A	(English)	EPAB96	2667
Total word count - document A			3218
Total word count - document B			0
Total word count - documents A + B			3218

18/3,AB/9 (Item 9 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00710359

*VACCINES***
IMPFSTOFFE
*VACCINS***

PATENT ASSIGNEE:

SMITHKLINE BEECHAM BIOLOGICALS S.A., (1311860), 89 rue de l'Institut,
1330 Rixensart, (BE), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

MOMIN, P.M., SmithKline Beecham Bio.(S.A.), 89, rcue de l'Institut,

09/489711

B-1330 Rixensart, (BE)

GARCON, N. Marie-J., SmithKline Beecham Bio.(S.A.), 89, rue de l'Institut
, B-1330 Rixensart, (BE)

LEGAL REPRESENTATIVE:

Dalton, Marcus Jonathan William (60102), SmithKline Beecham plc Corporate
Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8
9EP, (GB)

PATENT (CC, No, Kind, Date): EP 735898 A1 961009 (Basic)
EP 735898 B1 990310
WO 9517210 950629

APPLICATION (CC, No, Date): EP 95904511 941220; WO 94EP4246 941220

PRIORITY (CC, No, Date): GB 9326253 931223

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; PT; SE

INTERNATIONAL PATENT CLASS: A61K-039/39;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9910	270
CLAIMS B	(German)	9910	257
CLAIMS B	(French)	9910	284
SPEC B	(English)	9910	3624
Total word count - document A			0
Total word count - document B			4435
Total word count - documents A + B			4435

18/3,AB/10 (Item 10 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00598055

The use of tyloxapol as a nanoparticle *stabilizer*** and dispersant
Anwendung von Tyloxapol als Nanopartikelstabilisator und Dipergiermittel
Utilisation du tyloxapol comme *stabilisateur*** de nanoparticules et agent
dispersant

PATENT ASSIGNEE:

NanoSystems L.L.C., (2106910), 1250 South Collegeville Road, Bldg. 1,
Collegeville, Pennsylvania 19426, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

June, Siegfried K., c/o STERLING WINTHROP INC., 90 Park Avenue, New York,
New York 10016, (US)

LEGAL REPRESENTATIVE:

Baillie, Iain Cameron et al (27951), Ladas & Parry, Dachauerstrasse 37,
80335 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 602702 A1 940622 (Basic)
EP 602702 B1 990414

APPLICATION (CC, No, Date): EP 93203365 931201;

PRIORITY (CC, No, Date): US 990874 921215

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; PT; SE

INTERNATIONAL PATENT CLASS: A61K-009/14; A61K-009/51; A61K-049/04;

ABSTRACT EP 602702 A1

A composition comprising nanoparticles having tyloxapol adsorbed on the

09/489711

surface thereof, preferably containing a diagnostic or therapeutic agent, and most preferably including a further surface modifier associated therewith is described.

A method of making such nanoparticles and a method of diagnosis comprising administering to a mammal of a contrast effective amount of particles of nanoparticles having tyloxapol adsorbed on the surface thereof is also described.

ABSTRACT WORD COUNT: 67

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9915	132
CLAIMS B	(German)	9915	139
CLAIMS B	(French)	9915	147
SPEC B	(English)	9915	3329
Total word count - document A			0
Total word count - document B			3747
Total word count - documents A + B			3747

18/3,AB/11 (Item 11 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00524051

*Vaccine*** *adjuvant*** comprising a tetra-polyol
Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
*Adjuvant*** pour *vaccin*** comprenant un tetra-polyol
PATENT ASSIGNEE:

SYNTEX (U.S.A.) INC., (200863), 3401 Hillview Avenue, Palo Alto
California 94304, (US), (applicant designated states:
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Allison, Anthony Clifford, 2513 Hastings Dr., Belmont, CA 94002, (US)
Byars, Noelene Elva, 1092 Syracuse Dr., Sunnyvale, CA 94087, (US)
Fu, Cherng-Chyi, 14050 Shadow Oaks Way, Saratoga, CA 95070, (US)
Lidgate, Deborah Marilyn, 325 Arboleda Drive, Los Altos, CA 94022, (US)
Felgner, Philip Lewis, P.O. Box 3302, Rancho Sante Fe, CA 92067, (US)
Foster, Linda Cheryl, 733 Carolina Avenue, Sunnyvale, CA 94086, (US)
Lee, William Alfred, 749 Anderson Drive, Los Altos, CA 94022, (US)

LEGAL REPRESENTATIVE:

Witte, Hubert et al (78221), F.Hoffmann-La Roche AG Patent Department
(PLP), 124 Grenzacherstrasse, 4070 Basel, (CH)

PATENT (CC, No, Kind, Date): EP 513861 A1 921119 (Basic)
EP 513861 B1 970226

APPLICATION (CC, No, Date): EP 92113037 881102;

PRIORITY (CC, No, Date): US 116425 871103

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE

RELATED PARENT NUMBER(S) - PN (AN):

EP 315153 (EP 881182638)

INTERNATIONAL PATENT CLASS: A61K-039/39;

ABSTRACT EP 513861 A1

An adjuvant for potentiating the immunogenicity of an antigen, suitable for manufacture on a commercial scale, is an emulsion having oily particles dispersed in a continuous aqueous phase, which emulsion comprises: an emulsion-forming amount of a non-toxic tetra-polyol;

09/489711

optionally, an emulsion-forming amount of a non-toxic metabolizable oil; optionally, an emulsion-stabilizing amount of a glycol ether-based surfactant; and an immunopotentiating amount of a glycopeptide.
ABSTRACT WORD COUNT: 65

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	859
CLAIMS B	(English)	EPAB97	847
CLAIMS B	(German)	EPAB97	822
CLAIMS B	(French)	EPAB97	972
SPEC A	(English)	EPABF1	6064
SPEC B	(English)	EPAB97	5609
Total word count - document A			6923
Total word count - document B			8250
Total word count - documents A + B			15173

18/3,AB/12 (Item 12 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00449812

FLUORINE AND PHOSPHOROUS-CONTAINING *AMPHIPHILIC*** MOLECULES WITH
*SURFACTANT*** PROPERTIES.

FLUOR- UND PHOSPHORHALTIGE AMPHIPHILISCHE MOLEKULE MIT OBERFLACHENAKTIVEN
EIGENSCHAFTEN.

MOLECULES AMPHIPHILIQUES CONTENANT DU FLUOR ET DU PHOSPHORE, PRESENTANT DES
PROPRIETES TENSIO-ACTIVES.

PATENT ASSIGNEE:

APPLICATIONS ET TRANSFERTS DE TECHNOLOGIES AVANCEES ATTA, (889381), 47,
Corniche des Oliviers, F-06000 Nice, (FR), (applicant designated
states: AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

RIESS, Jean, Les Giaines, F-06950 Falicon, (FR)
JEANNEAUX, Francois, 135, avenue Saint-Lambert, F-06100 Nice, (FR)
KRAFFT, Marie-Pierre, 34, rue Vernier, F-06100 Nice, (FR)
SANTAELLA, Catherine, 74, avenue Saint-Barthelemy, F-06100 Nice, (FR)
VIERLING, Pierre, Les Giaines, F-06950 Falicon, (FR)

LEGAL REPRESENTATIVE:

Kedinger, Jean-Paul et al (16351), c/o Cabinet Malemont 42, avenue du
President Wilson, F-75116 Paris, (FR)

PATENT (CC, No, Kind, Date): EP 478686 A1 920408 (Basic)
EP 478686 B1 930811
WO 9015807 901227

APPLICATION (CC, No, Date): EP 90910640 900621; WO 90EP991 900621

PRIORITY (CC, No, Date): EP 89401777 890622

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C07F-009/10; A61K-031/675; C07F-009/09;
C07F-009/6533;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1333
CLAIMS B	(German)	EPBBF1	1250

09/489711

CLAIMS B (French) EPBBF1 1490
SPEC B (English) EPBBF1 7814
Total word count - document A 0
Total word count - document B 11887
Total word count - documents A + B 11887

18/3,AB/13 (Item 13 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00361147

*Vaccines*** for the protection of animals against hypodermosis.
Vakzine zum Schutz von Tieren gegen Hypodermosis.
*Vaccins*** pour la protection des animaux contre l'hypodermose.

PATENT ASSIGNEE:

THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF
AGRICULTURE, (834250), United States Department of Agriculture,
Washington, DC 20250, (US), (applicant designated states:
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
CODON, (601482), 213 East Grand Avenue, South San Francisco CA 94080,
(US), (applicant designated states:
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Pruett, John H. ,Jr., 212 Stephanie, Herrville Texas 87028, (US)
Files, James G., 1911 Lyon Avenue, Belmont California 94002, (US)
Kuhn, Irene, 24A Cumberland Street, San Francisco California 78257, (US)
Temeyer, Kevin B., 25115, Danna Marie Drive, San Antonio Texas 78257,
(US)

LEGAL REPRESENTATIVE:

Thomson, Paul Anthony et al (36701), Potts, Kerr & Co. 15, Hamilton
Square, Birkenhead Merseyside L41 6BR, (GB)

PATENT (CC, No, Kind, Date): EP 326419 A2 890802 (Basic)
EP 326419 A3 910925

APPLICATION (CC, No, Date): EP 89300829 890127;

PRIORITY (CC, No, Date): US 148749 880127

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12N-015/00; C12N-001/20; C12N-001/18;
C12N-005/00; A61K-037/547; C12N-009/64;

ABSTRACT EP 326419 A2

This invention relates to the development of a vaccine against
hypodermosis, a disease resulting from a maggot invasion by an insect
taxonomically classified within the genus Hypoderma. The effective
ingredients of the disclosed vaccines are hypodermins A, B, and C.
Hypodermins A, B and C are serine proteases. Hypodermin C is generally
known as collagenase. The hypodermins are produced naturally by the
larvae of the insect. Methods for producing the hypodermins by
recombinant genetics are disclosed as well as vaccines containing pure
hypodermins and selected mixtures. Methods for immunoprotecting animals
from Hypoderma species, especially Hypoderma lineatum are also provided.
The precursor sequence of Hypodermin A and B is also disclosed for use as
a general purpose signal sequence for the secretion of heterologous
proteins expressed by recombinant insect cells.

ABSTRACT WORD COUNT: 133

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

09/489711

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	549
SPEC A	(English)	EPABF1	9201
Total word count - document A			9750
Total word count - document B			0
Total word count - documents A + B			9750

18/3,AB/14 (Item 14 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00332096

*LIPID*** MICROEMULSIONS FOR CULTURE MEDIA
*LIPIDMIKROEMULSIONEN*** FUR WACHSTUMSMEDIEN
MICRO-EMULSIONS DE LIPIDES POUR DES MILIEUX DE CULTURE
PATENT ASSIGNEE:

CHIRON CORPORATION, (572530), 4560 Horton Street, Emeryville, California
94608, (US), (applicant designated states:
AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

INLOW, Duane, 630 Mariposa, Apt. 310, Oakland, CA 94610, (US)

LEGAL REPRESENTATIVE:

Bizley, Richard Edward et al (28352), Hepworth, Lawrence, Bryer & Bizley
Merlin House Falconry Court Baker's Lane, Epping Essex CM16 5DQ, (GB)
PATENT (CC, No, Kind, Date): EP 377582 A1 900718 (Basic)

EP 377582 B1 971015
WO 8901027 890209

APPLICATION (CC, No, Date): EP 88906679 880720; WO 88US2440 880720

PRIORITY (CC, No, Date): US 77189 870724

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12N-005/00;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9710W2	592
CLAIMS B	(German)	9710W2	524
CLAIMS B	(French)	9710W2	710
SPEC B	(English)	9710W2	7687
Total word count - document A			0
Total word count - document B			9513
Total word count - documents A + B			9513

18/3,AB/15 (Item 15 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00329638

PAUCILAMELLAR *LIPID*** VESICLES.
PAUCILAMELLARE *LIPIDVESIKEL***.
VESICULES DE LIPIDES PAUCILAMELLAIRES.
PATENT ASSIGNEE:

MICRO VESICULAR SYSTEMS, INC., (1024770), 20 Cotton Road Birch Pond
Business Center Suite 230, Nashua New Hampshire 03063, (US), (applicant
designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

09/489711

INVENTOR:

WALLACH, Donald, F., H., 45 Marshall Street, Brookline, MA 02146, (US)

LEGAL REPRESENTATIVE:

Price, Vincent Andrew et al (79513), FRY HEATH & SPENCE The Old College
53 High Street, Horley Surrey RH6 7BN, (GB)

PATENT (CC, No, Kind, Date): EP 352282 A1 900131 (Basic)
EP 352282 B1 920108
WO 8806883 880922

APPLICATION (CC, No, Date): EP 88903062 880308; WO 88US723 880308

PRIORITY (CC, No, Date): US 25525 870313; US 157571 880303

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-009/127;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1557
CLAIMS B	(German)	EPBBF1	1452
CLAIMS B	(French)	EPBBF1	1819
SPEC B	(English)	EPBBF1	7076
Total word count - document A			0
Total word count - document B			11904
Total word count - documents A + B			11904

18/3,AB/16 (Item 16 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00301600

*Vaccine*** *adjuvant***.

Impfstoff-Adjuvans.

*Adjuvant*** pour *vaccin***.

PATENT ASSIGNEE:

SYNTEX (U.S.A.) INC., (200860), 3401 Hillview Avenue, Palo Alto
California 94303, (US), (applicant designated states:
AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Allison, Anthony Clifford, 2513 Hastings Drive, Belmont, CA 94002, (US)
Byars, Noelene Elva, 1092 Syracuse Drive, Sunnyvale, CA 94087, (US)
Fu, Cherng-Chyi, 14050 Shadow Oaks Way, Saratoga, CA 95070, (US)
Lidgate, Deborah Marilyn, 325 Arboleda Drive, Los Altos, CA 94022, (US)
Felgner, Philip Lewis, P.O. Box 3392, Rancho Santa Fe, CA 92067, (US)
Foster, Linda Cheryl, 733 Carolina Avenue, Sunnyvale, CA 94086, (US)
Lee, William Alfred, 749 Anderson Drive, Los Altos, CA 94022, (US)

LEGAL REPRESENTATIVE:

Barz, Peter, Dr. et al (1461), Patentanwalt Dipl.-Ing. G. Dannenberg Dr.
P. Weinhold, Dr. D. Gudel Dipl.-Ing. S. Schubert, Dr. P. Barz
Siegfriedstrasse 8, D-80803 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 315153 A2 890510 (Basic)
EP 315153 A3 890809
EP 315153 B1 940511

APPLICATION (CC, No, Date): EP 88118263 881102;

PRIORITY (CC, No, Date): US 116425 871103

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/39;

ABSTRACT EP 315153 A2

An adjuvant for potentiating the immunogenicity of an antigen, suitable for manufacture on a commercial scale, is an emulsion having oily particles dispersed in a continuous aqueous phase, which emulsion comprises: an emulsion-forming amount of a non-toxic tetra-polyol or polyoxyethylene-polyoxypropylene (POP-POE) block polymer; optionally, an emulsion-forming amount of a non-toxic metabolizable oil; optionally, an emulsion-stabilizing amount of a glycol ether-based surfactant; and an immunopotentiating amount of a glycopeptide;

wherein substantially all of said oily particles have a diameter less than about 800 nm if a POP-POE block polymer is present.

ABSTRACT WORD COUNT: 94

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	2479
CLAIMS B	(German)	EPBBF1	2354
CLAIMS B	(French)	EPBBF1	2924
SPEC B	(English)	EPBBF1	8557
Total word count - document A			0
Total word count - document B			16314
Total word count - documents A + B			16314

Set	Items	Description
S19	8267	AU=(ROBERTS, D? OR ROBERTS D?)
S20	8	AU=(SWEARINGIN, L? OR SWEARINGIN L?)
S21	10	AU=(SUITER, B? OR SUITER B?)
S22	1	S19 AND S20 AND S21
S23	7	S19 AND (S20 OR S21)
S24	1	S20 AND S21
S25	8277	S19 OR S20 OR S21
S26	6	S25 AND RHUSIOPATH?
S27	5	(S22 OR S23 OR S24 OR S26) NOT (S17 OR S4)
S28	4	RD (unique items)

- Author(s)

>>>No matching display code(s) found in file(s): 65, 113

28/3,AB/1 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

01175011

Adjuvants for use in vaccines
Adjuvanzen zur Verwendung in Impfstoffen
Adjuvants pour utilisation dans des vaccins
PATENT ASSIGNEE:

Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut
06340, (US), (Applicant designated States: all)

INVENTOR:

Dearwester, Don Alan, Pfizer Inc., Central Res. Div., Eastern Point Road,
Groton, Connecticut 06340, (US)
*Swearingin, Leroy Allen, Pfizer Inc."**, Central Res. Div., Eastern
Point Road, Groton, Connecticut 06340, (US)
*Roberts, David Stewart"**, 604 Washington Square South, Apt. 303,
Philadelphia, Pennsylvania 19106, (US)

LEGAL REPRESENTATIVE:

Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 30
Welbeck Street, London W1M 7PG, (GB)

09/489711

PATENT (CC, No, Kind, Date): EP 1023904 A2 000802 (Basic)
APPLICATION (CC, No, Date): EP 99310514 991223;
PRIORITY (CC, No, Date): US 117705 990129; US 121760 990226
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61K-039/39; A61K-039/02; A61K-039/
A61K-039/10; A61K-039/40; A61P-031/04

ABSTRACT EP 1023904 A2

The invention relates to adjuvants that contain a lecithin, an
an amphiphilic surfactant and that are capable of forming a stable
oil-in-water emulsion vaccine so as to minimize local reactions to the
vaccine in the injected animal.

ABSTRACT WORD COUNT: 40

NOTE:

Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200031	541
SPEC A	(English)	200031	6736
Total word count - document A			7277
Total word count - document B			0
Total word count - documents A + B			7277

28/3,AB/2 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00705427

GRAM-NEGATIVE BACTERIAL VACCINES.
GRAM-NEGATIVE BAKTERIELLE VAKZINE.
VACCINS BACTERIENS GRAM-NEGATIFS.
PATENT ASSIGNEE:

SMITHKLINE BEECHAM CORPORATION, (201243), P.O. Box 7929 1 Franklin Plaza,
Philadelphia Pennsylvania 19101, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;SE)

INVENTOR:

DEARWESTER, Donald, A., 7640 Davies Drive, Lincoln, NB 68506, (US)
*ROBERTS, David, S."**, 1020 Rockhurst Drive, Lincoln, NB 68510, (US)
*SWEARINGIN, Leroy, A."**, 934 South 33rd Street, Lincoln, NB 68510, (US)

LEGAL REPRESENTATIVE:

Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 91
Wimpole Street, London W1M 8AH, (GB)

PATENT (CC, No, Kind, Date): EP 669971 A1 950906 (Basic)
WO 9310216 930527

APPLICATION (CC, No, Date): EP 92925307 921113; WO 92US9944 921113
PRIORITY (CC, No, Date): US 792488 911115
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; SE

INTERNATIONAL PATENT CLASS: C12N-001/36; A61K-039/02;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

09/489711

28/3,AB/3 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00632408

PASTEURELLA MULTOCIDA TOXOID VACCINES.

Pasteurella multocida Toxoid-Vakzine.

VACCINS A BASE D'ANATOXINES DE PASTEURELLA MULTOCIDA.

PATENT ASSIGNEE:

SMITHKLINE BEECHAM CORPORATION, (201243), P.O. Box 7929 1 Franklin Plaza,
Philadelphia Pennsylvania 19101, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;SE)

INVENTOR:

FRANTZ, Joseph, C., 3027 Browning, Lincoln, NB 68506, (US)

KEMMY, Richard, J., 437 Brentwood Drive, Gretna, NB 68028, (US)

*ROBERTS, David, S."**, 1020 Rockhurst Drive, Lincoln, NB 68510, (US)

*SWEARINGIN, Leroy, A."**, 934 South 33rd, Lincoln, NB 68510, (US)

LEGAL REPRESENTATIVE:

Russell, Brian John et al (45993), SmithKline Beecham plc Corporate
Intellectual Property SB House Great West Road, Brentford, Middlesex
TW8 9BD, (GB)

PATENT (CC, No, Kind, Date): EP 614371 A1 940914 (Basic)
EP 614371 A1 950607
WO 9309809 930527

APPLICATION (CC, No, Date): EP 92925340 921113; WO 92US10008 921113

PRIORITY (CC, No, Date): US 792490 911115

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/00; A61K-039/02;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

28/3,AB/4 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2001 Derwent Publ Ltd. All rts. reserv.

0258641 DBA Accession No.: 2000-13131 PATENT

Vaccine containing lecithin, oil and surfactant as adjuvant, useful for
protection against bacterial or viral pathogens, particularly in pigs,
does not cause significant local reactions - Bordetella bronchiseptica,
Pasteurella multocida culture and antigen use in vaccine for pig
protection from infection

AUTHOR: Dearwester D A; *Swearingin L A"; *Roberts D S"

CORPORATE SOURCE: Groton, CT, USA.

PATENT ASSIGNEE: Pfizer 2000

PATENT NUMBER: EP 1023904 PATENT DATE: 20000802 WPI ACCESSION NO.:
2000-516029 (2047)

PRIORITY APPLIC. NO.: US 121760 APPLIC. DATE: 19990226

NATIONAL APPLIC. NO.: EP 99310514 APPLIC. DATE: 19991223

LANGUAGE: English

ABSTRACT: A vaccine composition (A) comprises 0.25-12.5 vol% lecithin (I),
1-23 vol% oil (II), 1.5-3.5 vol% at least one amphipathic surfactant
(III) plus an antigen (Ag). Also claimed are: an adjuvant composition
(B) of (I)-(III); preparation of vaccines by adding (B) to a Ag
composition; an Ag composition (C) comprising a Bordetella

09/489711

bronchiseptica culture inactivated by adding formalin and then glutaraldehyde; a vaccine composition (D) of (C) plus an adjuvant; inactivating a B. bronchiseptica culture by adding formalin and glutaraldehyde; a vaccine for protection against B. bronchiseptica infection comprising cells from a culture inactivated by the claimed method plus a carrier; and a method for protecting a piglet against atrophic rhinitis. (A) can be formulated with Ag from any bacterial or viral pathogen, especially for protection of animals, piglets against B. bronchiseptica and/or Pasteurella multocida. The antigen is from Pasteurella multocida, Bordetella bronchiseptica, Erysipelothrix *rhusiopathiae"**, Escherichia coli, Actinobacillus pleuropneumoniae or Pasteurella hemolytica culture. In an example, B. bronchiseptica 2-9NADL was cultured. (12pp)

? log y

17oct01 13:30:56 User219783 Session D1751.3

Roberts
Devi, S.
09/489711

09/489711

FILE 'REGISTRY' ENTERED AT 12:16:56 ON 17 OCT 2001

- L1 7 SEA ABB=ON PLU=ON ("ALUMINUM HYDROXIDE"/CN OR "ALUMINUM HYDROXIDE (AL(18OH)3)"/CN OR "ALUMINUM HYDROXIDE (AL(OD))"/CN OR "ALUMINUM HYDROXIDE (AL(OD)2)"/CN OR "ALUMINUM HYDROXIDE (AL(OD)3)"/CN OR "ALUMINUM HYDROXIDE (AL(OH))"/CN OR "ALUMINUM HYDROXIDE (AL(OH)2)"/CN OR "ALUMINUM HYDROXIDE (AL(OH)3)"/CN)
E ALUMINUM HYDROXIDE/CN 5
- L2 6 SEA ABB=ON PLU=ON ("CALCIUM HYDROXIDE"/CN OR "CALCIUM HYDROXIDE (40CA(OH))"/CN OR "CALCIUM HYDROXIDE (CA(OD))"/CN OR "CALCIUM HYDROXIDE (CA(OD)2)"/CN OR "CALCIUM HYDROXIDE (CA(OH)(OT))"/CN OR "CALCIUM HYDROXIDE (CA(OH))"/CN OR "CALCIUM HYDROXIDE (CA(OH)2)"/CN)
E CALCIUM HYDROXIDE/CN 5
- L3 4 SEA ABB=ON PLU=ON ("ZINC HYDROXIDE"/CN OR "ZINC HYDROXIDE (65ZN(OH)2)"/CN OR "ZINC HYDROXIDE (ZN(OD))"/CN) OR "ZINC HYDROXIDE (ZNOH)"/CN
E ALUMINUM PHOSPHATE/CN
- L4 13 SEA ABB=ON PLU=ON ("ALUMINUM PHOSPHATE"/CN OR "ALUMINUM PHOSPHATE (1:1)"/CN) OR ("ALUMINUM PHOSPHATE (AL(PO4))"/CN OR "ALUMINUM PHOSPHATE (AL0.5(PO4)0.5)"/CN OR "ALUMINUM PHOSPHATE (AL2(HPO4)3)"/CN OR "ALUMINUM PHOSPHATE (AL2(OH)3(PO4))"/CN OR "ALUMINUM PHOSPHATE (AL2O3(P2O5)5)"/CN OR "ALUMINUM PHOSPHATE (AL2P6O18)"/CN OR "ALUMINUM PHOSPHATE (AL3(OH)3(PO4)2)"/CN OR "ALUMINUM PHOSPHATE (AL3(PO4)(OH)6)"/CN OR "ALUMINUM PHOSPHATE (AL4(P4O12)3)"/CN OR "ALUMINUM PHOSPHATE (AL4P10O31)"/CN OR "ALUMINUM PHOSPHATE (ALH2P3O10)"/CN) OR "ALUMINUM PHOSPHATE (ALP3O9)"/CN
E CALCIUM PHOSPHATE/CN 5
- L5 6 SEA ABB=ON PLU=ON ("CALCIUM PHOSPHATE"/CN OR "CALCIUM PHOSPHATE (1:1)"/CN OR "CALCIUM PHOSPHATE (1:2)"/CN OR "CALCIUM PHOSPHATE (3:2)"/CN OR "CALCIUM PHOSPHATE (CA(H2PO4)2)"/CN OR "CALCIUM PHOSPHATE (CA(PO3)2)"/CN OR "CALCIUM PHOSPHATE (CA2P2O7)"/CN
E ALUM/CN
- L6 2 SEA ABB=ON PLU=ON ALUM/CN
- L7 38 SEA ABB=ON PLU=ON L1 OR L2 OR L3 OR L4 OR L5 OR L6

-key terms

FILE 'CAPLUS' ENTERED AT 12:24:42 ON 17 OCT 2001

- L8 156919 SEA ABB=ON PLU=ON L7 OR (STABILIS? OR STABILIZ?) (3A)AGE NT OR (METAL OR AL OR ALUMIN? OR CALCIUM OR CA OR ZINC OR ZN) (W) (OH OR HYDROXIDE) OR CAOH OR ALOH OR ZNOH OR (METAL OR ALUMIN? OR CALCIUM OR AL OR CA) (W) (PO# OR PHOSPHATE) OR ALPO# OR CAPO# OR ALUM
- L9 2 SEA ABB=ON PLU=ON L8 AND (ERYSIPEL? OR E) (W) RHUSIOPATH?

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:544802 CAPLUS

DOCUMENT NUMBER: 133:155383

TITLE: **Erysipelothrix rhusiopathiae**

antigen compositions and their vaccine
compositions for prevention and treatment of
swine erysipelas

INVENTOR(S): Roberts, David Stewart; Swearingin, Leroy Alan;
Suiter, Brian Thomas

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

09/489711

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000219637	A2	20000808	JP 2000-17930	20000124
AU 9959445	A1	20000803	AU 1999-59445	19991116
EP 1027895	A2	20000816	EP 1999-309202	19991118
EP 1027895	A3	20010718		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
 PT, IE, SI, LT, LV, FI, RO

CN 1262129	A	20000809	CN 1999-126163	19991215
BR 9905853	A	20001114	BR 1999-5853	19991215

PRIORITY APPLN. INFO.: US 1999-117704 P 19990129

AB The antigen compns. contain fluid fraction of cultured **E.**

rhusiopathiae, and stabilizers, e.g. **metal hydroxides** or phosphates. Rehydragel [Al(OH)₃ gel] prevented loss of activity of formalin- or .beta.-propiolactone-inactivated **E. rhusiopathiae** antigen.

IT 1305-62-0, Calcium hydroxide, biological studies 7784-30-7, Aluminum phosphate

10103-46-5, Calcium phosphate

20427-58-1, Zinc hydroxide

21645-51-2, Rehydragel, biological studies

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gel, stabilizer; vaccines contg. **erysipelo**thrix

rhusiopathiae antigen for treatment of swine erysipelas)

IT 10043-67-1, Alum

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stabilizer; vaccines contg. **erysipelo**thrix

rhusiopathiae antigen for treatment of swine erysipelas)

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:451503 CAPLUS

DOCUMENT NUMBER: 131:92494

TITLE: Adjuvant combination for vaccines

INVENTOR(S): Neubert, Andreas; Reuter, Torsten

PATENT ASSIGNEE(S): Impfstoffwerk Dessau-Tornau G.m.b.H., Germany

SOURCE: Ger. Offen., 4 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19801834	A1	19990715	DE 1998-19801834	19980114

AB Vaccine adjuvants made of mineral oil and Al(OH)₃ gel as oil-in-water emulsion combinations and process of their prepn. are described. The mineral oil-Al(OH)₃

09/489711

ratios may be 1:0.1 to 0.1:1. The adjuvant can be used for the prepn. of vaccines against swine parvovirus, influenza virus, or **Erysipelthrix rhusiopathiae**. The antigen is first mixed with **Al(OH)3** gel for 12 at 4-8.degree.C and then emulsified with mineral oil. A vaccine against swine parvovirus was prepd. and tested in pigs and guinea pigs. The vaccine with mineral oil and **Al(OH)3** adjuvant had superior immunizing properties compared to vaccines with **Al(OH)3** only or with **Al(OH)3-saponin** adjuvant.

IT 21645-51-2, Aluminum hydroxide, biological studies

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aluminum hydroxide and mineral oil emulsions as adjuvants for swine vaccines)

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, PHIC, PHIN, TOXLIT, TOXLINE' ENTERED AT 12:29:05 ON 17 OCT 2001).

L10
L11

23 S L9

23 DUP REM L10 (0 DUPLICATES REMOVED)

L11 ANSWER 1 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2001-381498 [40] WPIDS
DOC. NO. CPI: C2001-116878
TITLE: Composition for enhancing immunogenic effect of a vaccine comprises an extract of a ginseng plant and an aluminum salt.
DERWENT CLASS: B01 B04
INVENTOR(S): RIVERA VEGA, E
PATENT ASSIGNEE(S): (STAT-N) STATENS VETERINAERMEDICINSKA ANSTALT
COUNTRY COUNT: 94
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001041802	A1	20010614	(200140)*	EN	50
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001041802	A1	WO 2000-SE2478	20001208

PRIORITY APPLN. INFO: US 1999-169613 19991208; SE 1999-4480 19991208

AN 2001-381498 [40] WPIDS
AB WO 200141802 A UPAB: 20010719
NOVELTY - Composition for enhancing immunogenic effect of a vaccine

09/489711

comprising an extract of a ginseng plant and an aluminum salt, is prepared by providing an extract of a ginseng plant comprising at least one ginsenoside; and adding the aluminum salt to the extract.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (i) a kit comprising a composition as above; and
- (ii) a preparation comprising a composition as above, and optionally an immunogenic substance.

ACTIVITY - Immunostimulant.

Mice were vaccinated with either: diluted

Erysipelothrix rhusiopathiae and NaCl solution

(vaccine 1); diluted virus and 3 % Al(OH)₃

(Vaccine 2); vaccine 1 + Ginseng; or vaccine 2 + Ginseng (no amounts given). After vaccination mean group antibody titers were calculated. Vaccine 1 gave 10.0 plus or minus 0.0, vaccine 1 + ginseng gave 13.3 plus or minus 4.7, vaccine 2 gave 13.3 plus or minus 4.7 and vaccine 2 + ginseng gave 13.3 plus or minus 4.7. After 2 boosters vaccine 1 gave 80.0 plus or minus 0.0, vaccine 1 + ginseng gave 320.0 plus or minus 0.0, vaccine 2 gave 66.6 plus or minus 18.9 and vaccine 2 + ginseng gave 173.3 plus or minus 14.6.

MECHANISM OF ACTION - Vaccine.

USE - The composition is used for enhancing the immunogenic effect of a vaccine.

ADVANTAGE - The amount of aluminum salt required is reduced compared to prior art. The composition has a strong adjuvant effect, and is safe and effective with no local or general side-effects.

Dwg.0/2

L11 ANSWER 2 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-484844 [43] WPIDS
DOC. NO. CPI: C2000-145992
TITLE: Novel antigen comprising fluid function from an
Erysipelothrix rhusiopathiae
culture, useful as a vaccine.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): ROBERTS, D S; SUITER, B T; SWEARINGEN, L A;
SWEARINGIN, L A
PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
COUNTRY COUNT: 31
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1027895	A2	20000816	(200043)*	EN	13
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2000219637	A	20000808	(200043)		12
AU 9959445	A	20000803	(200046)		
CA 2290078	A1	20000729	(200051)	EN	
CN 1262129	A	20000809	(200055)		
BR 9905853	A	20001114	(200064)		
ZA 9907138	A	20010627	(200140)		23

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 1027895	A2	EP 1999-309202	19991118

Searcher : Shears 308-4994

09/489711

JP 2000219637	A	JP 2000-17930	20000124
AU 9959445	A	AU 1999-59445	19991116
CA 2290078	A1	CA 1999-2290078	19991116
CN 1262129	A	CN 1999-126163	19991215
BR 9905853	A	BR 1999-5853	19991215
ZA 9907138	A	ZA 1999-7138	19991116

PRIORITY APPLN. INFO: US 1999-117704 19990129

AN 2000-484844 [43] WPIDS

AB EP 1027895 A UPAB: 20000907

NOVELTY - Antigen (I) comprising a fluid fraction from an **Erysipelothrix rhusiopathiae** culture and a stabilizing agent, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a vaccine comprising an antigen as in (I) and an adjuvant; and

(2) making an antigen comprising adding a stabilizing agent to a fluid fraction from an **E. rhusiopathiae** culture.

ACTIVITY - Antibacterial.

MECHANISM OF ACTION - Vaccine.

Pigs were vaccinated intramuscularly with two 2 ml doses of vaccine with Al gel (3 and 6 weeks). Immunity was tested at 9 weeks with intramuscular injections of **E. rhusiopathiae**. Protection due to vaccine was 100 %.

USE - The antigen composition of (I) and a vaccine comprising it are used to vaccinate an animal, especially a pig against **E. rhusiopathiae** infection and erysipelas (claimed).

ADVANTAGE - The vaccine provides long term protection from **E. rhusiopathiae**.

Dwg.0/0

L11 ANSWER 3 OF 23 TOXLIT

ACCESSION NUMBER: 2000:54719 TOXLIT

DOCUMENT NUMBER: CA-133-155383R

TITLE: **Erysipelothrix rhusiopathiae**

antigen compositions and their vaccine compositions for prevention and treatment of swine erysipelas.

AUTHOR: Roberts DS; Swearingin LA; Suiter BT

SOURCE: (2000). Jpn. Kokai Tokkyo Koho PATENT NO. 2000219637 08/08/2000 (Pfizer Products Inc.).

CODEN: JKXXAF.

PUB. COUNTRY: UNITED STATES

DOCUMENT TYPE: Patent

FILE SEGMENT: CA

LANGUAGE: Japanese

OTHER SOURCE: CA 133:155383

ENTRY MONTH: 200009

AB The antigen compns. contain fluid fraction of cultured **E. rhusiopathiae**, and stabilizers, e.g. metal hydroxides or phosphates. Rehydragel [Al(OH)₃ gel] prevented loss of activity of formalin- or .beta.-propiolactone-inactivated **E. rhusiopathiae** antigen.

09/489711

L11 ANSWER 4 OF 23 TOXLIT

ACCESSION NUMBER: 1999:44980 TOXLIT

DOCUMENT NUMBER: CA-131-092494P

TITLE: Adjuvant combination for vaccines.

AUTHOR: Neubert A; Reuter T

SOURCE: (1999). Ger. Offen. PATENT NO. 19801834 07/15/1999
(Impfstoffwerk Dessau-Tornau G.m.b.H.).
CODEN: GWXXBX.

PUB. COUNTRY: GERMANY, FEDERAL REPUBLIC OF

DOCUMENT TYPE: Patent

FILE SEGMENT: CA

LANGUAGE: German

OTHER SOURCE: CA 131:92494

ENTRY MONTH: 199908

AB Vaccine adjuvants made of mineral oil and Al(OH)₃ gel as oil-in-water emulsion combinations and process of their prepn. are described. The mineral oil-Al(OH)₃ ratios may be 1:0.1 to 0.1:1. The adjuvant can be used for the prepn. of vaccines against swine parvovirus, influenza virus, or *Erysipelthrix rhusiopathiae*. The antigen is first mixed with Al(OH)₃ gel for 12 at 4-8.degree.C and then emulsified with mineral oil. A vaccine against swine parvovirus was prepd. and tested in pigs and guinea pigs. The vaccine with mineral oil and Al(OH)₃ adjuvant had superior immunizing properties compared to vaccines with Al(OH)₃ only or with Al(OH)₃-saponin adjuvant.

L11 ANSWER 5 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1999-60845 VETU

TITLE: Protective activity of the purified protein antigen of *Erysipelothrix rhusiopathiae*.

AUTHOR: Yamazaki Y; Sato H; Sakakura H; Shigeto K; Nakano K; Saito H

CORPORATE SOURCE: Univ.Kitasato

LOCATION: Aomori, Jap.

SOURCE: J.Vet.Med.Ser.B (46, No. 1, 47-55, 1999) 5 Fig. 2 Tab. 16 Ref.

CODEN: JVMBE9

AVAIL. OF DOC.: Department of Veterinary Microbiology, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori 034, Japan. (7 authors).

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1999-60845 VETU

AB The protein antigen (P64), which contains 66 and 64 kDa proteins, was purified from the alkaline extract (AE) of whole cells of *Erysipelothrix rhusiopathiae* strain Agata (serovar 5) to determine the protective activity of the antigen against *E. rhusiopathiae* infection in pigs. S.c. immunization with P64 antigen or live cell erysipelas vaccine resulted in a rapid increase in the serum antibody titer against P64. Pigs vaccinated with P64 antigen or live cell vaccine were protected from challenge 3 wk after 1st immunization. The results indicate that a specific antibody against the 64 kDa protein was raised in pigs immunized with P64 or a live cell vaccine and that this anti-P64 antibody has a strong protective effect against

E. rhusiopathiae infection in pigs.

ABEX 20 Mixed breed pigs (2-mth-old) were divided into 5 groups and immunized s.c. with 500, 100 or 20 ug of P64 mixed in **aluminum phosphate** gel or live erysipelas vaccine, or acted as nonimmunized controls. 2 Wk after 1st immunization, each of 4 pigs immunized with P64 was re-immunized with the above doses of P64. Pigs possessing a high serum antibody titer were challenged s.c. with **E. rhusiopathiae** strain Fujisawa (serotype 1a) 3 wk after 1st immunization. The serum antibody titer against P64 rapidly increased in pigs immunized with 500 and 100 ug P64 and attained peak values at 3 wk after 1st immunization. However, the serum antibody titers were not increased in pigs immunized with 20 ug P64 and in nonimmunized controls. In pigs immunized with the live cell vaccine, serum titers against P64 also increased at 1-2 wk postimmunization. On challenge, all nonimmunized pigs showed typical clinical signs of swine erysipelas, while all pigs immunized with 500 and 100 ug of P64 and live cell vaccine showed no clinical signs of disease. In Western blot analysis, sera from pigs immunized with P64 and live cell vaccine strongly reacted with the 64 kDa protein. In contrast, the serum from nonimmunized pigs did not react with any proteins.

L11 ANSWER 6 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1996-63321 VETU

TITLE: Reliable protection of pigs against parvovirus and erysipelas by vaccination with the combination vaccine Erysorb Parvo ad us. vet.
(Zuverlässiger Schutz von Schweinen vor Parvovirose und Rotlauf)

AUTHOR: Klein N; Goddard R; Pugh C

CORPORATE SOURCE: Hoechst; Cent.Vet.Lab.U.K.

LOCATION: Marburg, Ger.; Weybridge; Milton Keynes, U.K.

SOURCE: Prakt.Tierarzt (77, No. 9, 838, 841-44, 1996) 1 Fig. 4 Tab. 19 Ref.

CODEN: PRTIAV

AVAIL. OF DOC.: Behringwerke AG, Veterinär Unit, Postfach 11 40, 35001 Marburg.

LANGUAGE: German

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1996-63321 VETU

AB The efficacy of a combined vaccine, Erysorb Parvo (Hoechst) for s.c. immunization against porcine parvovirus (PPV) and erysipelas (ERY) was evaluated in pregnant gilts, which received 2 injections, 3 wk apart. The vaccine contained inactivated **Erysipelothrix rhusiopathiae** serotypes 1 (strain P) and 2 (strain CN 3342) and inactivated PPV with **aluminum hydroxide** and Quil A as adjuvants. The combined vaccine was very well tolerated by the pigs without apparent side-effects. Following experimental infection of the gilts with PPV, none of the fetuses in the vaccinated animals showed evidence of infection. The vaccine also protected against experimental ERY infection with all the vaccinated pigs remaining healthy. The combined vaccine demonstrated comparable efficacy against both infections to those of the individual monovalent products.

ABEX 8 Gilts (5.6-7 mth-old) were vaccinated with Erysorb Parvo as 2 doses given 3 wk apart, while 6 similar sows remained

unvaccinated to serve as controls. All animals were covered after vaccination and then experimentally infected with PPV strain CVL 1243 between days 40-43 of pregnancy. Fetuses from the slaughtered sows were examined clinically and anatomically and infection detected by ELISA assay of fetal organ samples and hemagglutination inhibition (HI) antibody titers in fetal sera. 5 Gilts (aged 10 wk) were vaccinated as above, while 5 similar animals served as controls with all being experimentally infected 2 wk later with ERY serotypes 1 and 2 by i.d. injection. In the 1st vaccination study, 101 fetuses were produced by the vaccinated gilts of which 91 fetuses survived. No infection was detected by immunoassays in any of these fetuses. The control pigs produced 71 fetuses of which 30 survived (41 were mummified) and PPV infection was detected in 57/71 (80.3%) fetuses. At 1 wk after the 2nd vaccination, all the pigs had seroconverted with HI titers of 1:64 to 1:512. Infection resulted in a marked booster effect and at slaughter, the mean titer was 1:1722. In controls, all the animals at slaughter had high titers with most being above 1:4096. In the 2nd study, all unvaccinated pigs experimentally infected with ERY displayed the typical severe clinical signs (temperature above 40 deg, lethargy) and skin lesions of the disease. In contrast, none of these were observed in the vaccinated pigs subsequently infected with ERY.

L11 ANSWER 7 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 1997-63620 VETU

TITLE: The prevention of atrophic rhinitis in swine by vaccination with Rhinogen CTE 5000.
 AUTHOR: Udovicic I; Bilic V; Valpotic I; Vrbanac I; Lausin M
 CORPORATE SOURCE: Croatian-Vet.Inst.; Univ.Zagreb
 LOCATION: Zagreb, Croatia
 SOURCE: Proc.Int.Pig Vet.Soc.Congress (14 Meet., 255, 1996) 1 Tab. 3 Ref.
 AVAIL. OF DOC.: Croatian Veterinary Institute, Zagreb, Croatia.
 LANGUAGE: English
 DOCUMENT TYPE: Journal
 FIELD AVAIL.: AB; LA; CT
 AN 1997-63620 VETU

AB In an intensive rearing pig farm in Croatia during an outbreak of atrophic rhinitis (AR) for which enrofloxacin (Enroxil, Krka) had been given, vaccination of sows i.m. and offspring s.c. with AR vaccine (Rhinogen CTE 5000, Upjohn) effectively prevented symptoms. There were no side effects of the vaccine. The vaccine contained *Bordetella bronchiseptica*, *Erysipelothrix rhusiopathiae* and *Pasteurella multocida* serotypes D bacterin-toxoid adsorbed on aluminum hydroxide gel adjuvant. Enroxil given at the beginning of the outbreak prevented and controlled AR on the farm; Rhinogen, along with chemotherapy, seems to be an effective means of control of AR in pigs. (conference abstract).

ABEX In 1995 the farm (360 sows/gilts) had 20% of pigs with clinical AR and was treated with Enroxil. 10 Sows received 2 ml Rhinogen at and 2 wk after farrowing; their 67 suckling offspring received 2 ml vaccine at 7 and 28 days-old. 10 Sows and their offspring served as unvaccinated controls. No adverse reactions were seen at the injection site or systemically. Weight gain, farrowed, liveborn, stillborn, weaned and prefattener pigs/litter did not differ between treated and control groups. From birth to 115 days-old, 3.65% control vs. 0 treated pigs showed sneezing,

snuffling, serous nasal discharge and copious shed of tears, and 1.2% vs. 0 showed deformed nasal bones and marked brachygnathia..

L11 ANSWER 8 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1996-60759 VETU

TITLE: Growth ability and immunological properties of *Erysipelothrix rhusiopathiae* serotype 2.

AUTHOR: Zarkasie K; Sawada T; Yoshida T; Takahashi I; Takahashi T

CORPORATE SOURCE: Univ.Nippon-Vet.+Anim.Sci.

LOCATION: Tokyo, Jap.

SOURCE: J.Vet.Med.Sci. (58, No. 1, 87-90, 1996) 3 Fig. 2 Tab. 24 Ref.

AVAIL. OF DOC.: Department of Veterinary Microbiology, Nippon Veterinary and Animal Science University, Musashino, Tokyo 180, Japan.

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1996-60759 VETU

AB The growth ability and immunogenicity of *Erysipelothrix rhusiopathiae* serotype 2 strains are reported. The strains grew better in tryptose phosphate broth (TPB) than Feist medium. After 20 hr culture, the strains were inactivated with formalin (Wako-Pure-Chem.) and emulsified with **aluminum hydroxide** gel (Nippon). In mice vaccinated s.c. and then challenged, the most effective strain was Tama-96 followed by Shizuoka-63, 82-510, 82-527 and strain 44. Tama-96 prepared from brain heart infusion (BHI) with 10% horse serum was more immunogenic than vaccines prepared in BHI plus Tween 80 or Feist medium. Western blots revealed no quantitative or qualitative differences between strains and that the 66 to 64 kDa proteins predominated.

ABEX *E. rhusiopathiae* strains 82-510, 82-527, 44, Shizuoka-63 and Tama-96 and 2 reference strains (Kg-2, SE-9) were grown in modified Feist medium or tryptose phosphate broth (TPB, plus Tween-80) at 37 deg for 23 hr. SDS-PAGE and immunoblotting were performed on solubilized cell surface proteins. Cultures (20 hr) of each strain were inactivated with formalin and mixed with 1:5 v/v **aluminum hydroxide** gel. Female mice (5-wk-old) were inoculated s.c. with 0.5 ml vaccine diluted serially in 33% **aluminum hydroxide** gel and 3 wk later challenged with virulent strain Fujisawa (6.5 x 10 power 3 CFU/ml). All strains except for strain 82-150 were in the logarithmic phase by 4 hr of incubation while stationary phase cultures were only detected in TPB (vs. Feist) by 23 hr. Western blots revealed no quantitative or qualitative differences between strains. Protein of 66 to 64 kDa were dominant while 76, 74, 56, 45 and 38 kDa proteins were also identified. In mice, the most effective strain was Tama-96 (PD50 12 ul) followed by Shizuoka-63 (PD50 32 ul), 82-510 and 82-527 (both 45 ul) and strain 44 (117 ul). Tama-96 vaccine prepared from brain heart infusion (BHI) with 10% horse serum was more immunogenic than vaccines prepared in BHI plus Tween 80 or Feist medium.

L11 ANSWER 9 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1995-63559 VETU

TITLE: Protective activity and antigenic analysis of fractions of culture filtrates of **Erysipelothrix rhusiopathiae**.

AUTHOR: Sato H; Hirose K; Saito H

CORPORATE SOURCE: Univ.Kitasato

LOCATION: Aomori, Jap.

SOURCE: Vet.Microbiol. (43, No. 2-3, 173-82, 1995) 4 Fig. 2
Tab. 10 Ref.
CODEN: VMICDQ

AVAIL. OF DOC.: Department of Veterinary Microbiology, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori 034, Japan.

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1995-63559 VETU

AB The protective activity and antigenic analysis of fractions of culture filtrates of 11 **Erysipelothrix rhusiopathiae** strains are reported. In SPF mice, protection was achieved using the first (P-1) fraction obtained by Sephadex G-200 gel filtration of culture filtrate. In active and passive immunization trials, s.c. strain Agata, Fujisawa, Koganei 65-0.15 and SE-9 P-1 fractions were protective while in active immunization trials, strain Shizuoka-63 P-1 was also effective. Growth agglutination (GA) titers of protective antisera ranged from 80 to 320. Electrophoresis showed over 20 bands in each strain and Western blot analysis showed that protective antisera reacted with the 64 and 43 kDa proteins.

ABEX Culture filtrate from 11 strains of **E. rhusiopathiae** was fractionated and fractions concentrated by ultrafiltration. SPF female mice (4-wk-old) were injected s.c. with 250 ug strain Koganei 65-0.15 P-1 or P-2 fraction in **aluminum phosphate** gel and challenged s.c. 3 wk later with strain Fujisawa (1 x 10 power 3 CFU). In active immunization ED50 trials, mice were injected s.c. with 100, 20 or 4 ug P-1 of 1 of the 11 strains in **aluminum phosphate** gel and challenged as above. Antisera against P-1 fraction was raised in mice given 200 ug P-1 in Freund's complete adjuvant twice over 2 wk. In passive immunization ED50 trials, 1:1, 1:10, 1:100, 1:1000 and 1:10,000 diluted antisera was injected s.c. 4 hr before challenge. Only fractions P-1 and P-2 were eluted from culture filtrates and only fraction P-1 protected mice against challenge. The P-1 protein content was highest for strain Shizuoka-63 (7.1 ug) and was 2.2 to 4.6 mg for the other strains. In active immunization trials, PD50 was low at 2 ug or less for strains Agata, Fujisawa, Shizuoka-63, Koganei-65-0.15 and SE-9. In passive immunization trials, PD50 was highest for strains Agata and SE-9 while all strains except for 2179 and 2553 showed protective activity. GA titers of protective antisera ranged from 80 to 320. Electrophoresis of sonicated antigens showed over 20 bands in each strain and bands of 76 to 26 kDa. Western blot analysis showed that protective antisera reacted with the 64 and 43 kDa proteins.

L11 ANSWER 10 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1995-61995 VETU

TITLE: Prevention of clinical outbreak of erysipelas caused by **E. rhusiopathiae** type 10.

09/489711

AUTHOR: Riising H J; Horslund Pedersen E
CORPORATE SOURCE: Intervet
LOCATION: Copenhagen; Logstrup, Den.
SOURCE: Int.Pig Vet.Soc.Congress (13 Meet., 228, 1994) 2 Tab. 2
Ref.
AVAIL. OF DOC.: Intervet Scandinavia AS, Copenhagen, Denmark.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1995-61995 VETU
AB In a pig herd with a clinical outbreak of erysipelas despite routine vaccination with a conventional vaccine, subsequent vaccination with Combinord, a formalin inactivated vaccine containing **Erysipelothrix rhusiopathiae** types 2 and 10 and Haemophilus parasuis antigens and Alhydrogel (**aluminum hydroxide**) adjuvant, allowed no further outbreaks. Vaccination with a conventional vaccine containing only type 2 cells allowed further infections. Combinord induced antibodies against both serotypes, while type 2 or type 10 vaccines showed higher responses to the homologous antigen. There were no side effects. (conference abstract).
ABEX Sows vaccinated with a conventional vaccine yrly developed occasional outbreaks of erysipelas caused by serotypes 10 and/or 11. 12, 7, 2 And 7 pigs were vaccinated with Combinord, type 2 or type 10 vaccine or unvaccinated, respectively. ELISA titers to type 2 were 10, 38.8, 6.9 and 1.9, respectively, and to type 10 were 13, 16.9, 21.3 and 1.8, respectively. 135 Sows were then vaccinated with Combinord and 138 with the conventional type 2 vaccine. They had 1393 vs. 1430 live piglets. Clinical erysipelas developed in 0 and 3 cases, respectively, all showing type 10 or type 10/11 antigens.
L11 ANSWER 11 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1993-182249 [22] WPIDS
CROSS REFERENCE: 1992-024125 [03]
DOC. NO. CPI: C1993-080684
TITLE: Pasteurella multocida typed strain 4677 bacterin vaccine - contain bordetella bronchiseptica and/or **erysipelothrix rhusiopathiae** bacterins used to inoculate animals against atropic rhinitis and erysipelas.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): FRANTZ, J C; KEMMY, R J; ROBERTS, D S; SWEARINGIN, L A
PATENT ASSIGNEE(S): (PFIZ) PFIZER INC; (SMIK) SMITHKLINE BEECHAM CORP
COUNTRY COUNT: 20
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9309809	A1	19930527	(199322)*	EN	66
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE					
W: AU CA JP US					
AU 9331430	A	19930615	(199340)		
EP 614371	A1	19940914	(199435)	EN	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE					
JP 07501334	W	19950209	(199515)		
EP 614371	A4	19950607	(199616)		

Searcher : Shears 308-4994

09/489711

AU 669681 B 19960620 (199632)
US 5695769 A 19971209 (199804) 14

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9309809	A1	WO 1992-US10008	19921113
AU 9331430	A	AU 1993-31430	19921113
EP 614371	A1	EP 1992-925340	19921113
		WO 1992-US10008	19921113
JP 07501334	W	WO 1992-US10008	19921113
		JP 1993-509531	19921113
EP 614371	A4	EP 1992-925340	
AU 669681	B	AU 1993-31430	19921113
US 5695769	A CIP of	US 1990-537454	19900613
	Cont of	US 1991-792490	19911115
		WO 1992-US10008	19921113
		US 1994-244052	19940711

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9331430	A Based on	WO 9309809
EP 614371	A1 Based on	WO 9309809
JP 07501334	W Based on	WO 9309809
AU 669681	B Previous Publ.	AU 9331430
	Based on	WO 9309809
US 5695769	A CIP of	US 5536496
	Based on	WO 9309809

PRIORITY APPLN. INFO: US 1991-792490 19911115; US 1990-537454
19900613; US 1994-244052 19940711

AN 1993-182249 [22] WPIDS

CR 1992-024125 [03]

AB WO 9309809 A UPAB: 19980316

Vaccine compsn. comprises a *Pasteurella multocida* type D strain 4677 bacterin with a cell-bound toxoid, which upon admin. neutralised antibody to the toxin.

Also claimed are: (1) a *P. multocida* type D strain 4677 bacterin with a cell-bound toxoid, which on admin. to an animal induced the prodn. of neutralising antitoxin; (2) a vaccine compsn. comprising the bacterin of (1) and a *P. multocida* soluble free toxoid; and (3) a vaccine compsn. comprising the components of (2) and a *Bordetella bronchiseptica* bacterin and an *Arysipelothrix rhusiopathiae* bacterin.

The vaccine is pref. produced by treating *P. multocida* in the exponential phase of growth with formaldehyde to inactivate the intracellular toxin. The vaccine dosage comprises 0.5-3 ml of a sterile suspension of an immunogenic amt. of the *P. multocida* bacterin with cell-bound toxoid, esp. 150 relative toxoid units/ml free toxoid. The vaccine also comprises an adjuvant, pref.

Al(OH)4, a saponin, **Mg(OH)2**, **Al phosphate**, **Mg phosphate** or a **Ca cpd.**

USE/ADVANTAGE - The vaccines are used to vaccinate animals against atropic rhinitis and erysipelas. The vaccine is storage stable at 4 deg.C for at least 24 hours. Free and cell-bound toxoids

have been seen to act synergistically in a single prepn.. Other vaccine components include E. coli, pneumonic P. multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Clostridium perfringens C and D toxoids, pseudorabies virus (modified live and/or killed virus), rotavirus vaccine (modified live), coronavirus vaccine (modified live virus) and M. hyopneumoniae. Swine are pref. vaccinated at 1 week of age, with a booster dose at weaning age. Pregnant dams are given 2 doses, with the last given 2 weeks before farrowing. Booster doses are given prior to each subsequent farrowindy
Dwg.0/0

ABEQ US 5695769 A UPAB: 19980126

Vaccine compsn. comprises a Pasteurella multocida type D strain 4677 bacterin with a cell-bound toxoid, which upon admin. neutralised antibody to the toxin.

Also claimed are: (1) a P.multocida type D strain 4677 bacterin with a cell-bound toxoid, which on admin. to an animal induced the prodn. of neutralising antitoxin; (2) a vaccine compsn. comprising the bacterin of (1) and a P.multocida soluble free toxoid; and (3) a vaccine compsn. comprising the components of (2) and a Bordetella bronchiseptica bacterin and an Arysipelothrix rhusiopathiae bacterin.

The vaccine is pref. produced by treating P. multocida in the exponential phase of growth with formaldehyde to inactivate the intracellular toxin. The vaccine dosage comprises 0.5-3 ml of a sterile suspension of an immunogenic amt. of the P. multocida bacterin with cell-bound toxoid, esp. 150 relative toxoid units/ml free toxoid. The vaccine also comprises an adjuvant, pref.

Al(OH)4, a saponin, Mg(OH)2, Al phosphate, Mg phosphate or a Ca cpd..

USE/ADVANTAGE - The vaccines are used to vaccinate animals against atropic rhinitis and erysipelas. The vaccine is storage stable at 4 deg.C for at least 24 hours. Free and cell-bound toxoids have been seen to act synergistically in a single prepn.. Other vaccine components include E. coli, pneumonic P. multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Clostridium perfringens C and D toxoids, pseudorabies virus (modified live and/or killed virus), rotavirus vaccine (modified live), coronavirus vaccine (modified live virus) and M. hyopneumoniae. Swine are pref. vaccinated at 1 week of age, with a booster dose at weaning age. Pregnant dams are given 2 doses, with the last given 2 weeks before farrowing. Booster doses are given prior to each subsequent farrowindy
Dwg.0/0

L11 ANSWER 12 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1992-61129 VETU

TITLE: Priming Defences Against the Challenge of Disease.

AUTHOR: Walkland C

LOCATION: U.K.

SOURCE: Pig Farming (40 No. 3, 36-37, 1992)

AVAIL. OF DOC.: No Reprint Address.

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1992-61129 VETU

AB The production of a combined E. coli and erysipelas vaccine is described. The vaccine contains **Erysipelothrix**

rhusiopathiae serotypes 1 and 2, *E. coli* antigens K88ab, K88ac, K99 and 987P, labile toxin B fragment and 12 strains of inactivated whole *E. coli* bacteria. The total production time for manufacture of the vaccine is 12 wk from the beginning of antigen production to dispatch.

ABEX The first combined *E. coli* and erysipelas vaccine has recently been launched. It contains *E. rhusiopathiae* serotypes 1 and 2 and selected *E. coli* antigens K88, K99, 987P and labile toxin B fragment (LTB). It also contains 12 strains of inactivated whole *E. coli* bacteria. The whole cells provide added protection against less common diseases such as septicemia and endotoxin-mediated edema disease. LTB is included because some *E. coli* strains contain a toxin which disrupts the ionic balance in the gut, resulting in diarrhea. Specific antibodies to sub unit B, produced in response to the LTB in the vaccine, inhibit the attachment of the toxin to the gut wall. The antigen K88 also inhibits initial bacterial colonization. There are 22 serotypes of *E. rhusiopathiae*, the most important being serotype 2. Vaccines containing serotype 2 will protect against most other serotypes, but an increased incidence of serotype 1 infection prompted the incorporation of serotype 1 antigens into the vaccine. Production of each antigen can take between 2 and 14 days. For *E. coli* antigens, the pili are stripped off the bacterial surface and centrifuged and then inactivated with formaldehyde. Several weeks of potency and sterility tests then take place; there are over 100 quality tests for each batch of vaccine. Each batch of vaccine is 1800 l in volume, equivalent to 36,000 bottles. The antigens are then blended with a preservative, thiomersal, and added to a base of **aluminum hydroxide** gel. Further potency tests, taking up to 5 wk, are carried out and sterility is again tested. Total production time from antigen production to distribution is 12 wk. (CLW)

L11 ANSWER 13 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1990-63448 VETU M

TITLE: Cloning and Expression in *Escherichia coli* of a Protective Antigen of **Erysipelothrix rhusiopathiae**.

AUTHOR: Galan J E; Timoney J F

LOCATION: Ithaca; Stony Brook, N.Y., USA

SOURCE: Infect.Immun. (58, No. 9, 3116-21, 1990) 5 Fig. 2 Tab. 34 Ref. (J35/VDM)
CODEN: INFIBR

AVAIL. OF DOC.: Department of Veterinary Microbiology, New York State College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, U.S.A.

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1990-63448 VETU M

AB S.c. immunization of mice with either of 2 clones (lambda gt11/ersA and lambda gt11/ersB from a lambda gt11 library of **Erysipelothrix rhusiopathiae** gave partial protection against subsequent challenge. Antisera raised in guinea pigs against the recombinant clones reacted with polypeptides of 66, 64 and 43 kDa. These polypeptides were also the major bands detected by convalescent pig serum. Mice immunized with both recombinant clones had a higher survival rate, than those immunized

with the negative control (lambda gt11). Western and Southern blot analysis revealed that the cloned genes were present in all of the **E. rhusiopathiae** strains examined.

ABEX Inbred ICR female mice (8 wk-old) were immunized s.c. with recombinant proteins (500 ug) in **aluminium hydroxide** on 2 occasions 15 days apart. Mice were then challenged with 100 x 50% lethal dose of **E. rhusiopathiae** El-6P. Antisera against recombinant proteins was produced by s.c. inoculation of guinea pigs with protein (500 ug) in Freund's complete adjuvant. Mice immunized with recombinant proteins had a significantly increased mean time to death (6.4 and 6.5 for the 2 clones) compared to controls (4.3 days). No survivors were seen in mice immunized with lambda gt11 alone although the survival rates for lambda gt11/ersB and lambda gt11/ersA were 14 and 17%, respectively. Agarose gel electrophoresis of EcoRI digests of the 2 clones suggested that they were identical.

L11 ANSWER 14 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1990-61127 VETU M T

TITLE: Value and Limitations of Vaccines and of Vaccination of Pigs.

(Interet et Limites des Vaccins et de la Vaccination chez le Porc)

AUTHOR: Laval A

LOCATION: Maisons Alfort, Fr.

SOURCE: Recl.Med.Vet. (165, No. 8-9, 697-706, 1989) 2 Fig. 3 Tab. 82 Ref. (M25/JLC)

CODEN: RMVEAG

AVAIL. OF DOC.: Service de Pathologie Medicale du Betail et des Animaux de Bosse-Cour, Ecole Nationale Veterinaire d'Alfort, 94704 Maisons Alfort Cedex, France.

LANGUAGE: French

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1990-61127 VETU M T

AB The causes of vaccination failure in the pig are reviewed. The vaccine virus, vaccine type, protocol, rearing conditions, concomitant therapy (antibiotics), toxic factors (aflatoxin, T2 toxin or ochratoxin A), pollutants (polychlorobiphenyls or PCB, Pb, Cd and DDT) and nutritional factors (deficiency in vitamins A, D or E, Se, Cu, Zn, Fe or Co) are all implicated in vaccine failure. Problems with Aujeszky disease, *Treponema hyodysenteriae*, edema disease (*E. coli* vaccine), *Strept. suis* type 2, *Actinobact. parasuis* or *pleuropneumoniae*, **Erysipelothrix rhusiopathiae**, TGE, FMD, swine fever, porcine parvovirus, influenza and atrophic rhinitis vaccines are discussed. Local intolerance is more common with oil-adjuvanted inactivated vaccines, but general intolerance may be unavoidable.

ABEX Only inactivated FMD or live swine fever vaccines afford full protection and prevent viral shedding. *E. coli* 0139 K82 Ent-K88 glutaraldehyde-inactivated vaccine (edema disease) almost eliminates mortality and reduces symptoms, but not viral replication. Oil-adjuvanted inactivated *Treponema* vaccine induces diarrhea. Inactivated **Al-hydroxide**-adjuvanted *A. parasuis* vaccine eliminates symptoms, mortality and bacteriosis. The only pathogen-related vaccinal failure concerns African swine fever. *A. pleuropneumoniae* vaccination is often ineffective due to

the abundance of field serotypes and **E. rhusiopathiae** type 2 does not protect against types 9 or 10. Live virus must be adaptable to antigenic variations. In inactivated vaccines, **Al-hydroxide** adjuvant is unsatisfactory in the pig, while oil-adjuvant can cause local intolerance, especially with hypersensitizing bacterial antigen (*Actinobac.*), intradermal injection avoids this problem. Animal-related failures include those due to poor physiological status, environment, concomitant therapy, toxic factors, pollutants or a deficiency in vitamins A, D or E, Se, Zn, Cu, Fe or Co. General intolerance must be balanced against the benefit of vaccination, but may be minimized by dietary adaptation. Vaccinal cell lines or immune sera may be contaminated by bovine viral diarrhea or Border disease and trypsin by porcine coronavirus. Live vaccines may themselves spread infection.

L11 ANSWER 15 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1989-61034 VETU M

TITLE: Use of a Live Oral Vaccine to Immunize Turkeys against Erysipelas.

AUTHOR: Bricker J M; Saif Y M

LOCATION: Wooster, Ohio, USA

SOURCE: Avian Dis. (32, No. 4, 668-73, 1988) Tab. 15 Ref.

CODEN: AVDIAI

AVAIL. OF DOC.: Food Animal Health Research Program, and Department of Poultry Science, Ohio Agricultural Research and Development Center, Ohio State University, Wooster, Ohio 44691, U.S.A. (Y.M.S.).

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1989-61034 VETU M

AB Medium-bodied white (EL) and broad-breasted large white young SPF turkeys vaccinated p.o. with Hydrovac (live **Erysipelothrix rhusiopathiae** serotype 1a, Anchor) comprising 1 to 3 doses administered 2 to 3 wk apart or s.c. with the inactivated **aluminum-hydroxide** absorbed erysipelas bacteria Ersipelin (Am.Home-Products) were protected against challenge with **E. rhusiopathiae** serotype 1a (VS). The live bacterin-production strain of **E. rhusiopathiae** serotype 2 (EW-2, Franklin) was not effective as a vaccine. The results indicate the potential usefulness of a p.o. live vaccine in erysipelas control in turkeys.

ABEX EL and SPF turkeys (5 to 9 wk-old) received s.c. Ersipelin or various doses of Hydrovac (8.8×10^9 power 9, 7 or 5 CFU) or EW2 (2.2×10^9 power 9 or 2.5×10^7 power 7 CFU) p.o. in drinking water with skimmed milk (1.3 g/L). Birds were challenged with 1 ml s.c. VS either from broth culture or twice yolk passaged. 31-95% Unvaccinated challenged EL or SPF turkeys died with generalized septicemia 40-96 hr post challenge with VS. Vaccinees that died had similar clinical signs. **E. rhusiopathiae** was isolated from the liver, heart blood, lung and spleen of all birds that died after challenge. Only 1 bird (EL) given E did not survive. Hydrovac at 8.8×10^9 power 9 CFU did not protect EL birds from VS challenge (9.6×10^4 power 4 CFU) but 2 doses 3 wk apart did. Hydrovac at 8.8×10^9 power 9 CFU or EW-2 (2.2×10^9 power 9 CFU), or 2 doses EW-2 3 wk apart (2nd dose 2.5×10^7 power 7 CFU) did not protect SPF birds but 2 doses Hydrovac 3 wk apart did. EL

birds given 1, 2 or 3 p.o. doses Hydrovac (8.6 x 10 power 9 CFU) over 6 hr were not protected from VS (3.2 x 10 power 9 CFU) 3 wk later but a 2nd treatment with 2 or 3 doses was effective. 1 Treatment of 2 doses Hydrovac given over 48 hr was not effective whilst 2 treatments 3 wk apart were. 2 Treatments 3 wk apart of 2 doses Hydrovac (8.8 x 10 power 9 CFU) 3 hr apart protected EL birds against VS (1.4 x 10 power 9 CFU) after 2 wk. Birds given lower vaccine doses were not protected. SPF birds treated similarly but with 2 wk between treatments and 4.3 x 10 power 9 CFU Hydrovac/dose were protected following challenge.5

L11 ANSWER 16 OF 23 CABA COPYRIGHT 2001 CABI

ACCESSION NUMBER: 84:126993 CABA

DOCUMENT NUMBER: 842248940

TITLE: Swine erysipelas vaccine as a model of study of enhanced immunogenic activity owing to a double adjuvant

AUTHOR: Seimenis, A.; Skyrianos, G.; Menasse, I.; Stoforos, E.; F.M. Cancellotti [EDITOR]; D. Galassi [EDITOR]

CORPORATE SOURCE: Vet. Inst. Infectious Parasitic Dis., Min. Agric., Athens, Greece.

SOURCE: (1984) pp. 203-208. 8 ref.
Publisher: Commission of the European Communities.
Meeting Info.: Agriculture-adjuvants, interferon and non-specific immunity. A seminar in the CEC Programme of Coordination of Research on Animal Pathology, Venice, April 1983.

PUB. COUNTRY: Luxembourg

DOCUMENT TYPE: Miscellaneous

LANGUAGE: English

AB The immunogenicity of an inactivated **Erysipelothrix rhusiopathiae** vaccine was improved by adding 15% **aluminium hydroxide** gel, and an oil mixture (Bayol F 8.5 parts, Arlacel A 1.5 parts). Efficacy of the vaccine with and without the adjuvants was tested in mice and swine challenged with **E. rhusiopathiae** 21 days after vaccination. The vaccine caused no adverse effects.

L11 ANSWER 17 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1984-62439 VETU M T

TITLE: Swine Erysipelas-a Review of Prevalence and Research.

AUTHOR: Wood r L

LOCATION: Ames, Iowa, USA

SOURCE: J.Am.Vet.Med.Assoc. (184, No. 8, 944-49, 1984) 4 Fig. 2
tab. 63 Ref
CODEN: JAVMA4

AVAIL. OF DOC.: National Animal Disease Center, Agricultural Research Service, USDA, PO Box 70, Ames, IA 50010, U.S.A.

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

AN 1984-62439 VETU M T

AB A review of swine erysipelas is presented with regard to incidence in USA, etiology, immunology, epizootiology, pathogenesis, and vaccine development.

ABEX Heat stable antigens consisting of fragments of the cell wall form the basis for division of the species into serotypes. The glycolipoprotein is an essential component of whole-culture bacterins. Methods for attenuation of **Erysipelothrix rhusiopathiae** have included air-drying and passage in media containing acridine dyes. Avirulent vaccine is used in both parenteral and oral dosage forms. Aerosol vaccination is used in some parts of Europe and USSR. A bacterin consisting of formalin-killed whole culture adsorbed on an **aluminum hydroxide** gel is usually made from selected strains of serotype 2. Most of the immunizing antigen is found in the culture filtrate. There have been no significant differences found in the efficacy of avirulent live vaccines and bacterins under experimental conditions. Inactivated cells of *Corynebact. spp.* given with **E. rhusiopathiae** bacterin raised the potency of the bacterin in mice 1.35 to 2.15 times.

L11 ANSWER 18 OF 23 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1985:391670 BIOSIS

DOCUMENT NUMBER: BA80:61662

TITLE: THE INFLUENCE OF IMMUNOMODULANTS ON THE DEVELOPMENT OF SECONDARY-TYPE ANTIBACTERIAL ANTI **ERYSIPELOTHRIX-RHUSIOPATHIAE** IMMUNITY.

AUTHOR(S): KULCSAR A; PADANYI M; RETHY L A; RETHY L; BACSKAI L

CORPORATE SOURCE: PHYLAXIA, SZALLAS-U 5., H-1107 BUDAPEST, HUNGARY.

SOURCE: ANN IMMUNOL HUNG, (1984 (RECD 1985)) 24 (0), 171-176.
CODEN: AIMHA3. ISSN: 0570-1708.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB The influence of *Corynebacterium parvum* (*Propionibacterium acnes*) and *C. lymphophilum*-originating immunomodulants on the development of the secondary type antibacterial immunity as investigated. As test antigen, **E. rhusiopathiae bacterium** was applied (3 times. 109 inactivated bacterial cells, absorbed onto aluminium **hydroxide carrier**). The adjuvant-type immuno modulating activity of the immuno modulants was present if given mainly prior to, or together with the 1st immunization (priming) with the bacterium.

L11 ANSWER 19 OF 23 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1984:267008 BIOSIS

DOCUMENT NUMBER: BA78:3488

TITLE: IMMUNO MODULATION WITH INACTIVATED BACTERIUM SUSPENSIONS OR DERIVATIVES 2. THE INFLUENCE OF *CORYNEBACTERIUM* SUSPENSIONS ON THE DEVELOPMENT OF PRIMARY TYPE ANTI TOXIC AND ANTI BACTERIAL IMMUNITY.

AUTHOR(S): SOLTENSZKY J; RAJHATHY B; GERESI M; ECSI R; PADANYI M; RETHY L A JR; KULCSAR A; GELENCSEI F; HEGEDUS L; ET AL

CORPORATE SOURCE: HUMAN INST. SEROBACTERIOL. PRODUCTION RES., LAB. NO. 229., DEP. ACTIVE IMMUNIZATION, DEP. BIOL. CONTROL.

SOURCE: ANN IMMUNOL HUNG, (1980 (1983)) 20 (0), 97-108.
CODEN: AIMHA3. ISSN: 0570-1708.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB Having investigated the influence of *Corynebacterium* suspensions on the development of primary type antitoxic and antibacterial immunity

[in mice] the results can be summarized as follows. The immunizations were carried out with the following vaccines: **aluminium-phosphate**-adsorbed tetanus toxoid, **aluminium-hydroxide** adsorbed perfringens epsilon toxoid and **aluminium-hydroxide** adsorbed **Erysipelothrix rhusiopathiae** vaccine. All the vaccines were tested in active immunization toxin virulent bacterium challenge model. The results concerning the effect of corynebacterial immunostimulants/modulators on the development of anti-tetanus (primary-type) antitoxic immunity unanimously show that the corynebacterial immunostimulants except 1 strain generally increase the degree of protection against tetanus in case of joint application with tetanus toxoid. Among the *Corynebacterium* strains investigated, only *C. parvum* RR-1 [*Propionibacterium acnes*] exhibited an adjuvant effect on the development of the primary antitoxin immunity against perfringens epsilon toxin. One of the 2 *C. parvum* strains suppressed both the development of tetanus and anti-perfringens primary immune responses. The *C. parvum* RR-1 potentiated while the unrelated *C. parvum* RR-1-2 suppressed the immune reactions. Results concerning the development of antibacterial immunity show that immunological adjuvanting effect could be demonstrated if the vaccine was administered simultaneously with the immunomodulator. The subsequent application suppressed the development of the primary anti-**E. rhusiopathiae** immunity.

L11 ANSWER 20 OF 23 CABA COPYRIGHT 2001 CABI
 ACCESSION NUMBER: 80:123255 CABA
 DOCUMENT NUMBER: 802257219
 TITLE: Comparison of the efficacy of swine erysipelas vaccines
 Sravnitel'naya effektivnost vaktsin protiv rozhi
 AUTHOR: Konyaev, M. T.; Shcherbinin, V. K.
 CORPORATE SOURCE: Vses. Inst. Nezaraznykh Boleznei Zhivotnykh, Voronezh, USSR.
 SOURCE: Veterinariya, Moscow, USSR, (1980) No. 3, pp. 33-34.
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 AB Trials were conducted on 500 pigs aged 10-14 weeks with the classical "depot" vaccine of D.F. Konev (1899), live attenuated "VR-2" vaccine, and a concentrated **aluminium hydroxide** vaccine, all three in various doses, with a second dose being given 14, 30 or 46 days after the first. Challenge infection by i/m inoculation of 800 million **E. rhusiopathiae** was done 62 days after the first vaccination. Protection was best with the live vaccine in a dose of 0.5-1.0 ml, with a second dose given after 30 or 46 days.

L11 ANSWER 21 OF 23 VETB COPYRIGHT 2001 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 1981-62260 M T
 TITLE: EFFECTS OF ANTIBIOTICS ON THE IMMUNE SYSTEM OF ANIMALS. I. MOUSE EXPERIMENTS WITH THE LOW-VIRULENCE VR2 STRAIN OF **ERYSIPELOTHRIX RHUSIOPATHIAE**. II. MOUSE EXPERIMENTS WITH AN INACTIVATED ADSORBED VACCINE AGAINST SWINE ERYSIPELAS. III. EXPERIMENTS IN PIGS IMMUNIZED WITH LIVE AND INACTIVATED SWINE

09/489711

ERYSIPELAS VACCINES.
AUTHOR: TU T D
LOCATION: BUDAPEST, HUNG.
SOURCE: ACTA VET. ACAD. SCI. HUNG. (28, NO.3, 297-331, 1980)
LANGUAGE: English

L11 ANSWER 22 OF 23 VETB COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1981-62257 M
TITLE: THE DEVELOPMENT OF PRIMARY ANTIBACTERIAL IMMUNE

PROTECTION AGAINST **ERYSIPELOTHRIX**
RHUSIOPATHIAE AND THE EFFECT OF ANAEROBIC
CORYNEBACTERIAL IMMUNOSTIMULANTS.

AUTHOR: PADANYI M
CORPORATE SOURCE: PHYLAXIA
LOCATION: BUDAPEST, HUNG.
SOURCE: ACTA VET. ACAD. SCI. HUNG. (28, NO.3, 273-75, 1980)
LANGUAGE: English

L11 ANSWER 23 OF 23 JAPIO COPYRIGHT 2001 JPO

ACCESSION NUMBER: 2000-219637 JAPIO

TITLE: **ERYSIPELOTHRIX RHUSIOPATHIAE**

ANTIGEN COMPOSITION AND VACCINE PREPARATION

INVENTOR: DAVID STEWART ROBERTS; SWEARINGIN LEROY A; BRIAN
THOMAS SUIITAA

PATENT ASSIGNEE(S): PFIZER PROD INC)

PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 2000219637A		20000808	Heisei	A61K039-02

JP

APPLICATION INFORMATION

ST19N FORMAT: JP2000-017930 20000124

ORIGINAL: JP2000017930 Heisei

PRIORITY APPLN. INFO.: US1999 117704 19990129

SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined
Applications, Vol. 2000

AN 2000-219637 JAPIO

AB PROBLEM TO BE SOLVED: To obtain the subject vaccine composition that
is useful as a vaccine for vaccinating animals, preferably
mammalians or birds by using a fluid fraction originating from a
specific culture mixture and stabilizers.

SOLUTION: This vaccine composition comprises (A) a fluid fraction
originating from the culture mixture of **Erysipelothrix**
rhusiopathiae (swine erysipelas) and (B) a stabilizer. The
component B is selected from **metal hydroxides**,

metal phosphates, **aluminum**
hydroxide gel, **aluminum phosphate gel**,
calcium phosphate gel, **zinc**
hydroxide/calcium hydroxide gel or

alum. In the component B, the culture mixture is deactivated
with formalin or β -propiolactone and the fraction is preferably
concentrated in 3-30 times. For example, the **aluminum**
hydroxide gel is added on the concentrate of the culture
mixture so that the final concentration may reach about 10-40 vol.%.
COPYRIGHT: (C)2000, JPO

09/489711

(FILE 'CAPLUS' ENTERED AT 12:33:02 ON 17 OCT 2001)

- L1 7 SEA FILE=REGISTRY ABB=ON PLU=ON ("ALUMINUM HYDROXIDE"/CN
N OR "ALUMINUM HYDROXIDE (AL(18OH)3)"/CN OR "ALUMINUM
HYDROXIDE (AL(OD))"/CN OR "ALUMINUM HYDROXIDE (AL(OD)2)"/
CN OR "ALUMINUM HYDROXIDE (AL(OD)3)"/CN OR "ALUMINUM
HYDROXIDE (AL(OH))"/CN OR "ALUMINUM HYDROXIDE (AL(OH)2)"/
CN OR "ALUMINUM HYDROXIDE (AL(OH)3)"/CN)
- L2 6 SEA FILE=REGISTRY ABB=ON PLU=ON ("CALCIUM HYDROXIDE"/CN
OR "CALCIUM HYDROXIDE (40CA(OH))"/CN OR "CALCIUM
HYDROXIDE (CA(OD))"/CN OR "CALCIUM HYDROXIDE (CA(OD)2)"/C
N OR "CALCIUM HYDROXIDE (CA(OH)(OT))"/CN OR "CALCIUM
HYDROXIDE (CA(OH))"/CN OR "CALCIUM HYDROXIDE (CA(OH)2)"/C
N)
- L3 4 SEA FILE=REGISTRY ABB=ON PLU=ON ("ZINC HYDROXIDE"/CN
OR "ZINC HYDROXIDE (65ZN(OH)2)"/CN OR "ZINC HYDROXIDE
(ZN(OD))"/CN OR "ZINC HYDROXIDE (ZNOH)"/CN)
- L4 13 SEA FILE=REGISTRY ABB=ON PLU=ON ("ALUMINUM PHOSPHATE"/C
N OR "ALUMINUM PHOSPHATE (1:1)"/CN) OR ("ALUMINUM
PHOSPHATE (AL(PO4))"/CN OR "ALUMINUM PHOSPHATE (AL0.5(PO4
)0.5)"/CN OR "ALUMINUM PHOSPHATE (AL2(HPO4)3)"/CN OR
"ALUMINUM PHOSPHATE (AL2(OH)3(PO4))"/CN OR "ALUMINUM
PHOSPHATE (AL2O3(P2O5)5)"/CN OR "ALUMINUM PHOSPHATE
(AL2P6O18)"/CN OR "ALUMINUM PHOSPHATE (AL3(OH)3(PO4)2)"/C
N OR "ALUMINUM PHOSPHATE (AL3(PO4)(OH)6)"/CN OR "ALUMINUM
PHOSPHATE (AL4(P4O12)3)"/CN OR "ALUMINUM PHOSPHATE
(AL4P10O31)"/CN OR "ALUMINUM PHOSPHATE (ALH2P3O10)"/CN)
OR "ALUMINUM PHOSPHATE (ALP3O9)"/CN)
- L5 6 SEA FILE=REGISTRY ABB=ON PLU=ON ("CALCIUM PHOSPHATE"/CN
OR "CALCIUM PHOSPHATE (1:1)"/CN OR "CALCIUM PHOSPHATE
(1:2)"/CN OR "CALCIUM PHOSPHATE (3:2)"/CN OR "CALCIUM
PHOSPHATE (CA(H2PO4)2)"/CN) OR "CALCIUM PHOSPHATE
(CA(PO3)2)"/CN OR "CALCIUM PHOSPHATE (CA2P2O7)"/CN)
- L6 2 SEA FILE=REGISTRY ABB=ON PLU=ON ALUM/CN
- L7 38 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2 OR L3 OR L4
OR L5 OR L6
- L12 462119 SEA FILE=CAPLUS ABB=ON PLU=ON L7 OR STABILIS? OR
STABILIZ? OR (METAL OR AL OR ALUMIN? OR CALCIUM OR CA OR
ZINC OR ZN) (W) (OH OR HYDROXIDE) OR CAOH OR ALOH OR ZNOH
OR (METAL OR ALUMIN? OR CALCIUM OR AL OR CA) (W) (PO# OR
PHOSPHATE) OR ALPO# OR CAPO# OR ALUM
- L13 3 SEA FILE=CAPLUS ABB=ON PLU=ON L12 AND (ERYSIPEL? OR
E) (W) RHUSIOPATH?

=> s l13 not 19

L14 1 L13 NOT L9

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:403420 CAPLUS

DOCUMENT NUMBER: 135:24648

TITLE: Ether-type surfactant-free oil adjuvants and
animal vaccines containing the adjuvants

INVENTOR(S): Hashimoto, Satoru; Ogiya, Toshiaki; Katayama,
Shigeji; Oda, Kenji

PATENT ASSIGNEE(S): Nihon Surfactants Industry Co., Ltd., Japan;
Microbiochemical Research Foundation; Nikko
Chemicals Co., Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF

09/489711

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001151699	A2	20010605	JP 1999-337421	19991129

AB Oil adjuvants, which have good emulsion stability and do not cause necrosis, induration, pain, etc., at the inoculation sites, comprise O/W emulsion contg. animal fats and/or vegetable oils, polyhydric alc. fatty acid esters having no polyoxyalkylene structure as emulsifiers, and sugar or sugar alc. fatty acid esters as immunostimulants. Animal vaccines contg. the oil adjuvants and .gtoreq.1 antigens are also claimed. An O/W emulsion was prepd. from squalane 50.0, dl-.alpha.-tocopherol 0.02, mannitol oleate 2.5, sorbitan monolaurate 1.0, hexaglycerin monolaurate 2.0, decaglycerin monolaurate 2.0, glucose 20.0, and H2O 22.48%. Time course of neutralizing antibody titer, pyrogenicity, and behavioral change in a cat inoculated with felid herpesvirus and the adjuvant were examd.

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, PHIC, PHIN, TOXLIT, TOXLINE' ENTERED AT 12:34:26 ON 17 OCT 2001)

L15 28 S L13
L16 5 S L15 NOT L10
L17 5 DUP REM L16 (0 DUPLICATES REMOVED)

L17 ANSWER 1 OF 5 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-516029 [47] WPIDS
DOC. NO. CPI: C2000-154021
TITLE: Vaccine containing lecithin, oil and surfactant as adjuvant, useful for protection against bacterial or viral pathogens, particularly in pigs, does not cause significant local reactions.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): DEARWESTER, D A; ROBERTS, D S; SWEARINGIN, L A
PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
COUNTRY COUNT: 32
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1023904	A2	20000802	(200047)*	EN	12
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
AU 9965372	A	20000803	(200047)		
CA 2296244	A1	20000729	(200051)	EN	
JP 2000219636	A	20000808	(200052)		11
CN 1270838	A	20001025	(200104)		
BR 2000000126	A	20010502	(200129)		
NZ 502341	A	20010831	(200157)		
ZA 2000000142	A	20010829	(200157)		22

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

Searcher : Shears 308-4994

09/489711

EP 1023904	A2	EP 1999-310514	19991223
AU 9965372	A	AU 1999-65372	19991221
CA 2296244	A1	CA 2000-2296244	20000119
JP 2000219636	A	JP 2000-17032	20000126
CN 1270838	A	CN 2000-101175	20000128
BR 2000000126	A	BR 2000-126	20000119
NZ 502341	A	NZ 2000-502341	20000114
ZA 2000000142	A	ZA 2000-142	20000114

FILING DETAILS:

PATENT NO	KIND	PATENT NO
NZ 502341	A Div in	NZ 513202

PRIORITY APPLN. INFO: US 1999-121760 19990226; US 1999-117705
19990129

AN 2000-516029 [47] WPIDS

AB EP 1023904 A UPAB: 20000925

NOVELTY - Vaccine composition (A) comprises (by volume) 0.25-12.5% lecithin (I); 1-23% oil (II); 1.5-3.5% at least one amphipathic surfactant (III) plus an antigen (Ag).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) adjuvant composition (B) containing (I)-(III) in the above proportions;

(2) preparation of vaccines by adding (B) to a composition containing Ag;

(3) antigen composition (C) comprising a Bordetella bronchiseptica culture that has been inactivated by adding formalin and then glutaraldehyde;

(4) vaccine composition (D) containing (C) plus an adjuvant;

(5) method for inactivating a B. bronchiseptica culture by adding formalin and then glutaraldehyde;

(6) composition containing B. bronchiseptica, formalin and glutaraldehyde;

(7) vaccine for protection against B. bronchiseptica infection comprising cells from a culture inactivated by method (5) plus a carrier; and

(8) method for protecting a piglet against atrophic rhinitis.

ACTIVITY - Antibacterial; antiviral.

Erysipelothrix rhusiopathiae cells were killed by treating with formalin and then glutaraldehyde, clarified, concentrated 10-fold and **stabilized** by adding aluminum gel at 30%. The product was mixed with 25 %volume of an adjuvant containing 20% mineral oil/lecithin and 16% Tween 80 plus Span 80, also containing thiomerosal and ethylenediamine tetraacetic acid as preservatives. Pigs were immunized with 2 ml doses of the product at 3 and 6 weeks of age, then challenged (at 9 weeks or 6 months of age) with virulent **E. rhusiopathiae**. Protection was 100% at 9 weeks and 75% at 6 months.

MECHANISM OF ACTION - Induction of a specific immune response.

USE - (A) can be formulated with Ag from any bacterial or viral pathogen, especially for protection of animals, specifically piglets against Bordetella bronchiseptica and/or Pasteurella multocida.

ADVANTAGE - (I)-(III) form a stable oil-in-water emulsion vaccine that induces minimal local reactions (irritation or inflammation) after vaccination (contrast other adjuvants containing

09/489711

mineral oil).
Dwg.0/1

L17 ANSWER 2 OF 5 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-388474 [33] WPIDS
DOC. NO. CPI: C1999-114642
TITLE: New capsule-deleted mutant of
Erysipelothrix rhusiopathiae YS-1
- has low pathogenicity and is genetically stable.
DERWENT CLASS: B04 D16
PATENT ASSIGNEE(S): (ARAI-I) ARAI K; (MORI-I) MORI Y; (NORQ)
NORINSUISANSO KACHIKU EISEI; (SEKI-I) SEKIZAKI T;
(SHIM-I) SHIMOCHI Y
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 11151084	A	19990608	(199933)*		12
JP 2992980	B2	19991220	(200005)		11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 11151084	A	JP 1997-333767	19971119
JP 2992980	B2	JP 1997-333767	19971119

FILING DETAILS:

PATENT NO	KIND	PATENT NO
JP 2992980	B2 Previous Publ.	JP 11151084

PRIORITY APPLN. INFO: JP 1997-333767 19971119

AN 1999-388474 [33] WPIDS

AB JP 11151084 A UPAB: 19990819

NOVELTY - A capsule-deleted mutant of **Erysipelothrix rhusiopathiae** YS-1 (FERM P-16446) which is derived from a transposon mutant of a virulent **Erysipelothrix rhusiopathiae** Fujisawa-SmR and shows tetracycline sensitivity, is new. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for the application of the above capsule-deleted mutant of **Erysipelothrix rhusiopathiae** YS-1 (FERM P-16446) as a live vaccine for the infectious disease of **Erysipelothrix rhusiopathiae**.

USE - The capsule deleted mutant is useful in the form of a vaccine.

ADVANTAGE - The mutant is low in pathogenicity and has no danger of restoring pathogenicity and is genetically stable.

Dwg.0/2

L17 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1994:175853 BIOSIS
DOCUMENT NUMBER: PREV199497188853
TITLE: Development of the technology of the production of dried live vaccines against avian Pasteurella

infection and porcine erysipelas.
 AUTHOR(S): Yartsev, M. Ya. (1); Basnak'yan, I. A.; Raevskii, A. A.; Sapegina, E. P.; Shishov, V. P.; Rogozhin, S. P.; Tokarik, E. F.; Maslak, A. A.
 CORPORATE SOURCE: (1) Res. Technol. Inst. Biol. Ind., Moscow Russia
 SOURCE: Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, (1993) Vol. 0, No. 3, pp. 63-70.
 ISSN: 0372-9311.
 DOCUMENT TYPE: Article
 LANGUAGE: Russian
 SUMMARY LANGUAGE: English

AB The technology of the production of dried live vaccine against Pasteurella infection of fowl from Pasteur's 2nd avirulent strain, strains AB and K, has been developed. This technology includes the process of batch cultivation of Pasteurella cells, controlled in such parameters as eH, pO-2 and glucose concentration, in fermenters in optimized culture medium, based on Hottinger hydrolysate and fermentative casein yeast hydrolysate, and preservation in improved saccharosegelatin medium prepared in potassium sulfate buffer solution. The new technology makes it possible to increase the yield of preparations with stable biological activity 5- to 13-fold in comparison with the traditional technology. Furthermore, the technology of the production of live dried vaccine against swine erysipelas from Erysipelothrix incidiosa strain BP-2 has been developed. This technology is based on maintaining the optimum conditions of the batch cultivation of E. incidiosa in meat medium based on Hottinger hydrolysate and media obtained from hydrolysate of pancreatic fermentation products of microbial biomass; the preparation thus obtained is **stabilized** in peptone-saccharose-gelatin medium prepared in potassium phosphate buffer solution. This increases the yield of the vaccine 8-fold in comparison with the traditional technology, while ensuring the stability of bacteria after drying and during prolonged storage.

L17 ANSWER 4 OF 5 CABA COPYRIGHT 2001 CABI

ACCESSION NUMBER: 90:137171 CABA
 DOCUMENT NUMBER: 902224377
 TITLE: Principles for the use of synchronous aerosol immunization of pigs against swine fever, erysipelas and salmonellosis
 Anwendungsgrundsätze für die synchrone aerogene Immunisierung gegen Schweinepest, Rotlauf und Salmonellose
 AUTHOR: Kaden, V.
 CORPORATE SOURCE: Friedrich-Loeffler-Inst., DDR-2201 Insel Riems, German Democratic Republic.
 SOURCE: Monatshefte für Veterinarmedizin, (1990) Vol. 45, No. 8, pp. 272-274. 8 ref.
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 SUMMARY LANGUAGE: English; Russian

AB Various refinements of the aerosol immunization technique, in use since 1982, were specified, included precise measurements for the enclosed space (or air lock) for holding the pigs. The dosage of vaccine mixture used is related to the space in the air lock irrespective of the number of animals. The immunization should be replaced by injection whenever the air temperature exceeded 25 deg C. Dried skimmed milk or spray-dried milk was added to the vaccine

mixture at 5% as a **stabilizer**.

L17 ANSWER 5 OF 5 CABA COPYRIGHT 2001 CABI

ACCESSION NUMBER: 83:113345 CABA

DOCUMENT NUMBER: 822211601

TITLE: Activity of vaccines against swine fever, Aujeszky's disease and swine erysipelas, combined and in aerosol form

AUTHOR: Khasanov, Ch. G.

CORPORATE SOURCE: Vet. Inst., Kazan, USSR.

SOURCE: Nauchnye Trudy Kazanskogo Gosudarstvennogo Veterinarnogo Instituta, (1981) Vol. 138, pp. 42-46. 2 ref.

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB Efficacy of the aerosol immunization method depends on the stability of the vaccine micro-organisms in the aerosol state. Dry defatted milk (5%) and glycerine (5%) were used to **stabilize** swine fever virus (Chinese strain), Aujeszky's virus strain BUK-628 and swine erysipelas (strains VR2 and Konev) vaccines. The swine erysipelas vaccine, immediately after mixing with the other vaccines, plus antibiotics, lost 50% of its activity, but in a mixture without antibiotics only 9%. After 1, 3 and 6 hours its activity in a mixture containing antibiotics was 62, 35 and 46%, but without antibiotics 94, 147 and 144%, either in the triple vaccine or in a monovaccine. The **stabilizers** made little difference initially, but after 3 and especially 6 hours the quantity of *Erysipelothrix rhusiopathiae* was less in triple vaccine without **stabilizers** than with them, and the same applied to swine erysipelas monovaccine. Similar results were recorded for the activity of swine erysipelas depot vaccine. Aujeszky's virus in the triple vaccine during storage at 37 deg C lost 5% activity after 1 hour, 8% after 3 and 16% after 6 hours relative to its activity in monovaccine, which remained unchanged. In an aerosol the swine erysipelas vaccine activity fell from 21 and 44% in the mixture of vaccines (strains VR-2 and Konev respectively) to 20 and 27%, 9 and 15%, 9 and 4%, 6 and 2% and 3 and 0% at 15, 30, 45, 60 and 120 min after spraying. Aujeszky's disease vaccine activity, similarly, after 25 min remained at 79% of the original level, and at 56, 51, 44 and 33% after 30, 45, 60 and 120 min. In the triple vaccine aerosol swine fever vaccine activity was 45% after 15 min, 63% after 30 min and 74% after 1 hour. Viability of swine fever vaccine virus in the triple vaccine remained adequate in the aerosol state.

FILE **REGISTRY** ENTERED AT 12:38:01 ON 17 OCT 2001

E LECITHIN/CN

E LECITHINS/CN

L18 1 SEA ABB=ON PLU=ON LECITHINS/CN

E MINERAL OIL/CN

L19 4 SEA ABB=ON PLU=ON "MINERAL OIL"/CN OR "MINERAL OILS"/CN

E TWEEN 80/CN

L20 1 SEA ABB=ON PLU=ON "TWEEN 80"/CN

E SPAN 80/CN

L21 1 SEA ABB=ON PLU=ON "SPAN 80"/CN

L22 2 SEA ABB=ON PLU=ON L20 OR L21

09/489711

FILE 'CAPLUS' ENTERED AT 12:39:08 ON 17 OCT 2001

L23 5027 SEA ABB=ON PLU=ON (L18 OR LECITHIN) AND (L19 OR OIL)
L24 294 SEA ABB=ON PLU=ON L23 AND (L22 OR (SPAN OR TWEEN) (W) 80
OR AMPHIPHIL? (3A) (SURFACTANT OR SURFACE ACTIVE))
L25 2 SEA ABB=ON PLU=ON L24 AND (ERYSIPEL? OR E) (W) RHUSIOPATH
L26 51 SEA ABB=ON PLU=ON L24 AND L12
L27 18 SEA ABB=ON PLU=ON L26 AND (ANTIGEN OR FILTRATE OR
SUPERNATANT OR PROTEIN OR PEPTIDE OR POLYPROTEIN OR
POLYPEPTIDE OR CARBOHYDRATE OR POLYSACCHARIDE OR POLY
SACCHARIDE OR GLYCOPROTEIN OR (GLYCO OR LIPO) (W) PROTEIN
OR LIPOPROTEIN OR LIPID)
L28 19 SEA ABB=ON PLU=ON L25 OR L27
L29 ~~18 SEA ABB=ON PLU=ON L28 NOT (L9 OR L14)~~

L29 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:136991 CAPLUS

DOCUMENT NUMBER: 134:198075

TITLE: Triglyceride-free compositions and methods for
enhanced absorption of hydrophilic therapeutic
agents

INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2001024658	A1	20010927	US 2000-751968	20001229
PRIORITY APPLN. INFO.:			US 1999-375636	A 19990817
			WO 2000-US18807	A 20000710

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the compn., or can be co-administered with the compn. as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a compn. contg. Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model, macromol. drug was enhanced by 991%.

IT 1338-43-8, Span 80 9005-65-6,
 Polysorbate 80 21645-51-2, Aluminum
 hydroxide, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. for enhanced absorption of hydrophilic drugs using
 combination of surfactants)
 REFERENCE COUNT: 1
 REFERENCE(S): (1) Cho; US 5858398 A 1999 CAPLUS

L29 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 2000:824063 CAPLUS
 DOCUMENT NUMBER: 133:362141
 TITLE: Use of additives to modify the taste
 characteristics of N-neohexyl-.alpha.-aspartyl-L-
 phenylalanine methyl ester
 INVENTOR(S): Gerlat, Paula A.; Walters, Gale C.; Bishay,
 Ihab; Prakash, Indra; Jarrett, Tammy C.; Desai,
 Nitin; Sawyer, Harold; Bechert, Claire-Lise
 PATENT ASSIGNEE(S): The Nutrasweet Company, USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069283	A1	20001123	WO 2000-US12584	20000510
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 1999-134064 P 19990513

AB This invention relates to the use of at least one taste modifying ingredient to modify at least one taste characteristic imparted by N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-phenylalanine 1-Me ester, or neotame, compns. contg. the same, and use of modified forms of neotame that possess an improved taste, wherein at least one taste characteristic imparted by neotame is pos. affected by the modification of neotame.

IT 9005-65-6, Polysorbate 80 10103-46-5,
 Calcium phosphate
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (use of additives to modify the taste characteristics of
 N-neohexyl-.alpha.-aspartyl-L-phenylalanine Me ester)

REFERENCE COUNT: 6
 REFERENCE(S): (1) Ajinomoto Kk; WO 9930574 A 1999 CAPLUS
 (2) Bishay, I; WO 0015049 A 2000 CAPLUS
 (3) Kurtz, R; US 5631295 A 1997 CAPLUS
 (4) Nutrasweet Co; WO 9912954 A 1999 CAPLUS
 (5) Nutrasweet Co; WO 9912956 A 1999 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:822526 CAPLUS

DOCUMENT NUMBER: 134:9337

TITLE: Adjuvant optimized for stability and biocompatibility for enhancing humoral and cellular immune responses

INVENTOR(S): Mueller, Rainer Helmut; Grubhofer, Nikolaus; Olbrich, Carsten

PATENT ASSIGNEE(S): Gerbu G.m.b.H., Germany; Pharmasol G.m.b.H.

SOURCE: Ger. Offen., 26 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10024788	A1	20001123	DE 2000-10024788	20000519
WO 2000071154	A2	20001130	WO 2000-EP4565	20000519
WO 2000071154	A3	20010628		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2000071077	A2	20001130	WO 2000-EP4644	20000522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000058091	A5	20001212	AU 2000-58091	20000522
PRIORITY APPLN. INFO.: DE 1999-19923256 A1 19990520				
WO 2000-EP4644 W 20000522				

AB A title adjuvant is disclosed for injection in combination with an **antigen**. The adjuvant consists of solid **lipid** particles or solid **lipid** mixts. It can be used for manuf. of efficient and biocompatible vaccines for immunization of human and other animals as well as for the prodn. of antibodies. By selection of the particle size, particle charge, and particle surface properties the strength of the immune response can be modulated. The optimized adjuvant can be used in combination with other adjuvants such as mol. adjuvants like GMDP.

IT **21645-51-2, Aluminum hydroxide**, biological studies

RL: BAC (Biological activity or effector, except adverse); PEP

09/489711

(Physical, engineering or chemical process); THU (Therapeutic use);
BIOL (Biological study); PROC (Process); USES (Uses)
(adjuvant optimized for stability and biocompatibility for
enhancing humoral and cellular immune responses)

IT 9005-65-6, Tween 80

RL: PEP (Physical, engineering or chemical process); THU
(Therapeutic use); BIOL (Biological study); PROC (Process); USES
(Uses)
(adjuvant optimized for stability and biocompatibility for
enhancing humoral and cellular immune responses)

L29 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:814284 CAPLUS

DOCUMENT NUMBER: 133:366419

TITLE: **Lipid** particles on the basis of
mixtures of liquid and solid **lipids**
and method for producing same for drug delivery
INVENTOR(S): Muller, Rainer Helmut; Jennings, Volkhard; Mader,
Karsten; Lippacher, Andreas
PATENT ASSIGNEE(S): Pharmasol G.m.b.H., Germany
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067728	A2	20001116	WO 2000-EP4112	20000508
WO 2000067728	A3	20010809		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

DE 19938371 A1 20010222 DE 1999-19938371 19990809

DE 19945203 A1 20001221 DE 1999-19945203 19990921

PRIORITY APPLN. INFO.:

DE 1999-19921034 A 19990507

DE 1999-19938371 A 19990809

DE 1999-19945203 A 19990921

DE 2000-10016357 A 20000331

AB The invention relates to **lipid** particles which do or do not carry active agents and comprise a mixed matrix consisting of solid and liq. **lipid** (so-called solid/liq. particles). The inventive particles are provided with a disordered structure (semicryst., mostly non-cryst. to amorphous) in the semisolid to solid condition. The invention also relates to a method for producing said dispersions and esp. a method for producing highly concd. **lipid** particle dispersions with a **lipid** content of 30 % to 95 % or a solids content of 30 % to 95 % (**lipid** and **stabilizer**). Said dispersions are integral particles unlike the biamphiphilic creams and/or the highly concd. particle dispersions result in free-flowing particle

09/489711

dispersions when dild. with the outer phase.

IT 9005-65-6, Tween 80

RL: PEP (Physical, engineering or chemical process); THU
(Therapeutic use); BIOL (Biological study); PROC (Process); USES
(Uses)

(lipid particles on the basis of mixts. of liq. and
solid lipids and method for producing same for drug
delivery)

L29 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:553455 CAPLUS

DOCUMENT NUMBER: 133:155507

TITLE: Implant comprising calcium cement and
hydrophobic liquid

INVENTOR(S): Bohner, Marc

PATENT ASSIGNEE(S): Mathys Robert Stiftung, Switz.; Stratec Medical
A.-G.

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045867	A1	20000810	WO 1999-EP684	19990202
W: AU, CA, CN, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9929241	A1	20000825	AU 1999-29241	19990202

PRIORITY APPLN. INFO.: WO 1999-EP684 A 19990202

AB The compn. comprises a hydraulic cement for implantation in the
human or animal body, said hydraulic cement comprising a first
component comprising a calcium source and a second component
comprising water, which hardens after mixing of the components. The
compn. further comprises a third component with a hydrophobic liq.
The compn. allows to obtain a cement with open macroporosity
enabling a rapid bone ingrowth. A mixt. of .alpha.-tri-
calcium phosphate 8, pptd. tricalcium phosphate
0.8, calcium cement 0.5 g, Cremophor EL 0.001, and Tegosoft M 8.0 mL
were stirred for 4 min. The mixt. was then poured into a syringe
and injected into a cavity. After hardening, the cavity was filled
with an open macroporous **calcium phosphate**
structure.

IT 1305-62-0, Calciumhydroxide, biological studies

1338-43-8, Sorbitan monooleate 7757-93-9,

Dicalcium phosphate 7758-23-8, Monocalcium phosphate

7758-87-4, .alpha.-Tricalcium phosphate 9005-65-6,

Polysorbate 80 10103-46-5, Calcium

phosphate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(implant comprising calcium cement and hydrophobic liq.)

REFERENCE COUNT: 14

REFERENCE(S):

(1) Advance Kk; JP 01268560 A 1989 CAPLUS

(5) Iino, S; US 4959104 A 1990 CAPLUS

(6) Mattei, F; US 4439420 A 1984 CAPLUS

(7) Ngk Spark Plug Co Ltd; JP 02198560 A 1990

09/489711

CAPLUS

(8) Nitta Gelatin Kk; EP 0538913 A 1993 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:534822 CAPLUS

DOCUMENT NUMBER: 133:140192

TITLE: Adjuvants for use in vaccines

INVENTOR(S): Dearwester, Don Alan; Swearingin, Leroy Allen;
Roberts, David Stewart

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1023904	A2	20000802	EP 1999-310514	19991223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9965372	A1	20000803	AU 1999-65372	19991221
BR 2000000126	A	20010502	BR 2000-126	20000119
JP 2000219636	A2	20000808	JP 2000-17032	20000126
CN 1270838	A	20001025	CN 2000-101175	20000128

PRIORITY APPLN. INFO.: US 1999-117705 P 19990129
US 1999-121760 P 19990226

AB The invention relates to adjuvants that contain a **lecithin**, an **oil** and an **amphiphilic surfactant** and that are capable of forming a stable **oil-in-water** emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

L29 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:722884 CAPLUS

DOCUMENT NUMBER: 131:327566

TITLE: Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality, and greater stability, and method for its production

INVENTOR(S): Penkler, Lawrence John; Mueller, Rainer Helmut;
Runge, Stephan Anton; Ravelli, Vittorino

PATENT ASSIGNEE(S): Pharmatec International, Italy

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9956733	A1	19991111	WO 1999-EP2892	19990429
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,				

09/489711

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
DE 19819273 A1 19991111 DE 1998-19819273 19980430
AU 9940351 A1 19991123 AU 1999-40351 19990429
EP 1073426 A1 20010207 EP 1999-923490 19990429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE,
FI

PRIORITY APPLN. INFO.: DE 1998-19819273 A 19980430
WO 1999-EP2892 W 19990429

AB Solid, particulate **lipid**-based excipients are provided which are loaded with cyclosporin. Said excipients have improved biopharmaceutical properties for cyclosporins in vivo, are of a better quality (in terms of fineness, homogeneity of the particles, and inclusion of the medicament), and are more phys. stable in the particulate formulation (no aggregation or gel formation). These cyclosporin formulations produce an av. blood level concn. in the steady state range of 300->1000 ng/mL which is maintained for .gtoreq.5 h in the absence of high initial blood level concns. >1200 ng/mL. Cyclosporin is dispersed in the **lipid** by either hot homogenization in a **lipid** melt, or cold homogenization with **lipid** microparticles in an emulsifier soln. Thus, a soln. of cyclosporin A 2 and Tagat S 2.5 in Imwitor 900 8 wt. parts at 85.degree. was dispersed in a soln. of Na cholate 0.5 in distd. water 87 wt. parts and homogenized at 500 bar and 85.degree.. After administration of this formulation to pigs (16 mg/kg by gavage), the mean blood level was 600-700 ng/mL at 1-6 h after treatment.

IT 1338-43-8, Span 80 9005-65-6,
Polysorbate 80

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical cyclosporin formulation with improved
biopharmaceutical properties, phys. quality, and stability)

REFERENCE COUNT: 2

REFERENCE(S): (1) Rudnic, E; US 5430021 A 1995 CAPLUS
(2) Shire Laboratories; WO 9913864 A 1999 CAPLUS

L29 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:458416 CAPLUS

DOCUMENT NUMBER: 129:153131

TITLE: Influence of stearylamine and dicetyl phosphate
on the physical properties of submicron O/W
emulsions

AUTHOR(S): Mbela, N.; Verschueren, E.; Ludwig, A.

CORPORATE SOURCE: Dep. Pharmaceutics and Drug Analysis, Fac.
Pharmaceutical Sciences, Univ. Kinshasa,
Kinshasa, Congo

SOURCE: J. Pharm. Belg. (1998), 53(2), 81-86

CODEN: JPBEAJ; ISSN: 0047-2166

PUBLISHER: Association Pharmaceutique Belge, Service
Scientifique

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Stearylamine and dicetyl phosphate were added to glycerol or
sorbitol isotonic sunflower oil, soybean oil and
medium chain triglyceride (MCT) oil-in-water submicron

emulsions **stabilized** using egg yolk and soybean **lecithins**, and blends of polysorbate/sorbate with the aim to induce pos. and neg. elec. charges. Glycerol isotonic emulsions contg. 0.3% (wt./wt.) stearylamine could only be obtained when **lecithins** dosing up to 80% phosphatidylcholine (PC) were employed, but they did not resist to long term storage up to 90 days. Sorbitol isotonic stearylamine emulsions were achieved only with **lecithins** having a PC content superior to 90% without more resistance to storage. Stearylamine did not influence the stability of emulsions prepd. with nonionic emulsifiers. So, the destabilizing effect of stearylamine on emulsions prepd. with **lecithins** could be due to interaction of its cationic group with anionic **lipids** and was not related to the nature of the **oil**. Dicapryl phosphate did not markedly affect emulsions supporting further the hypothesis of interaction of stearylamine with **lecithin** phospholipids.

IT 9005-65-6, PolySorbate 80

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stearylamine and dicetyl phosphate effect on phys. properties of submicron O/W emulsions)

L29 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:532205 CAPLUS

DOCUMENT NUMBER: 127:189892

TITLE: Food and vitamin preparations containing the natural isomer of reduced folates

INVENTOR(S): Bailey, Steven W.; Ayling, June E.

PATENT ASSIGNEE(S): South Alabama Medical Science Foundation, USA;

Bailey, Steven W.; Ayling, June E.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727764	A1	19970807	WO 1997-US1870	19970131
W: AU, CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2243981	AA	19970807	CA 1997-2243981	19970131
AU 9722602	A1	19970822	AU 1997-22602	19970131
AU 722050	B2	20000720		
EP 877563	A1	19981118	EP 1997-905791	19970131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1209729	A	19990303	CN 1997-191951	19970131
JP 2000505286	T2	20000509	JP 1997-527939	19970131
US 5997915	A	19991207	US 1998-117586	19980731
US 6254904	B1	20010703	US 1999-418649	19991015

PRIORITY APPLN. INFO.:

US 1996-10898 P 19960131
WO 1997-US1870 W 19970131
US 1998-117586 A1 19980731

AB A compn. for human or animal consumption for supplying folate which includes a natural isomer of reduced folate, such as (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid,

5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, and their polyglutamyl derivs. is disclosed. Such compns. include multivitamin preps. (with or without minerals and other nutrients); breakfast foods such as prepd. cereals, toaster pastries and breakfast bars; infant formulas; dietary supplements and complete diet and wt.-loss formulas and bars; animal feed (for example pet foods) and animal feed supplements (such as for poultry feed). The amt. of the natural isomer of a reduced folate in a compn. for human consumption can range between about 5 % and about 200 % of the daily requirement for folic acid per serving or dose.

IT 7758-87-4, Calcium phosphate

9005-65-6, Polysorbate 80

RL: BOC (Biological occurrence); FFD (Food or feed use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(food and vitamin preps. contg. the natural isomer of reduced folates)

L29 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:329144 CAPLUS

DOCUMENT NUMBER: 122:114761

TITLE: Structures of nanoparticles prepared from oil-in-water emulsions

AUTHOR(S): Sjoestroem, Brita; Kaplun, Alon; Talmon, Yeshayahu; Cabane, Bernard

CORPORATE SOURCE: Department Chemical Engineering, Technion, Haifa, 32000, Israel

SOURCE: Pharm. Res. (1995), 12(1), 39-48

CODEN: PHREEB; ISSN: 0724-8741

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Hydrophobic substances were dissolved in an org. solvent and emulsified with an aq. soln. at very high shear. Droplets of very small sizes (50-100 nm) were obtained by using surfactants which were combinations of **lecithins** and bile salts. After emulsification, the org. solvent was removed by evapn., yielding stable dispersions of solid particles. The sizes, shapes, and structures of the particles were examd. through quasi-elastic light scattering, small-angle neutron scattering and cryotransmission electron microscopy. Cholesteryl acetate particles **stabilized** by **lecithin** and bile salts were found to be platelets of 10-20 nm thickness and 80 nm diam. Cholesteryl acetate particles **stabilized** with POE-(20)-sorbitan monolaurate were dense spherical globules of diam. 100 nm. Particles with a compn. similar to the endogenously occurring **lipoprotein**, LDL, were large spherical globules studded with small vesicles. The subsequent evolution of the cholesteryl acetate dispersion upon aging was examd. There was no transfer of cholesteryl acetate between particles nor to large crystals. However, some aggregation of the particles was obsd. when the vol. fraction of the particles in the aq. dispersion exceeded 0.05. Thus, the structure of the nanoparticles obtained through deswelling of emulsion droplets changes according to the nature of the emulsifiers and to the compn. of the hydrophobic substances which they contain.

IT 9005-65-6, Tween 80

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

09/489711

(emulsifier; structure of nanoparticles prepd. by deswelling of oil-in-water emulsion droplets)

L29 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:79378 CAPLUS

DOCUMENT NUMBER: 116:79378

TITLE: Effect of preparation conditions of enzyme-encapsulating W/O/W emulsion on enzymic NAD⁺-recycling in the emulsion

AUTHOR(S): Kato, Keiichi; Yamasaki, Nobuyuki; Ii, Norikazu

CORPORATE SOURCE: Dep. Appl. Chem., Ehime Univ., Matsuyama, 790, Japan

SOURCE: J. Chem. Eng. Jpn. (1991), 24(6), 709-14

CODEN: JCEJQA; ISSN: 0021-9592

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of the prepn. conditions of W/O/W emulsion on the NAD⁺-recycling reaction catalyzed by yeast alc. dehydrogenase (ADH) and malate dehydrogenase (MDH) encapsulated in W/O/W emulsion were exptl. studied. The main results were as follows. (1) The first-stage emulsifying agent, such as Span80, protects the enzyme from enzymic activity loss which is caused when the enzyme is subject to the shearing force of a homomixer or is in contact with an org. agent during prepn. of the emulsion. (2) Addn. of soybean **lecithin** or cholesterol to Span80 makes W/O/W emulsion rigid and stable. Moreover, the additives increase the reaction rate of enzymic NAD⁺-recycling. (3) Addn. of soybean **lecithin** increases the stability of the enzyme in the emulsion. (4) Apparent enzymic reaction rate in the emulsion depends on the solubilities of ethanol and acetaldehyde in the oil phase of the emulsion. It is suggested that enzymic activity is enhanced by the interaction between the phospholipid of **lecithin** and the enzyme which is in the lipid membrane of the W/O/W emulsion, and also by the localization of enzymes or substrates in the compartment of the microenvironment of the emulsion. It is also pointed out that the study of enzyme-contg. emulsion may be useful as a model of a membrane-bound enzyme or a multi-enzyme system in a living cell.

IT 1338-43-8, Span80 9005-65-6, Tween80

RL: USES (Uses)

(NAD-recycling enzymes protection by, during encapsulation in water-in-oil-in-water emulsion)

L29 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1988:629160 CAPLUS

DOCUMENT NUMBER: 109:229160

TITLE: Aseptic fluid coffee whitener with increased shelf-stability at room temperature and process for preparing same

INVENTOR(S): McKenna, Ronald J.; Keller, David J.; Streiff, Paul J.

PATENT ASSIGNEE(S): Borden, Inc., USA

SOURCE: U.S., 7 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

09/489711

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4748028	A	19880531	US 1987-16131	19870218
ZA 8704607	A	19880330	ZA 1987-4607	19870625
CA 1329336	A1	19940510	CA 1988-555875	19880105

PRIORITY APPLN. INFO.: US 1987-16131 19870218

AB An aseptically packages, liq. non-dairy coffee whitener which is shelf-stable for several mos. at room temp. comprises water 75-91, vegetable fat (e.g. partially or wholly hydrogenated soybean oil) 5-15, edible emulsifier system (e.g. polysorbate 80) 0.07-0.3, and milk **protein** 0.2-2.6 wt.%. The whitener optionally contains a vegetable gum **stabilizer** such as carrageenan, flavoring agents, and/or salts such as Na tripolyphosphate. Browning of the whitener after opening is avoided by eliminating aldoses which have a dextrose equiv. >1 DE.

IT **9005-65-6**, Polysorbate 80
 RL: BIOL (Biological study)
 (in shelf-stable non-dairy coffee creamer)

L29 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1986:7512 CAPLUS

DOCUMENT NUMBER: 104:7512

TITLE: Some trials in **stabilizing** W/O/W emulsions under the presence of electrolytes
 AUTHOR(S): Matsumoto, Sachio; Kitayama, Tetsushi; Koh, Yumyoung

CORPORATE SOURCE: Coll. Agric., Univ. Osaka Prefect., Osaka, Japan
 SOURCE: Yukagaku (1985), 34(9), 688-95

CODEN: YKGKAM; ISSN: 0513-398X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Studies were carried out to det. relevant conditions for obtaining a stable water-oil-water (W/O/W) emulsion in the presence of electrolytes such as HOAc [64-19-7], ascorbic acid [10504-35-5], NaCl, and Na citrate [994-36-5] which cause the oil layer of this type of emulsion to be unstable. Two types of expts. were carried out, i.e., an examn. of the **stabilizing** function of **proteins** as protective hydrophilic colloids or polar **lipids** to reinforce the oil layer, and detn. of adequate condition of hydrophilic and hydrophobic emulsifiers to form a stable W/O/W emulsion during phase inversion in the presence of electrolytes. Although the addn. of lysozyme [9001-63-2] to the aq. phase or stearylamine [124-30-1] and oleic acid [112-80-1] to the foil phase effectively increased the stability of the oil layer, these additives were inadequate to bring about the complete **stabilization** of such an emulsion. However, a stable W/O/W emulsion may be obtainable by the phase inversion technique using an appropriate emulsifier compn.

IT **1338-43-8**
 RL: USES (Uses)
 (emulsifying agents, contg. hydrophobic colloids or polar **lipids**)

L29 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1984:489266 CAPLUS

DOCUMENT NUMBER: 101:89266

TITLE: Oleaginous compositions

INVENTOR(S): Roberts, Bruce A.

09/489711

PATENT ASSIGNEE(S): Procter and Gamble Co., USA
SOURCE: U.S., 12 pp. Cont. of U.S. Ser. No. 46,886,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4446165	A	19840501	US 1981-313063	19811019
PRIORITY APPLN. INFO.:			US 1979-46886	19790608

AB An emulsion-type compn. suitable for use as food, drug delivery vehicles, and cosmetic ointments comprises (I) an oil phase **stabilized** as a water-in-oil (W/O) emulsion, (II) an aq. phase, and (III) a component which destabilizes the W/O emulsion and converts it to an oil-in-water (O/W), pseudomelting emulsion on use. Thus, margarine was manufd. by mixing 3 components. Component I comprising 58.0% Crisco oil, 36.0% hardened coconut oil, 5.0% fully hardened erucic rape oil, 0.8% monoolein [25496-72-4], and 0.2% **lecithin** was heated to 66.degree., then blended with a W/O **stabilizer** (1 part Ca stearate [1592-23-0] and 2 parts fatty acid heated to 71.degree.) to a 98:2 ratio and butter flavor was added. Component II, an aq. phase Ca alginate [9005-35-0] gel, was mixed with Component I at a 70:30-40:6 ratio and cream and salt were added. This mixt. was homogenized at 27-32.degree. and Component III, an immobilized W/O emulsion destabilizing agent (35 parts 10% gelatin soln., 30 parts Tween 60 [9005-67-8] in oil (50:50), 35 parts 10% colloidal soln. of gum arabic [9000-01-5] to yield **Tween 80-oil** encoated beads of 0.1-3 .mu. diam.) was added. The final mixt. was homogenized at 27-32.degree. to yield a margarine with butter-like melting properties.

L29 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1981:531084 CAPLUS

DOCUMENT NUMBER: 95:131084

TITLE: Microencapsulation of cheese ripening systems: formation of microcapsules

AUTHOR(S): Magee, E. L., Jr.; Olson, N. F.

CORPORATE SOURCE: Cheese Res. Inst., Univ. Wisconsin, Madison, WI, 53706, USA

SOURCE: J. Dairy Sci. (1981), 64(4), 600-10

CODEN: JDSCAE; ISSN: 0022-0302

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Microcapsules were formed that consisted of a milk fat coat contg. aq. **protein** or glucose carrier vacuoles **stabilized** by sorbitan esters of stearate or oleate. Microencapsulation was accomplished by extruding a water-oil emulsion, consisting of an aq. soln. (carrier) dispersed in a molten mixt. of milk fat and emulsifier, under high pressure through an orifice submerged in a chilled dispersion fluid (water or milk). The extent of encapsulation was dependent on process variables, such as emulsifier type, concns. and proportions of emulsifier, dispersion fluid temp., ratio of aq. carrier soln. to milk fat, and concn. of solids in the

aq. vacuoles. Max. encapsulation efficiency was 80-90%.

IT 1338-43-8

RL: BIOL (Biological study)
(emulsifier, in encapsulation of cheese ripening system with milk fat)

L29 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1979:404090 CAPLUS

DOCUMENT NUMBER: 91:4090

TITLE: Formulation, storage possibilities, and chemical composition of ready-to-eat honey-tahena paste

AUTHOR(S): El-Shahaly, A. A.; Mohamed, M. S.; El-Zalaki, Estmat M.; Mohasseb, Zeinab S.

CORPORATE SOURCE: Fac. Agric., Univ. Alexandria, Alexandria, Egypt

SOURCE: Libyan J. Agric. (1978), 7, 65-72

CODEN: LJAGD3

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The formulation of ready-to-eat spreadable paste of honey (62.5%) and sesame seed butter tahena (37.4%) along with artificial honey flavor (0.1%) and various additives is described. The system is a multiphase with a predominant oil dispersed in a continuous polar phase. Sorbitol [50-70-4] (3%) decreased desiccation of the paste, and lecithin (2%) improved its texture and spreadability. Changes occurred in moisture, free fatty acids, peroxide value, oil sepn., and organoleptic properties of the paste upon storage up to 100 days at 25 and 6.degree.. Storage at 6.degree. was recommended for storing Al tubes contg. the paste (30 g each). Moisture, protein, fat, carbohydrates, ash, Fe, P, and Ca contents of the paste were 8.00, 11.76, 23.10, 55.00, 2.00, 0.024, 0.501, and 0.114%, resp. The essential amino acids were quant. estd.

IT 9005-65-6

RL: BIOL (Biological study)
(stabilizer, for honey-tahena paste)

L29 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1979:404053 CAPLUS

DOCUMENT NUMBER: 91:4053

TITLE: Formulation, storage possibilities, and chemical composition of ready-to-eat fish-tahena paste

AUTHOR(S): El-Shahaly, A. A.; Mohamed, M. S.; El-Zalaki, Esmat M.; Mohasseb, Zeinab S.

CORPORATE SOURCE: Fac. Agric., Univ. Alexandria, Alexandria, Egypt

SOURCE: Libyan J. Agric. (1978), 7, 59-64

CODEN: LJAGD3

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The formulation of ready-to-eat spreadable smoked-fish-tahena paste (1:1) along with various additives is described. The system was multiphase with a predominant oil dispersed in a continuous polar phase. Tween 80 [9005-65-6] and glycerol monostearate [31566-31-1] at 2% each had a high stabilizing effect. Sorbitol [50-70-4] (3%) slowed drying of the paste, while lecithin (2%) improved its texture and spreadability. Changes occurred in moisture, free fatty acids, peroxide value, oil sepn., and organoleptic properties of the paste, upon storage up to 100 days at

09/489711

25.degree. and 6.degree.. Storage at 6.degree. was more suitable for storage of Al tubes contg. the paste. Moisture, **protein**, fat, **carbohydrate**, ash, Fe, P, and Ca contents of the paste were 30, 29.5, 35, 3.7, 1.8, 0.0012, 0.76, and 0.619%, resp., (dry wt. basis). The essential amino acids were quant. estd.

IT 9005-65-6

RL: BIOL (Biological study)
(**stabilizer**, in fish-tahena paste)

L29 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1972:518162 CAPLUS

DOCUMENT NUMBER: 77:118162

TITLE: Integrated **stabilizers** of fatty emulsions

AUTHOR(S): Minina, S. A.; Abramova, N. V.; Abramzon, A. A.

CORPORATE SOURCE: Leningr. Khim.-Farm. Inst., Leningrad, USSR

SOURCE: Khim.-Farm. Zh. (1972), 6(6), 38-41

CODEN: KHFZAN

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB The effect of emulsifiers and their concn. on the formation of stable fatemulsions was detd. They were prepd. ultrasonically from soybean, olive and cotton-seed **oils** with addn. of the resp. emulsifiers. The highest stability was achieved with addn. of integrated emulsifier systems composed of low-mol. wt., surface active compds. and high-mol. compds., e.g. **proteins- lecithin**-serum blood etc.

IT 9005-65-6

RL: BIOL (Biological study)
(**stabilizer**, for fatty emulsions)

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, PHIC, PHIN, TOXLIT, TOXLINE' ENTERED AT 12:45:29 ON 17 OCT 2001)

L30 2 S L25

L31 17 S L27

L32 15 S (L30 OR L31) NOT (L10 OR L16)

L33 12 DUP REM L32 (3 DUPLICATES REMOVED)

L33 ANSWER 1 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 2000-224123 [19] WPIDS

DOC. NO. CPI: C2000-068311

TITLE: Non-stick chewing gum composition contains plasticized proteinaceous material containing **protein** and plasticizer components in combination with chewing gum base ingredients.

DERWENT CLASS: A97 D13

INVENTOR(S): ABDEL-MALLIK, M M; ORAMA, A M; VISHWANATHAN, A;
ABDEL-MALIK, M M

PATENT ASSIGNEE(S): (WARN) WARNER LAMBERT CO

COUNTRY COUNT: 76

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

WO 2000008944	A2	20000224	(200019)*	EN	39
---------------	----	----------	-----------	----	----

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC
MW NL OA PT SD SE SL SZ UG ZW

Searcher : Shears 308-4994

09/489711

W: AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS
JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL
TR TT UA UZ VN YU ZA
AU 9950923 A 20000306 (200030)
BR 9912890 A 20010508 (200129)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000008944	A2	WO 1999-US15388	19990708
AU 9950923	A	AU 1999-50923	19990708
BR 9912890	A	BR 1999-12890	19990708
		WO 1999-US15388	19990708

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9950923	A Based on	WO 200008944
BR 9912890	A Based on	WO 200008944

PRIORITY APPLN. INFO: US 1998-131771 19980811

AN 2000-224123 [19] WPIDS

AB WO 200008944 A UPAB: 20000419

NOVELTY - A non-stick chewing gum composition comprises 2-25 wt.% plasticized proteinaceous material containing **protein** and plasticizer components in combination with chewing gum base ingredients sufficient to impart non-stick characteristics to the composition on porous and non-porous surfaces in the absence of an elastomer solvent and wax.

DETAILED DESCRIPTION - The chewing gum composition comprises:

(a) 2-25 wt.% plasticized proteinaceous material containing **protein** and plasticizer components; and

(b) chewing gum base ingredients sufficient to impart non-stick characteristics to the composition on porous and non-porous surfaces in the absence of an elastomer solvent and wax. The solid state blend of the **protein** and plasticizer components are heated under controlled shear conditions at 20-140 deg. C.

USE - None given.

ADVANTAGE - The chewing gums possess high flavor properties similar to conventional chewing gums. It also has unique non-stick properties on a wide variety of substrate including porous and non-porous substrates like leather and rubber.
Dwg.0/0

L33 ANSWER 2 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 2000-160548 [14] WPIDS

DOC. NO. CPI: C2000-050062

TITLE: New injectable pharmaceutical formulation for treating pathologies sensitive to the action of the partricin derivative.

DERWENT CLASS: A96 B02

INVENTOR(S): BRUZZESE, T; FERRARI, V M

PATENT ASSIGNEE(S): (QUAT-N) QUATEX NV; (BRUZ-I) BRUZZESE T; (FERR-I) FERRARI V M

COUNTRY COUNT: 22

PATENT INFORMATION:

Searcher : Shears 308-4994

09/489711

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9966902	A1	19991229	(200014)*	EN	25
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: JP KR US					
EP 1089710	A1	20010411	(200121)	EN	
R: AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9966902	A1	WO 1999-EP1571	19990311
EP 1089710	A1	EP 1999-914507	19990311
		WO 1999-EP1571	19990311

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1089710	A1 Based on	WO 9966902

PRIORITY APPLN. INFO: IT 1998-MI1457 19980625

AN 2000-160548 [14] WPIDS

AB WO 9966902 A UPAB: 20000320

NOVELTY - A new injectable pharmaceutical formulation comprises at least one derivative, in the form of a free base, or its water-soluble salts, with pharmaceutically and pharmacologically acceptable acids, in a solubilizing/dispersing medium of a **lipid** and/or phospholipid emulsion in water, such that the resulting emulsion is iso-osmotic.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of preparing the formulation comprising (a) sterilization, preferably by sterilizing filtration of the solution, (b) miscellar pseudo-solution or suspension of sub-micronized particles of the partricin derivative, and (c) subsequent inclusion in the **lipid** and/or phospholipid emulsion.

USE - The injectable formulation is used for the preparation of drug for the clinical treatment of pathologies sensitive to the action of the partricin derivative (claimed). Five male New Zealand rabbits was daily injected intravenously, over a time of 2 min, 2 ml in total (1 mg of SPA-S-843) of both **lipid** and glucose solution into the marginal veins of the left and right ear, respectively. The treatment was repeated for 3 or more days. Mostly on left ears had no damaged or mild inflammation, while most of the right ear had inflammation/necrosis. The partricin derivative **lipid** formulation was better than the formulation in glucose solution and its tolerance by the vasal endothelium was good.

ADVANTAGE - Side effects involving the vascular system, brought by intravenous injections of known formulation of the partricin derivatives, can be considerably limited, or even avoided, by the use of this new formulation.

Dwg.0/0

L33 ANSWER 3 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-326901 [27] WPIDS
DOC. NO. CPI: C1999-096671

Searcher : Shears 308-4994

09/489711

TITLE: Topical composition for application to mucosal tissue, comprising active agent and micelle forming lipid carrier providing controlled and prolonged release.

DERWENT CLASS: A96 B05 D21 D22

INVENTOR(S): LURIYA, E; LURIYA, L

PATENT ASSIGNEE(S): (LURI-N) LURIDENT LTD

COUNTRY COUNT: 83

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9922703	A1	19990514	(199927)*	EN	35
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI					
GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK					
SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9895587	A	19990524	(199940)		
IL 122084	A	19990922	(200002)		
EP 1027029	A1	20000816	(200040)	EN	
R: AT DE FR GB IT NL					
CN 1283983	A	20010214	(200130)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9922703	A1	WO 1998-IL504	19981018
AU 9895587	A	AU 1998-95587	19981018
IL 122084	A	IL 1997-122084	19971031
EP 1027029	A1	EP 1998-949227	19981018
		WO 1998-IL504	19981018
CN 1283983	A	CN 1998-811388	19981018

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9895587	A Based on	WO 9922703
EP 1027029	A1 Based on	WO 9922703

PRIORITY APPLN. INFO: IL 1997-122084 19971031

AN 1999-326901 [27] WPIDS

AB WO 9922703 A UPAB: 19990714

NOVELTY - A formulation for topical application to mucosal tissue contains an active agent (A) and a lipid carrier (B) in the form of a colloidal micellar dispersion.

DETAILED DESCRIPTION - A formulation for topical application to nasal, ophthalmic, oral, gastrointestinal, respiratory, vaginal or rectal mucosal tissue comprises:

(A) an active agent consisting of an antibiotic, antiviral or antifungal agent, disinfectant, nutrient, antiinflammatory, local anesthetic or essential oil; and

(B) a lipid carrier including at least one lipid selected from amphiphilic phospholipids, yolk lecithin, soya lecithin and phosphatidyl glycerol.

The **lipid** is in the form of a colloidal micellar dispersion with a particle size less than 200 nm, such that the carrier adheres strongly to mucosal tissue. The ratio of (A) to **lipid** is 1:10 to 10:1 (preferably 1:3 to 3:1) and the two form mixed micelles so that (A) is released in a sustained and prolonged manner.

An INDEPENDENT CLAIM is included for a method of topically administering the formulation to mucosal tissue.

USE - The formulations are personal care and hygiene formulations. They are useful for the treatment of gum disease, caries, dry mouth, malodorous breath, microbial infection, inflammation, irritation or dryness. The formulation is especially a mouthwash (claimed).

ADVANTAGE - The carrier (B) shows good adhesion to mucosa (e.g. the gums, tongue and palate), has a high load capacity for (A) and can specifically target a relatively large amount of (A) to the mucosa to ensure controlled and sustained release at the surface. Typically an antimicrobial formulation for oral hygiene applications can be effective for a long as 24 hours (i.e. suitable for once a day use). The formulations have wide range of applications.
Dwg.0/1

L33 ANSWER 4 OF 12 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 1
ACCESSION NUMBER: 1999088423 EMBASE
TITLE: Preparation of gadolinium-containing emulsions

stabilized with phosphatidylcholine-surfactant mixtures for neutron-capture therapy.
AUTHOR: Miyamoto M.; Hirano K.; Ichikawa H.; Fukumori Y.; Akine Y.; Tokuyue K.

CORPORATE SOURCE: M. Miyamoto, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan

SOURCE: Chemical and Pharmaceutical Bulletin, (1999) 47/2 (203-208).

Refs: 13

ISSN: 0009-2363 CODEN: CPBTAL

COUNTRY: Japan

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 023 Nuclear Medicine
037 Drug Literature Index
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Gadolinium-containing **lipid** emulsions for neutron-capture therapy were designed to fulfill the following requirements: particle size smaller than 100 nm; gadolinium content as high as possible; surface of the emulsions modified with hydrophilic moieties to provide prolonged circulation in the blood. Emulsions containing soybean oil, water, Gd-diethylenetriaminepentaacetic acid-distearylamide (Gd-DTPA-SA), as an amphiphilic drug, and hydrogenated egg yolk phosphatidylcholine (HEPC), as an emulsifier, in a weight ratio of 7.36:92:1:2 were prepared without co-surfactants by the thin-layer hydration method using a bath-type sonicator. The mean particle size of the emulsions was 280.7 nm. In order to make the droplet size of the emulsions smaller than 100 nm, as well as to modify the emulsion surfaces, a co-surfactant, Tween.RTM. 80, HCO.RTM.-60, Pluronic.RTM. F68, polyoxyethylene alkyl ether (Brij.RTM.) or polyoxyethylene alkyl

ester (Myrj.RTM.), was introduced into the standard system. **Tween 80**, HCO-60, Brij 76, 78 and 700 were effective in reducing the particle size to below 100 nm when the co-surfactant weight ratio (CWR), defined as co-surfactant/(HEPC+Gd-DTPA-SA) (w/w), was larger than 0.67; the particle size with **Tween 80** and HCO-60 was reduced to 52.7 and 74.7 nm, respectively, at a CWR of 1.0 (w/w). In order to increase the gadolinium content, the weight ratio of Gd-DTPA-SA to HEPC was increased from 1:2 of the standard-Gd formulation to 2:1 of the high-Gd formulation. The measured particle size of the HCO-60 high-Gd emulsions was 78.7nm when the CWR was 1.0 (w/w). In this case, the calculated gadolinium content reached 3.0 mg Gd/ml. These results indicate that HCO-60 is an effective co-surfactant not only in terms of particle size reduction but also with respect to gadolinium enrichment.

L33 ANSWER 5 OF 12 TOXLIT

ACCESSION NUMBER: 1998:106365 TOXLIT

DOCUMENT NUMBER: CA-129-153131A

TITLE: Influence of stearylamine and dicetyl phosphate on the physical properties of submicron O/W emulsions.

AUTHOR: Mbela N; Verschueren E; Ludwig A

CORPORATE SOURCE: Dep. Pharmaceuticals and Drug Analysis, Fac. Pharmaceutical Sciences, Univ. Kinshasa, Kinshasa J. Pharm. Belg., (1998). Vol. 53, No. 2, pp. 81-86. CODEN: JPBEAJ. ISSN. 0047-2166.

SOURCE: CONGO

PUB. COUNTRY: CONGO

DOCUMENT TYPE: Journal; Journal Article

FILE SEGMENT: CA

LANGUAGE: English

OTHER SOURCE: CA 129:153131

ENTRY MONTH: 199809

AB Stearylamine and dicetyl phosphate were added to glycerol or sorbitol isotonic sunflower oil, soybean oil and medium chain triglyceride (MCT) oil-in-water submicron emulsions **stabilized** using egg yolk and soybean **lecithins**, and blends of polysorbate/sorbate with the aim to induce pos. and neg. elec. charges. Glycerol isotonic emulsions contg. 0.3% (wt./wt.) stearylamine could only be obtained when **lecithins** dosing up to 80% phosphatidylcholine (PC) were employed, but they did not resist to long term storage up to 90 days. Sorbitol isotonic stearylamine emulsions were achieved only with **lecithins** having a PC content superior to 90% without more resistance to storage. Stearylamine did not influence the stability of emulsions prepd. with nonionic emulsifiers. So, the destabilizing effect of stearylamine on emulsions prepd. with **lecithins** could be due to interaction of its cationic group with anionic **lipids** and was not related to the nature of the oil. Dicetyl phosphate did not markedly affect emulsions supporting further the hypothesis of interaction of stearylamine with **lecithin** phospholipids.

L33 ANSWER 6 OF 12 JICST-EPlus COPYRIGHT 2001 JST

ACCESSION NUMBER: 960069225 JICST-EPlus

TITLE: Absorption of Insulin Using Water-in-Oil -in-Water Emulsion from an Enteral Loop in Rats.

AUTHOR: MATSUZAWA A; MORISHITA M; TAKAYAMA K; NAGAI T

CORPORATE SOURCE: Hoshi Univ., Tokyo, JPN

09/489711

SOURCE: Biol Pharm Bull, (1995) vol. 18, no. 12, pp.
1718-1723. Journal Code: S0989A (Fig. 6, Tbl. 2, Ref.
41)
ISSN: 0918-6158
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Article
LANGUAGE: English
STATUS: New

AB The present work was undertaken to prepare water-in-oil
-in-water(W/O/W) emulsions as a carrier for insulin via the enteral
route. The emulsions were prepared by a two-step procedure using a
homogenizer. To avoid insulin escape from the inner aqueous phase,
3, 5 or 10% gelatin was added in the inner phase. The oily phase was
composed of 5% **lecithin**, 20% **Span 80**
and 75% soybean oil. The purified water containing 3%
Tween 80 was used for the outer aqueous phase. In
addition, these emulsions were filtered with a membrane filter
(0.45.MU.m) to obtain smaller emulsion particles. The stability of
the emulsions was evaluated by a turbidity measurement method and
photomicrographic observation. By the addition of gelatin to the
inner aqueous phase and storage at 4.DEG.C., the stability of the
emulsions could be improved. The hypoglycemic effects of insulin
after administration of emulsion to the stomach, the duodenum, the
jejunum, the ileum and the colon were examined using an in situ loop
method in rats. A significant hypoglycemic effect was observed at
the ileum and colon loops after administration of the filtered
emulsions containing 5% gelatin in the inner phase. These findings
suggest that the W/O/W multiple emulsions **stabilized** by
gelatin can improve ileal and colonic absorption of insulin. (author
abst.)

L33 ANSWER 7 OF 12 TOXLIT
ACCESSION NUMBER: 1995:37509 TOXLIT
DOCUMENT NUMBER: CA-122-114761S
TITLE: Structures of nanoparticles prepared from oil
-in-water emulsions.
AUTHOR: Sjoestroem B; Kaplun A; Talmon Y; Cabane B
CORPORATE SOURCE: Department Chemical Engineering, Technion, Haifa
SOURCE: Pharm. Res, (1995). Vol. 12, No. 1, pp. 39-48.
CODEN: PHREE. ISSN. 0724-8741.
PUB. COUNTRY: Israel
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 122:114761
ENTRY MONTH: 199503

AB Hydrophobic substances were dissolved in an org. solvent and
emulsified with an aq. soln. at very high shear. Droplets of very
small sizes (50-100 nm) were obtained by using surfactants which
were combinations of **lecithins** and bile salts. After
emulsification, the org. solvent was removed by evapn., yielding
stable dispersions of solid particles. The sizes, shapes, and
structures of the particles were examd. through quasi-elastic light
scattering, small-angle neutron scattering and cryotransmission
electron microscopy. Cholesteryl acetate particles
stabilized by **lecithin** and bile salts were found
to be platelets of 10-20 nm thickness and 80 nm diam. Cholesteryl
acetate particles **stabilized** with POE-(20)-sorbitan

Searcher : Shears 308-4994

monolaurate were dense spherical globules of diam. 100 nm. Particles with a compn. similar to the endogenously occurring **lipoprotein**, LDL, were large spherical globules studded with small vesicles. The subsequent evolution of the cholesteryl acetate dispersion upon aging was examd. There was no transfer of cholesteryl acetate between particles nor to large crystals. However, some aggregation of the particles was obsd. when the vol. fraction of the particles in the aq. dispersion exceeded 0.05. Thus, the structure of the nanoparticles obtained through deswelling of emulsion droplets changes according to the nature of the emulsifiers and to the compn. of the hydrophobic substances which they contain.

L33 ANSWER 8 OF 12 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 3
 ACCESSION NUMBER: 94230381 EMBASE
 DOCUMENT NUMBER: 1994230381
 TITLE: Preparation of drug-carrier emulsions

stabilized with phosphatidylcholine-surfactant mixtures.

AUTHOR: Lundberg B.
 CORPORATE SOURCE: Department of Biochemistry/Pharmacy, Abo Akademi University, BioCity P. O. Box 66, Abo 20521, Finland
 SOURCE: Journal of Pharmaceutical Sciences, (1994) 83/1 (72-75).

ISSN: 0022-3549 CODEN: JPMSAE

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 027 Biophysics, Bioengineering and Medical Instrumentation
 030 Pharmacology
 037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB A method has been developed to produce **lipid** emulsion particles for parenteral use as drug carriers. The technique uses a mixture of a triacylglycerol oil and purified egg yolk phosphatidylcholine (EPC) as the basic system and sonication under mild conditions to produce the emulsion. A large number of mild 'biological' surfactants were tested for their ability to improve the dispersing and stability properties of the basic system. The results showed a preference for polysorbate 80, and a suitable combination of oil and emulsifiers was found to be castor oil:EPC:polysorbate 80 (1:0.4:0.12, weight ratios). Repeated preparation of this emulsion system in phosphate-buffered saline (PBS) gave particles with a mean diameter near 50 nm, in a reproducible way and with a low polydispersity. The stability of the emulsion was very good (>3 months), both in PBS and in 2.5% glycerol. The method was also tested with two lipophilic anticancer drugs, which were solubilized in castor oil, with satisfactory results. The **lipid** emulsion particles described in this study also have a potential use as targetable carriers for site-specific drug delivery.

L33 ANSWER 9 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 1990-009141 [02] WPIDS
 DOC. NO. CPI: C1990-003911
 TITLE: Transparent compsn. with excellent stability and safety - comprises **amphiphilic** substance,

09/489711

DERWENT CLASS: surfactant, oily component and water.
INVENTOR(S): B07 D21
PATENT ASSIGNEE(S): KAKOKI, H; KUMANO, Y; NISHIYAMA, S; YAMAGUCHI,
COUNTRY COUNT: (SHIS) SHISEIDO CO LTD
PATENT INFORMATION: 13

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 349150	A	19900103	(199002)*	EN	11
R: CH DE ES FR GB IT LI NL SE					
AU 8936676	A	19891221	(199016)		
JP 02078432	A	19900319	(199017)		
US 5162377	A	19921110	(199248)		7
EP 349150	B1	19940817	(199432)	EN	11
R: CH DE ES FR GB IT LI NL SE					
DE 68917544	E	19940922	(199437)		
CA 1339029	C	19970401	(199725)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 349150	A	EP 1989-305991	19890613
JP 02078432	A	JP 1989-149959	19890613
US 5162377	A	US 1989-366569	19890615
EP 349150	B1	EP 1989-305991	19890613
DE 68917544	E	DE 1989-617544	19890613
		EP 1989-305991	19890613
CA 1339029	C	CA 1989-602693	19890613

FILING DETAILS:

PATENT NO	KIND	PATENT NO
DE 68917544	E Based on	EP 349150

PRIORITY APPLN. INFO: JP 1988-150195 19880620

AN 1990-009141 [02] WPIDS

AB EP 349150 A UPAB: 19930928

Transparent compsn. comprises an **amphiphilic** substance, a **surfactant**, an oily component and water.

Pref. 10 pts. by wt. or less of a surfactant is contained per 1 pt. by wt. of an oily component. The **amphiphilic surfactant** is e.g. **lecithin**, a quat. ammonium salt type synthetic **lipid** such as dialkyl dimethylammonium chloride and a mixt. of a quat. ammonium salt with a higher alcohol. The surfactant is any nonionic or ionic surfactant partic. sugar or sugar alcohol fatty acid esters such as sucrose fatty acid ester and maltitol fatty esters etc. The oily component may be any liq. **oil**, solid **oil** or semi-solid **oil** components, or substances not easily solubilised in water.

USE/ADVANTAGE - The compsn. has an excellent transparency, stability with a lapse of time, and safety. The irritation which occurs when a large amt. of surfactant is added is avoided, and thus the compsn. has an excellent safety factor.

0/0

ABEQ US 5162377 A UPAB: 19930928

09/489711

Carrier compsn. comprises a dispersion of a pharmaceutical or cosmetic **oil** component 1 pts. wt.), a nonionic and/or cationic surfactant (up to 10 pts. wt.), a phospholipid (0.001-100 pts. wt. per pt. wt. surfactant), and water. Prodn. of these carriers comprises mixing the components under strong shearing forces.

USE - The prods. are stable, transparent carriers for pharmaceutical or cosmetic compsns.

0/0

ABEQ EP 349150 B UPAB: 19940928

A transparent composition comprising (a) a phospholipid, (b) a nonionic surfactant, (c) an oily component and (d) water, wherein a mixture of (a) phospholipid, (b) a nonionic surfactant, (c) an oily component and (d) water is subjected to a strong shearing force treatment which comprises operating a high pressure homogeniser under a pressure of at least 3447 KPa (500 psi), a colloid mill at least 1000 rpm, or an ultrasonication emulsifier and wherein 10 parts by weight or less of the nonionic surfactant is contained per 1 part by weight of the oily component, and 0.002 to 100 parts by weight of the nonionic surfactant is contained per 1 part by weight of the phospholipid.

Dwg.0/0

L33 ANSWER 10 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1979:244820 BIOSIS

DOCUMENT NUMBER: BA68:47324

TITLE: FORMULATION STORAGE POSSIBILITIES AND CHEMICAL COMPOSITION OF READY TO EAT HONEY TAHENA PASTE.

AUTHOR(S): EL-SHAHALY A A; MOHAMED M S; EL-ZALAKI E M; MOHASSEB Z S

CORPORATE SOURCE: FOOD SCI. TECHNOL. DEP., FAC. AGRIC., ALEXANDRIA UNIV., ALEXANDRIA, EGYPT.

SOURCE: LIBYAN J AGRIC, (1978 (RECD 1979)) 7, 65-72.
CODEN: LJAGD3.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB The formulation of ready-to-eat spreadable paste of honey (62.5%) and sesame seed butter tahena (37.4%) along with artificial honey flavor (0.1%) and various additives is described. The system is a multiphase with a predominant **oil**, dispersed in a continuous polar phase. **Tween 80** and glycerol mono-stearate at 1% each gave the best **stabilizing** effect. Sorbitol (3%) decreases the desiccation of the paste and **lecithin** (2%) improved its texture and spreadability. Changes occurred in moisture, free fatty acids, peroxide value, **oil** separation and organoleptic properties of the paste upon storage up to 100 days at 25 and 6.degree. C. Storage at 6.degree. C was recommended for storing the Al tubes containing the paste (30 grams per each). Moisture, **protein**, fat, **carbohydrates**, ash, Fe, P and Ca contents of the paste were 8.00, 11.76, 23.10, 55.00, 2.00, 0.024, 0.501 and 0.114%, respectively. The essential amino acids were quantitatively estimated.

L33 ANSWER 11 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1979:244821 BIOSIS

DOCUMENT NUMBER: BA68:47325

TITLE: FORMULATION STORAGE POSSIBILITIES AND CHEMICAL

COMPOSITION OF READY TO EAT FISH TAHENA PASTE.
 AUTHOR(S): EL-SHAHALY A A; MOHAMED M S; EL-ZALAKI E M; MOHASSEB Z S
 CORPORATE SOURCE: FOOD SCI. TECHNOL. DEP., FAC. AGRIC., UNIV. ALEXANDRIA, ALEXANDRIA, EGYPT.
 SOURCE: LIBYAN J AGRIC, (1978 (RECD 1979)) 7, 59-64.
 CODEN: LJAGD3.
 FILE SEGMENT: BA; OLD
 LANGUAGE: English

AB The formulation of ready-to-eat spreadable smoked fish-tahena paste (1:1) along with various additives is described. The system is multiphase with a predominant **oil**-dispersed in a continuous polar phase. **Tween 80** and glycerol monostearate at 2% of each showed a high **stabilizing** effect. Sorbitol (3%) decreased the desiccation of the paste while **lecithin** (2%) improved its texture and spreadability. Changes occurred in moisture, free fatty acids, peroxide value, **oil** separation, and organoleptic properties of the paste, upon storage up to 100 days of storage at 25.degree. C and 6.degree. C. Storage at 6.degree. C was more suitable for storage of Al tubes containing the paste. Moisture, **protein**, fat, **carbohydrates**, ash, Fe, P and Ca contents of the paste were 30, 29.5, 35, 3.7, 1.8, 0.0012, 0.76 and 0.619%, respectively (results are based on dry weight basis). The essential amino acids were quantitatively estimated.

L33 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1978:144526 BIOSIS

DOCUMENT NUMBER: BA65:31526

TITLE: PREPARATION OF **LIPID** VESICLES ON THE BASIS OF A TECHNIQUE FOR PROVIDING WATER OIL WATER EMULSIONS.

AUTHOR(S): MATSUMOTO S; KOHDA M; MURATA S-I

CORPORATE SOURCE: DEP. AGRIC. CHEM., COLL. AGRIC., UNIV. OSAKA PREF., SAKAI, OSAKA 591, JPN.

SOURCE: J COLLOID INTERFACE SCI, (1977) 62 (1), 149-157.
 CODEN: JCISA5. ISSN: 0021-9797.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB As one of the applications of a technique for providing W/O/W-type multiple-phase emulsions, an attempt was made to prepare an aqueous suspension of **lipid** vesicles as a model for 1-lamellar liposomes. The procedure tested was divided into 4 operations; preparation of a water-in-n-hexane emulsion **stabilized** by a mixture of soy **lecithin** and **Span-80**; removal of n-hexane from the emulsion under reduced pressure, thus obtaining a water-in-**lipid** mixture system; mixing of the above system with an aqueous solution of hydrophilic emulsifying agent so as to prepare an aqueous suspension of **lipid** vesicles composed of aqueous compartments 1-2 .mu.m in diameter, surrounded by the **lipid** layer; and dialysis of the **lipid** vesicle suspension against distilled water to remove the residue of the hydrophilic emulsifying agent from the aqueous suspending medium. The necessary weight fraction of soy **lecithin** to **Span-80** in the **lipid** mixture for attaining 90% or higher yields of the **lipid** vesicles ranges from 0.35-0.65 and that a relatively low concentration of the hydrophilic emulsifying agent is recommended to

provide the lipid vesicle suspension in a stable form.

(FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, PHIC, PHIN, TOXLIT, TOXLINE' ENTERED AT 12:52:51 ON 17 OCT 2001)

L34 12815 S ROBERTS D?/AU
 L35 20 S SWEARINGIN L?/AU
 L36 25 S SUITER B?/AU
 L37 3 S L34 AND L35 AND L36
 L38 18 S L34 AND (L35 OR L36)
 L39 3 S L35 AND L36
 L40 12 S (L34 OR L35 OR L36) AND RHUSIOPATH?
 L41 20 S L37 OR L38 OR L39 OR L40
 L42 17 DUP REM L41 (3 DUPLICATES REMOVED)

- Author(s)

L42 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1
 ACCESSION NUMBER: 2000:534822 CAPLUS
 DOCUMENT NUMBER: 133:140192
 TITLE: Adjuvants for use in vaccines
 INVENTOR(S): Dearwester, Don Alan; Swearingin, Leroy
 Allen; Roberts, David Stewart
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1023904	A2	20000802	EP 1999-310514	19991223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9965372	A1	20000803	AU 1999-65372	19991221
BR 2000000126	A	20010502	BR 2000-126	20000119
JP 2000219636	A2	20000808	JP 2000-17032	20000126
CN 1270838	A	20001025	CN 2000-101175	20000128
PRIORITY APPLN. INFO.:			US 1999-117705	P 19990129
			US 1999-121760	P 19990226

AB The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

L42 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 2000:544802 CAPLUS
 DOCUMENT NUMBER: 133:155383
 TITLE: Erysipelothrix rhusiopathiae antigen compositions and their vaccine compositions for prevention and treatment of swine erysipelas
 INVENTOR(S): Roberts, David Stewart;
 Swearingin, Leroy Alan; Suiter, Brian Thomas
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent

09/489711

LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000219637	A2	20000808	JP 2000-17930	20000124
AU 9959445	A1	20000803	AU 1999-59445	19991116
EP 1027895	A2	20000816	EP 1999-309202	19991118
EP 1027895	A3	20010718		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
 PT, IE, SI, LT, LV, FI, RO

CN 1262129	A	20000809	CN 1999-126163	19991215
BR 9905853	A	20001114	BR 1999-5853	19991215

PRIORITY APPLN. INFO.: US 1999-117704 P 19990129

AB The antigen compns. contain fluid fraction of cultured E.
rhusiopathiae, and stabilizers, e.g. metal hydroxides or
 phosphates. Rehydragel [Al(OH)₃ gel] prevented loss of activity of
 formalin- or .beta.-propiolactone-inactivated E.
rhusiopathiae antigen.

L42 ANSWER 3 OF 17 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 2000-484844 [43] WPIDS
 DOC. NO. CPI: C2000-145992
 TITLE: Novel antigen comprising fluid function from an
 Erysipelothrix **rhusiopathiae** culture,
 useful as a vaccine.
 DERWENT CLASS: B04 C06 D16
 INVENTOR(S): ROBERTS, D S; SUITER, B T;
 SWEARINGEN, L A; SWEARINGEN, L A
 PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
 COUNTRY COUNT: 31
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1027895	A2	20000816	(200043)*	EN	13
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2000219637	A	20000808	(200043)		12
AU 9959445	A	20000803	(200046)		
CA 2290078	A1	20000729	(200051)	EN	
CN 1262129	A	20000809	(200055)		
BR 9905853	A	20001114	(200064)		
ZA 9907138	A	20010627	(200140)		23

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 1027895	A2	EP 1999-309202	19991118
JP 2000219637	A	JP 2000-17930	20000124
AU 9959445	A	AU 1999-59445	19991116
CA 2290078	A1	CA 1999-2290078	19991116
CN 1262129	A	CN 1999-126163	19991215
BR 9905853	A	BR 1999-5853	19991215
ZA 9907138	A	ZA 1999-7138	19991116

09/489711

PRIORITY APPLN. INFO: US 1999-117704 19990129

AN 2000-484844 [43] WPIDS

AB EP 1027895 A UPAB: 20000907

NOVELTY - Antigen (I) comprising a fluid fraction from an Erysipelothrix **rhusiopathiae** culture and a stabilizing agent, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a vaccine comprising an antigen as in (I) and an adjuvant; and

(2) making an antigen comprising adding a stabilizing agent to a fluid fraction from an E. **rhusiopathiae** culture.

ACTIVITY - Antibacterial.

MECHANISM OF ACTION - Vaccine.

Pigs were vaccinated intramuscularly with two 2 ml doses of vaccine with Al gel (3 and 6 weeks). Immunity was tested at 9 weeks with intramuscular injections of E. **rhusiopathiae**. Protection due to vaccine was 100 %.

USE - The antigen composition of (I) and a vaccine comprising it are used to vaccinate an animal, especially a pig against E. **rhusiopathiae** infection and erysipelas (claimed).

ADVANTAGE - The vaccine provides long term protection from E. **rhusiopathiae**.
Dwg.0/0

L42 ANSWER 4 OF 17 TOXLIT

ACCESSION NUMBER: 2000:54719 TOXLIT

DOCUMENT NUMBER: CA-133-155383R

TITLE: Erysipelothrix **rhusiopathiae** antigen compositions and their vaccine compositions for prevention and treatment of swine erysipelas.

AUTHOR: Roberts DS; Swearingin LA; Suiter BT

SOURCE: (2000). Jpn. Kokai Tokkyo Koho PATENT NO. 2000219637 08/08/2000 (Pfizer Products Inc.).
CODEN: JKXXAF.

PUB. COUNTRY: UNITED STATES

DOCUMENT TYPE: Patent

FILE SEGMENT: CA

LANGUAGE: Japanese

OTHER SOURCE: CA 133:155383

ENTRY MONTH: 200009

AB The antigen compns. contain fluid fraction of cultured E. **rhusiopathiae**, and stabilizers, e.g. metal hydroxides or phosphates. Rehydragel [Al(OH)₃ gel] prevented loss of activity of formalin- or .beta.-propiolactone-inactivated E. **rhusiopathiae** antigen.

L42 ANSWER 5 OF 17 TOXLIT

ACCESSION NUMBER: 2000:52008 TOXLIT

DOCUMENT NUMBER: CA-133-140192D

TITLE: Adjuvants for use in vaccines.

AUTHOR: Dearwester DA; Swearingin LA; Roberts DS

SOURCE: (2000). Eur. Pat. Appl. PATENT NO. 1023904 08/02/2000 (Pfizer Products Inc.).
CODEN: EPXXDW.

09/489711

PUB. COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 133:140192
ENTRY MONTH: 200008

AB The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

L42 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:262603 CAPLUS
DOCUMENT NUMBER: 126:308794
TITLE: Method of preparing Gram-negative bacterial vaccines
INVENTOR(S): Roberts, David S.; Dearwester, Donald A.; Swearingin, Leroy A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 792,488, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5616328	A	19970401	US 1994-240649	19940711
WO 9310216	A1	19930527	WO 1992-US9944	19921113
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
PRIORITY APPLN. INFO.: US 1991-792488 B2 19911115 WO 1992-US9944 W 19921113				

AB There is provided by this invention a novel method of prepg. Gram-neg. bacterial vaccines. The method comprises providing a concd. Gram-neg. bacterial antigenic prepn., adsorbing the prepn. with a mineral carrier capable of binding free endotoxin in the antigenic prepn. in an amt. effective to produce optimal binding of endotoxin and antigen, and dilg. the adsorbed prepn. for use in a vaccine. Also provided by this invention is a vaccine produced by the method of this invention. A concn. of mineral carrier in the vaccine is less than 5.0 % by vol. Also provided by this invention is a method of vaccinating an animal against Gram-neg. bacterial infections comprising administering to the animal an effective amt. of a vaccine of this invention. Actinobacillus pleuropneumoniae, serotype 1, 5, and 7 were prepd. and cultured in a liq. medium. At the end of exponential growth, each culture was chilled to arrest growth; the chilled culture was centrifuged and the sediment collected as a very dense suspension of bacteria. The suspension was centrifuged and the supernatant fluid (ext.) collected, treated with preservatives, and filtered. The pH and total vol. were adjusted, Rehydragel carrier was added, followed by Amphigen adjuvant. The final concn. of Rehydragel carrier was 0.98% by vol. a very desirable value for the avoidance of tissue reactions at the injection site.

09/489711

L42 ANSWER 7 OF 17 TOXLIT
ACCESSION NUMBER: 1997:79428 TOXLIT
DOCUMENT NUMBER: CA-126-308794H
TITLE: Method of preparing Gram-negative bacterial vaccines.
AUTHOR: **Roberts DS**; Dearwester DA; **Swearingin**
LA
SOURCE: (1997). U.S. PATENT NO. 5616328 04/01/97 (Pfizer Inc.).
PUB. COUNTRY: United States
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 126:308794
ENTRY MONTH: 199707

AB There is provided by this invention a novel method of prepg. Gram-neg. bacterial vaccines. The method comprises providing a concd. Gram-neg. bacterial antigenic prepn., adsorbing the prepn. with a mineral carrier capable of binding free endotoxin in the antigenic prepn. in an amt. effective to produce optimal binding of endotoxin and antigen, and dilg. the adsorbed prepn. for use in a vaccine. Also provided by this invention is a vaccine produced by the method of this invention. A concn. of mineral carrier in the vaccine is less than 5.0 % by vol. Also provided by this invention is a method of vaccinating an animal against Gram-neg. bacterial infections comprising administering to the animal an effective amt. of a vaccine of this invention. Actinobacillus pleuropneumoniae, serotype 1, 5, and 7 were prepd. and cultured in a liq. medium. At the end of exponential growth, each culture was chilled to arrest growth; the chilled culture was centrifuged and the sediment collected as a very dense suspension of bacteria. The suspension was centrifuged and the supernatant fluid (ext.) collected, treated with preservatives, and filtered. The pH and total vol. were adjusted, Rehydragel carrier was added, followed by Amphigen adjuvant. The final concn. of Rehydragel carrier was 0.98% by vol. a very desirable value for the avoidance of tissue reactions at the injection site.

L42 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2
ACCESSION NUMBER: 1993:456132 CAPLUS
DOCUMENT NUMBER: 119:56132
TITLE: Gram-negative bacterial vaccines
INVENTOR(S): Dearwester, Donald A.; **Roberts, David S.**
; Swearingin, Leroy A.
PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9310216	A1	19930527	WO 1992-US9944	19921113
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9331413	A1	19930615	AU 1993-31413	19921113
AU 667858	B2	19960418		

Searcher : Shears 308-4994

09/489711

EP 669971 A1 19950906 EP 1992-925307 19921113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE

JP 3043809 B2 20000522 JP 1993-509495 19921113
US 5616328 A 19970401 US 1994-240649 19940711

PRIORITY APPLN. INFO.: US 1991-792488 A2 19911115
WO 1992-US9944 A 19921113

AB A novel method of prepg. Gram-neg. bacterial vaccines comprises providing a concd. Gram-neg. bacterial antigenic prepn., adsorbing the prepn. with a mineral carrier capable of binding free-endotoxin in the antigenic prepn. in an amt. (<5%) effective to produce optimal binding of endotoxin and antigen, and dilg. the adsorbed prepn. for use in a vaccine. Exts. of cultured Actinobacillus pleuropneumoniae was treated with a 25% soln. of glutaraldehyde, neutralized with lysine and stored at 4.degree. overnight. Al(OH)3 gel and Amphigen were added to the ext. at pH 6.5 and the vol. was adjusted with buffer to obtain final concn. of Al(OH)3 0.98 and Amphigen 5%vol./vol. in the vaccine. Efficacy of the vaccine was tested in pigs.

L42 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 3

ACCESSION NUMBER: 1993:456130 CAPLUS

DOCUMENT NUMBER: 119:56130

TITLE: Pasteurella multocida toxoid vaccines

INVENTOR(S): Frantz, Joseph C.; Kemmy, Richard J.;

Roberts, David S.; Swearingin,

Leroy A.

PATENT ASSIGNEE(S): Smithkline Beecham Corp., USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9309809	A1	19930527	WO 1992-US10008	19921113
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
WO 9119419	A1	19911226	WO 1991-US4092	19910610
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9181953	A1	19920107	AU 1991-81953	19910610
JP 05508407	T2	19931125	JP 1991-512282	19910610
JP 3178720	B2	20010625		
EP 651609	A1	19950510	EP 1991-913518	19910610
EP 651609	B1	19990811		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 183202	E	19990815	AT 1991-913518	19910610
ES 2136064	T3	19991116	ES 1991-913518	19910610
AU 9331430	A1	19930615	AU 1993-31430	19921113
AU 669681	B2	19960620		
EP 614371	A1	19940914	EP 1992-925340	19921113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 07501334	T2	19950209	JP 1992-509531	19921113
US 5695769	A	19971209	US 1994-244052	19940711

Searcher : Shears 308-4994

09/489711

AU 685659	B2	19980122	AU 1995-13628	19950303
AU 9513628	A1	19950810		
US 5536496	A	19960716	US 1995-439714	19950512

PRIORITY APPLN. INFO.:

US 1990-537454	A	19900613
US 1991-792490	A1	19911115
WO 1991-US4092	A	19910610
WO 1992-US10008	A	19921113
US 1993-87946	B1	19930706

AB A vaccine is manufd. for the protection of animals against disease assocd. with *P. multocida* infection. The vaccine elicits antitoxin formation. The vaccine comprises whole *P. multocida* killed cells (bacterins) with cell-bound toxoid, optionally also comprising free, sol. toxoid. The sol., cell-free toxoid is produced by subjecting the toxin to varying pH and temp. regimens. In addn., the vaccine may also comprise *Bordetella bronchiseptica* bacterin, *Erysipelothrix rhusiopathiae* bacterin and/or *Mycoplasma hyopneumoniae* ext.

L42 ANSWER 10 OF 17 TOXLIT

ACCESSION NUMBER: 1993:80690 TOXLIT

DOCUMENT NUMBER: CA-119-056132N

TITLE: Gram-negative bacterial vaccines.

AUTHOR: Dearwester DA; **Roberts DS; Swearingin**

LA

SOURCE: (1993). PCT Int. Appl. PATENT NO. 93 10216 05/27/93
(SmithKline Beecham Corp.).

PUB. COUNTRY: United States

DOCUMENT TYPE: Patent

FILE SEGMENT: CA

LANGUAGE: English

OTHER SOURCE: CA 119:56132

ENTRY MONTH: 199309

AB A novel method of prepg. Gram-neg. bacterial vaccines comprises providing a concd. Gram-neg. bacterial antigenic prepn., adsorbing the prepn. with a mineral carrier capable of binding free-endotoxin in the antigenic prepn. in an amt. (<5%) effective to produce optimal binding of endotoxin and antigen, and dilg. the adsorbed prepn. for use in a vaccine. Exts. of cultured *Actinobacillus pleuropneumoniae* was treated with a 25% soln. of glutaraldehyde, neutralized with lysine and stored at 4.degree. overnight. Al(OH)₃ gel and Amphigen were added to the ext. at pH 6.5 and the vol. was adjusted with buffer to obtain final concn. of Al(OH)₃ 0.98 and Amphigen 5%vol./vol. in the vaccine. Efficacy of the vaccine was tested in pigs.

L42 ANSWER 11 OF 17 TOXLIT

ACCESSION NUMBER: 1993:80688 TOXLIT

DOCUMENT NUMBER: CA-119-056130K

TITLE: *Pasteurella multocida* toxoid vaccines.

AUTHOR: Frantz JC; Kemmy RJ; **Roberts DS;**

Swearingin LA

SOURCE: (1993). PCT Int. Appl. PATENT NO. 93 09809 05/27/93
(Smithkline Beecham Corp.).

PUB. COUNTRY: United States

DOCUMENT TYPE: Patent

FILE SEGMENT: CA

LANGUAGE: English

OTHER SOURCE: CA 119:56130

ENTRY MONTH: 199309

09/489711

AB A vaccine is manufd. for the protection of animals against disease assocd. with P. multocida infection. The vaccine elicits antitoxin formation. The vaccine comprises whole P. multocida killed cells (bacterins) with cell-bound toxoid, optionally also comprising free, sol. toxoid. The sol., cell-free toxoid is produced by subjecting the toxin to varying pH and temp. regimens. In addn., the vaccine may also comprise Bordetella bronchiseptica bacterin, Erysipelothrix rhusiopathiae bacterin and/or Mycoplasma hyopneumoniae ext.

L42 ANSWER 12 OF 17 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 1992-024125 [03] WPIDS
 CROSS REFERENCE: 1993-182249 [22]
 DOC. NO. CPI: C1992-010389
 TITLE: Pasteurella multocida toxoid vaccines - used for protecting against e.g. atrophic rhinitis, pleuritic and pneumonic pasteurellosis and erysipelas particularly in pigs.
 DERWENT CLASS: B04 C06 D16
 INVENTOR(S): FRANTZ, J; KEMMY, R J; ROBERTS, D S; SWEARINGIN, L A; FRANTZ, J C
 PATENT ASSIGNEE(S): (PFIZ) PFIZER INC; (SMIK) SMITHKLINE BEECHAM; (SMIK) SMITHKLINE BEECHAM CORP
 COUNTRY COUNT: 18
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9119419	A	19911226	(199203)*		75
RW: BE CH DE DK ES FR GB GR IT LU NL SE					
W: AU CA JP US					
AU 9181953	A	19920107	(199217)		
JP 05508407	W	19931125	(199401)		18
EP 651609	A1	19950510	(199523)	EN	
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
AU 9513628	A	19950810	(199540)		
US 5536496	A	19960716	(199634)		12
AU 685569	B	19980122	(199811)		
EP 651609	B1	19990811	(199936)	EN	
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
DE 69131525	E	19990916	(199944)		
ES 2136064	T3	19991116	(200001)		
CA 2312296	A1	19911214	(200053)	EN	
JP 3178720	B2	20010625	(200138)		27

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 05508407	W	JP 1991-512282	19910610
		WO 1991-US4092	19910610
EP 651609	A1	EP 1991-913518	19910610
		WO 1991-US4092	19910610
AU 9513628	A	AU 1995-13628	19950303
	Div ex	AU 1991-81953	
US 5536496	A	US 1990-537454	19900613
	Cont of	US 1993-87946	19930706
	Cont of	US 1995-439714	19950512
AU 685569	B	AU 1995-13628	19950303

Searcher : Shears 308-4994

09/489711

		Div ex	AU 1991-81953	
EP 651609	B1		EP 1991-913518	19910610
			WO 1991-US4092	19910610
DE 69131525	E		DE 1991-631525	19910610
			EP 1991-913518	19910610
			WO 1991-US4092	19910610
ES 2136064	T3		EP 1991-913518	19910610
CA 2312296	A1 Div ex		CA 1991-2086258	19910610
			CA 1991-2312296	19910610
JP 3178720	B2		JP 1991-512282	19910610
			WO 1991-US4092	19910610

FILING DETAILS:

PATENT NO	KIND		PATENT NO
JP 05508407	W	Based on	WO 9119419
EP 651609	A1	Based on	WO 9119419
AU 685569	B	Previous Publ.	AU 9513628
EP 651609	B1	Based on	WO 9119419
DE 69131525	E	Based on	EP 651609
		Based on	WO 9119419
ES 2136064	T3	Based on	EP 651609
JP 3178720	B2	Previous Publ.	JP 05508407
		Based on	WO 9119419

PRIORITY APPLN. INFO: US 1990-537454 19900613; US 1993-87946
19930706; US 1995-439714 19950512

AN 1992-024125 [03] WPIDS
CR 1993-182249 [22]
AB WO 9119419 A UPAB: 20010711

A vaccine compsn. for internal administration to an animal comprises an immunogenic amt. of a soluble free-toxoid of Pasteurella multocida (PM) and a carrier suitable for internal administration; the compsn. may further comprise one or more additional antigens, e.g. a Bordetella bronchiseptica bacteria, and Erysipelothrix rhusiopathiae bacteria or a PM tye A bacteria.

A PM toxoid prepd. by incubating a clarified lysate of PM whole cells at 12-19 deg.C at a pH greater than 9 fro at least 12 hrs., and a method for detoxifying PM necrotising toxin which comprises incubating the toxin at greater than pH 9 at 12-19 deg.C for at least 12 hrs also claimed. A method fro vaccinating an animal against PM which comprises internally adminisitering to the animal an fmmunogenic amt. of PM toxoid.

USE - Vaccines are used for preventing diseases resulting from infection with PM such as atrophic rhinitis, pleuritic and pneumonic pasteurcellosis and erysipelas, in animals such as pigs. The soluble toxoid can be elicit antibodies that can bind to the toxin and neutralise its toxicity. The toxoid is stable at 4 deg.C for at least 24 months.

Dwg.0/0

ABEQ US 5536496 A UPAB: 19960829

An alkaline-toxoided Pateurella multocida protein necrotizing toxin prepared by incubating a toxin extracted from a culture of a dermonecrotic necrotizing protein toxin producing strain of P. multocida whole cells at a temperature of between 12 and 19deg. C. under conditions of pH greater than about 10.5 for at least 12

09/489711

hours, wherein said toxoid is capable of inducing production of an amount of antitoxin effective to neutralize the toxin.

Dwg.0/0

L42 ANSWER 13 OF 17 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1992-007209 [01] WPIDS
DOC. NO. CPI: C1992-003083
TITLE: Swine pneumonia vaccine - contains vaccine component of inactivated Mycoplasma hyopneumoniae and opt. other antigens.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): DAYALU, K I; FRANTZ, J C; KEMMY, R J; PEETZ, R H; ROBERTS, D S; SWEARINGIN, L A
PATENT ASSIGNEE(S): (SMIK) SMITHKLINE BEECHAM CORP; (SMIK) SMITHKLINE BEECHAM; (SOLV) SOLVAY ANIMAL HEALTH INC; (AMCY) AMERICAN CYANAMID CO
COUNTRY COUNT: 17
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9118627	A	19911212	(199201)*		
RW: AT BE CH DE DK ES FR GB GR IT LU NL SE					
W: AU CA JP					
AU 9179078	A	19911231	(199215)		
JP 05507484	W	19931028	(199348)		37
EP 597852	A1	19940525	(199421)	EN	
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
AU 657907	B	19950330	(199521)		
AU 9517662	A	19951019	(199549)		
EP 597852	B1	19971203	(199802)	EN	16
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
DE 69128361	E	19980115	(199808)		
ES 2112274	T3	19980401	(199819)		
JP 3187419	B2	20010711	(200140)		11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 05507484	W	JP 1991-510290	19910524
		WO 1991-US3689	19910524
EP 597852	A1	EP 1991-911598	19910524
		WO 1991-US3689	19910524
AU 657907	B	AU 1991-79078	19910524
AU 9517662	A Div ex	AU 1991-79078	19910524
		AU 1995-17662	19950426
EP 597852	B1	EP 1991-911598	19910524
		WO 1991-US3689	19910524
DE 69128361	E	DE 1991-628361	19910524
		EP 1991-911598	19910524
		WO 1991-US3689	19910524
ES 2112274	T3	EP 1991-911598	19910524
JP 3187419	B2	JP 1991-510290	19910524
		WO 1991-US3689	19910524

FILING DETAILS:

Searcher : Shears 308-4994

09/489711

PATENT NO	KIND		PATENT NO
JP 05507484	W	Based on	WO 9118627
EP 597852	A1	Based on	WO 9118627
AU 657907	B	Previous Publ.	AU 9179078
		Based on	WO 9118627
EP 597852	B1	Based on	WO 9118627
DE 69128361	E	Based on	EP 597852
		Based on	WO 9118627
ES 2112274	T3	Based on	EP 597852
JP 3187419	B2	Previous Publ.	JP 05507484
		Based on	WO 9118627

PRIORITY APPLN. INFO: US 1990-634237 19901226; US 1990-530669
19900529; US 1990-575921 19900831

AN 1992-007209 [01] WPIDS

AB WO 9118627 A UPAB: 19960405

Vaccine component comprises inactivated *Mycoplasma hyopneumoniae* (MH) at a dosage of at least 5 x 10 power (8) CCU, the component being capable of inducing an immunological response in vaccinated swine against MH;

Also claimed is a vaccine capable of inducing immunity to MH in a mammal without serious side effects comprising the component above and an adjuvant to elicit an immunoprotective response in a porcine animal, the component having immunogenic activity in at least an amt. sufficient to protect the animal against challenge by MH; the adjuvant may be e.g. lecithin and mineral oil, saponins or Al(OH)3.

Prepn. of vaccine for protecting mammals against MH comprises (a) pretreating a culture medium capable of sustaining MH with an anion exchange resin, (b) inoculating the medium with MH, (c) increasing the dissolved oxygen content of the culture to 20-40% of saturation, (d) culturing MH to a titre of at least 1 x 10 power (8) CCU and (e) inactivating culture by addn. of an inactivating agent, e.g. binary ethyleneimine (BEI).

USE/ADVANTAGE - The vaccine components and vaccines are used in pigs to prevent infection by MH. They confer protection against MH challenge with a wild-type strain as well as other known virulent strains. Vaccine compsns. contg. an additional antigen can reduce the morbidity and mortality from secondary respiratory pathogens such as *Pasteurella multocida*. @ (37pp Dwg.No.0/0)
0/0

ABEQ JP 05507484 W UPAB: 19940120

Vaccine component comprises inactivated *Mycoplasma hyopneumoniae* (MH) at a dosage of at least 5 x 10 power (8) CCU and the component is capable of inducing an immunological response in vaccinated swine against MH.

Also new is a vaccine inducing immunity to MH in a mammal without serious side effects comprising the component above and adjuvant to elicit an immunogenic activity in at least an amt. sufficient to protect the animal against challenge by MH, and the adjuvant may be e.g. lecithin and mineral oil, saponins or Al(OH)3.

Prepn. of vaccine for protecting mammals against MH comprises (a) pretreating a culture medium sustaining MH with an anion exchange resin, (b) inoculating the medium with MH, (c) increasing the dissolved oxygen content of the culture to 20-40% of satn. (d) culturing MH to a titre of at least 1 x 10 power (8) CCU and (e) inactivating culture by addn. of an inactivating agent, e.g. binary ethyleneimine (BEI).

09/489711

USE/ADVANTAGE - The vaccine components and vaccines are used in pigs to prevent infection by MH. They confer protection against MH challenge with a wild-type strain and other known virulent strains. Vaccine compsns. contg. an additional antigen may reduce the morbidity and mortality from sec. respiratory pathogens e.g. *Pasteurella multocida*.

Dwg.0/0

ABEQ EP 597852 B UPAB: 19980112

Vaccine component comprises inactivated *Mycoplasma hyopneumoniae* (MH) at a dosage of at least 5×10^8 CCU, the component being capable of inducing an immunological response in vaccinated swine against MH;

Also claimed is a vaccine capable of inducing immunity to MH in a mammal without serious side effects comprising the component above and an adjuvant to elicit an immunoprotective response in a porcine animal, the component having immunogenic activity in at least an amt. sufficient to protect the animal against challenge by MH; the adjuvant may be e.g. lecithin and mineral oil, saponins or $Al(OH)_3$.

Prepn. of vaccine for protecting mammals against MH comprises (a) pretreating a culture medium capable of sustaining MH with an anion exchange resin, (b) inoculating the medium with MH, (c) increasing the dissolved oxygen content of the culture to 20-40% of saturation, (d) culturing MH to a titre of at least 1×10^8 CCU and (e) inactivating culture by addn. of an inactivating agent, e.g. binary ethyleneimine (BEI).

USE/ADVANTAGE - The vaccine components and vaccines are used in pigs to prevent infection by MH. They confer protection against MH challenge with a wild-type strain as well as other known virulent strains. Vaccine compsns. contg. an additional antigen can reduce the morbidity and mortality from secondary respiratory pathogens such as *Pasteurella multocida*.

Dwg.0/0

L42 ANSWER 14 OF 17 MEDLINE
ACCESSION NUMBER: 89191734 MEDLINE
DOCUMENT NUMBER: 89191734 PubMed ID: 3239853
TITLE: A standard antitoxin for *Pasteurella multocida*.
AUTHOR: **Roberts D S; Swearingin L A**
SOURCE: AMERICAN JOURNAL OF VETERINARY RESEARCH, (1988 Dec) 49 (12) 2168.
Journal code: 40C; 0375011. ISSN: 0002-9645.
PUB. COUNTRY: United States
Letter
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198905
ENTRY DATE: Entered STN: 19900306
Last Updated on STN: 19900306
Entered Medline: 19890502

L42 ANSWER 15 OF 17 VETB COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1971-61807 M
TITLE: A NOTE ON SPHEROPLASTS AND MYCOPLASMA IN SYNOVIAL FLUID.
AUTHOR: **ROBERTS D H; LITTLE T W A**
LOCATION: WEYBRIDGE, ENG.
SOURCE: BRIT.VET.J. (127, NO.3, 143-47, 1971)

09/489711

L42 ANSWER 16 OF 17 JAPIO COPYRIGHT 2001 JPO
ACCESSION NUMBER: 2000-219636 JAPIO
TITLE: ADJUVANT TO BE USED IN VACCINE
INVENTOR: DON ALAN DIAUESUTAA; ROBERTS DAVID
STEWART; SWEARINGIN LEROY A
PATENT ASSIGNEE(S): PFIZER PROD INC)
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 2000219636A		20000808	Heisei	A61K039-00

JP

APPLICATION INFORMATION

ST19N FORMAT: JP2000-017032 20000126
ORIGINAL: JP2000017032 Heisei
PRIORITY APPLN. INFO.: US1999 117705 19990129
PRIORITY APPLN. INFO.: US1999 121760 19990226
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined
Applications, Vol. 2000

AN 2000-219636 JAPIO

AB PROBLEM TO BE SOLVED: To obtain the subject adjuvant composition that is useful for enhancing immune response of an animal to an antigen, can form an oil-in-water type emulsion in a vaccine composition and minimize inflammation or the like on the vaccination sites.

SOLUTION: This adjuvant composition comprises (A) about 0.25-12.5%(v/v) of lecithin, (B) about 1-23% of oil (suitably mineral oil), (C) about 1.5-3.5% of amphiphatic surfactant, (D) an antigen, preferably in addition, (E) an aqueous carrier. The component D is selected from the group consisting of Erysipetothrix **rhysiopathiae** antigen, Bordetella bronchiseptica antigen, Pasteurella multocida antigen and the like. As for the two kinds of amphiphatic surfactants, one kind of a hydrophilic surfactant and one kind of lipophilic surfactant can be used preferably.

COPYRIGHT: (C)2000,JPO

L42 ANSWER 17 OF 17 JAPIO COPYRIGHT 2001 JPO
ACCESSION NUMBER: 2000-219637 JAPIO
TITLE: ERYSIPELOTHRIX **RHUSIOPATHIAE** ANTIGEN
COMPOSITION AND VACCINE PREPARATION
INVENTOR: DAVID STEWART ROBERTS; SWEARINGIN LEROY
A; BRIAN THOMAS SUIITAA
PATENT ASSIGNEE(S): PFIZER PROD INC)
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 2000219637A		20000808	Heisei	A61K039-02

JP

APPLICATION INFORMATION

ST19N FORMAT: JP2000-017930 20000124
ORIGINAL: JP2000017930 Heisei
PRIORITY APPLN. INFO.: US1999 117704 19990129
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined
Applications, Vol. 2000

AN 2000-219637 JAPIO

09/489711

AB PROBLEM TO BE SOLVED: To obtain the subject vaccine composition that is useful as a vaccine for vaccinating animals, preferably mammals or birds by using a fluid fraction originating from a specific culture mixture and stabilizers.

SOLUTION: This vaccine composition comprises (A) a fluid fraction originating from the culture mixture of *Erysipelothrix rhusiopathiae* (swine erysipelas) and (B) a stabilizer. The component B is selected from metal hydroxides, metal phosphates, aluminum hydroxide gel, aluminum phosphate gel, calcium phosphate gel, zinc hydroxide/calcium hydroxide gel or alum. In the component B, the culture mixture is deactivated with formalin or β -propiolactone and the fraction is preferably concentrated in 3-30 times. For example, the aluminum hydroxide gel is added on the concentrate of the culture mixture so that the final concentration may reach about 10-40 vol.%.

COPYRIGHT: (C)2000, JPO

FILE 'HOME' ENTERED AT 12:55:08 ON 17 OCT 2001